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The financial cost of medicinal waste in the UK is estimated as £300 million per year for 
prescribed medicines. Medicines reuse relates to the idea that unused prescribed medicines 
returned by one patient to a pharmacy can be re-dispensed to another patient as a strategy 
for reducing medicinal waste in the UK.   
Aims 
This thesis aimed to capture people’s beliefs and intentions towards reusing medicines that 
are returned to the pharmacies, using the Theory of Planned Behaviour (TPB).  
Methods and analysis 
The research uses a mixed method study design, using qualitative interviews to identify 
themes that were then classified using TPB (phase 1), in order to develop and validate a 
Medicine Reuse Questionnaire (MRQ) (phase 2), which was used to quantify the views of a 
large sample of respondents drawn from around the UK (phase 3) about medicines reuse. 
Results and discussions  
Medicines reuse was defined and people’s ideas about advantages and disadvantages, who 
might approve or disapprove, and factors that would impede or facilitate reusing medicines 
were mapped using thematic analysis. The MRQ was valid (confirmatory factor analysis 
showed the factor loading of all items to be >0.5; the item level content validity index was 
> 0.8) and reliable (Cronbach’s alpha measuring internal consistency of the direct measures 
19 
 
items was >0.7; Pearson’s correlation measuring stability of the indirect measures items 
was >0.5). A total of 1,003 valid responses were analysed and subjective norms had the 
strongest positive effect on intentions with standardized path coefficient of 0.55 (p < 0.001, 
n = 1003). 
Conclusion 
This research suggests that people living in the UK have positive intentions and could reuse 
medicine in the future. However, ensuring safety and quality of medicines that will be 




CHAPTER 1 THESIS OVERVIEW 
1.1 Overview of the area of the study 
Not all medicines that are prescribed to patients are fully used. In the UK, if a prescribed 
medicine is no longer being used, then conceptually that medicine is considered to be 
waste, because it ought to be discarded rather than used again. Pharmacies are required to 
accept the return of used and unused medicinal waste from patients and to dispose of these 
through appropriate routes (Pharmaceutical Service Negotiating Committee, 2017). 
Medicinal waste that is not disposed of appropriately has an impact on the environment and 
poses a risk to human health. In addition to this, the generation of medicinal waste has an 
economic impact.  
The environmental impact of medicinal waste relates to contact with the environment. For 
example, when unused medicinal waste is improperly disposed of by patients into 
household garbage, or flush down the sink or the toilet, it can reach the water system and 
seep into the environment (Tong et al., 2011). The presence of medicinal waste in the 
environment can have an effect by modifying the physiological function of living creatures, 
the implications of which are not completely known but, for example, this has been linked 
to the possible emergence of antibiotic resistant bacteria (e.g. vancomycin resistant 
enterococci and beta-lactam-hydrolysing enterobacteriaceae) and endocrine deactivating 
compounds (e.g. “feminising effects” of ethinyl estradiol on fish near wastewater treatment 
works) (Schwartz et al., 2003). In addition, medicinal waste can impact negatively on the 
environment through the “carbon footprint”. 
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The financial impact of medicinal waste has been described based on the extrapolated costs 
of the amount of unused medicinal waste returned to community pharmacies (CPs), general 
practitioners (GPs), and hospitals, which may even underestimate the total cost of 
medicinal waste. Nonetheless, the general consensus in the UK is that the estimated 
extrapolated cost of medicinal waste each year is £300 million (Trueman et al., 2010).  
Finally, risk to human health exists if unused medicines stockpiled at home are used by 
others, for example, for self-medication (Wu and Juurlink, 2014). Self-medication with 
antibiotics is a common practice in Europe, most often for a sore throat which is caused 
predominantly by viral infections. The use of antibiotics in this way has an added risk of 
creating bacterial resistance (an antibiotic-specific risk) without any potential for benefit 
(Grigoryan et al., 2010). In addition, there is the risk of accidental poisoning, especially if 
such medicines are used by children. There is also a potential for medicinal abuse 
especially if the medicines stockpiled are controlled drugs (CDs) or otherwise have 
addictive properties (Mackridge, 2005). 
There are many factors that contribute to medicinal waste. These can be described as 
avoidable (e.g. excess supply of medicines, errors, and non-adherence) and non-avoidable 
(e.g. patient death, and treatment prescription changes) causes (Hawksworth et al., 1996; 
Braybrook et al., 1999; Jesson et al., 2005). The non-avoidable causes of medicinal waste 
are the most commonly reported in the literature (West et al., 2014).  
To reduce medicinal waste, one approach is to prevent medicinal waste in the first place. 
For example, strategies devised in order to reduce the generation of medicinal waste 
include those that address adherence, such as the services of Medicines Use Review 
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(MUR) and the New Medicine Service (NMS), medicinal waste campaigns, and the use of 
Monitored Dosage Systems (MDSs). Other strategies also include limiting prescriptions to 
28 days’ supply, introducing small prescription charges, and medicinal waste campaigns 
(Jesson et al., 2005; and Trueman et al., 2010). The evaluation of these preventive 
strategies is limited and there is a distinctive lack of evidence about the effectiveness of 
these preventive strategies in addressing medicinal waste (Trueman et al., 2010; and West 
et al., 2014). In addition, these preventive strategies fail to address medicinal waste 
generated due to unavoidable causes (e.g. medicine adverse reaction, prescriptions being 
changed or stopped, and patient death) which are considered more common causes of 
medicinal waste and are estimated to account for more than 50% of medicinal waste 
generated in primary care (Trueman et al., 2010).  
To address the problems of medicinal waste at a waste management level, unused 
medicinal waste, especially those produced as a result of unavoidable causes could in 
theory be redistributed to other patients (Jesson et al., 2005; and Trueman et al., 2010). The 
redistribution of returned unused medicines to other patient is known as ‘medicines reuse’. 
Medicine reuse is potentially an effective approach to reducing medicinal waste as it could 
address both avoidable and non-avoidable causes of medicinal waste. In this way, 
medicines reuse can potentially provide a more sustainable use of returned unused 
medicinal waste, while reducing the environmental impact of current disposal practices 
(Mackridge and Marriott, 2007). Medicine reuse remains largely unexplored in the UK 
because unused medicines are not currently permitted to be redistributed to other patient.  
Medicine reuse has the potential to be implemented in the UK if its feasibility is explored. 
Firstly, as described earlier, medicine reuse would have the potential to address both 
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avoidable and non-avoidable causes of medicinal waste compared to current interventions 
that are not able to address the non-avoidable causes of medicinal waste. Secondly, people 
in the UK, anecdotally, often ask for medicines they are returning to a pharmacy to be 
reused. In fact, a NHS sustainability survey carried out by Ipsos MORI in 2011 reported 
half of the respondents were likely to accept re-issued medicines returned to pharmacies 
(NHS Sustainable Development Unit, 2011). Finally, there is precedence for medicines 
reuse in other countries. For example, in the United States unused medicines are collected 
and redistributed to patients who are less able to afford the cost of medicines (Cauchi, 
2012). 
The application of medicine reuse in the UK depends on many factors, which are explored 
in this thesis. However, it is worth pointing out some existing supporting evidence relating 
to the idea of medicines reuse. For example, the characteristics that may allow or preclude 
medicines reuse include the visual aesthetic characteristics of unused medicines and this is 
an area where some research already exists. These characteristics can in theory be 
qualitatively assessed by pharmacists to determine if the unused medicine is suitable for 
reuse (e.g. oral solid dosage form medicines that are in sealed blister packaging, unopened, 
and within the expiry date). Data from a UK study by Mackridge and Marriott (2007), a 
Swedish study by Ekedahl (2003), and Omani study by (Al-Siyabi and Al-Riyami, 2007) 
showed that the majority of the returned unused medicinal waste were unopened and within 
the expiry date, and probably suitable for reuse. In addition, the authenticity of returned 
medicines is an issue. There will be an opportunity to check for counterfeit and/or 
tampered medicines by using a unique identifier (a 2-dimension barcode) and an anti-
tampering device in the near future. This is because in the UK, manufacturers will be 
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required to place the safety features (i.e. a unique identifier of a 2-dimension barcode and 
an anti-tampering device) on the packaging of most prescription medicines and certain non-
prescription medicines by 9 February 2019 (European Medicines Agency, 2016). 
Before medicines reuse is introduced there is a need to formally examine the general 
public’s views about this concept and whether they are willing themselves to reuse 
medicines returned to CPs in the future. No previous research has formally examined 
people’s beliefs about medicine reuse. This thesis set out to investigate people’s beliefs and 
attitudes as well as intentions to reuse returned unused medicines in the future through a 
psychological approach. The Theory of Planned Behaviour was selected as the 
psychological framework for this research, enabling people’s behavioural, normative, and 
control beliefs about medicine reuse to be explored and measured. TPB allows a range of 
question to be answer such as what would or would not encourage people to reuse 
medicines, what do people think in terms of advantages and disadvantages of reusing 
medicines in the future, would social norms (e.g. what family and friends think and do) 
influence people’s decision to reuse or not reuse medicines, and what are the factors or 
circumstances that make it difficult or easy for people to reuse medicines (Ajzen, 1991; 
Ajzen, 2006; and Ajzen, 2011). 
1.2 Aims and objectives 
The aim of this thesis was to capture people’s beliefs and intentions toward reusing 
medicines in the future by applying a mixed method study design and using the Theory of 
Planned Behaviour (TPB) as a tool to develop the Medicine Reuse Questionnaire (MRQ). 
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The objectives were first to use qualitative interviews to define medicines reuse as a 
behaviour; and identify behavioural, normative, and control beliefs about medicines reuse 
(phase 1). Then, to construct, validate, pilot and develop the MRQ (phase 2) to finally  
capture the views of respondents drawn from around the UK about medicines reuse and 
their willingness to reuse medicine in the future (phase 3).  
1.3 The importance of doing this research in the UK and internationally 
Medicinal waste is a growing problem in the UK and in different parts of the world. Other 
studies have investigated the causes of medicinal waste, impact of medicinal waste, and the 
interventions to reduce medicinal waste (Trueman et al., 2010; and West et al., 2014). 
Historically, the UK medicinal waste management strategies that have occurred in CPs 
such as disposal of medicinal waste and intermittent medicines take-back campaigns are at 
the foot of what is known as the waste hierarchy, meaning that they address the least 
environmentally favoured option of ‘disposal’ (EWFD, 2008; and UK Department of 
Health, 2013). As described earlier, a range of waste management strategies in the UK 
have been applied. These include MURs, MDS, educational campaigns, and limiting 
prescriptions to 28 days. These attempt to address the avoidable causes of medicinal waste 
such as non-adherence, excess supply and stockpiling, and prescription and dispensing 
errors (Jesson et al., 2005; and Trueman et al., 2010). The evaluation of these preventive 
strategies is limited and there is a distinctive lack of evidence about the effectiveness of 
these preventive strategies in addressing medicinal waste (Trueman et al., 2010; and West 
et al., 2014). Moreover, these preventive strategies fail to address medicinal waste 
generated due to unavoidable causes (e.g. medicine adverse reaction, prescriptions being 
changed or stopped), which are considered more common causes of medicinal waste (West 
26 
 
et al., 2014) and are estimated to account for more than 50% of primary care medicinal 
waste (Trueman et al., 2010).  
To address the problems of current waste management practices, unused medicinal waste, 
especially those produced as a result of unavoidable causes could in theory be redistributed 
to other patients (Jesson et al., 2005; and Trueman et al., 2010). The redistribution of the 
returned unused medicines to other patient is known as medicines reuse. Medicine reuse 
could have a positive financial impact (Mackridge and Marriott, 2007) as well as a 
potential to provide a more sustainable solution to medicinal waste, while reducing the 
environmental impact of current disposal practices (Daughton, 2003). There is therefore a 
rationale for wanting to implement medicine reuse as an intervention because it can address 
both avoidable and non-avoidable causes of medicinal waste. However, medicines are not 
currently permitted to be redistributed to other patient and the idea of medicines reuse 
remains largely unexplored in the UK. 
There is precedence for medicines reuse in other countries. For example, in the United 
States unused medicines are collected and redistributed to patients who are less able to 
afford the cost of medicines (Cauchi, 2012). Therefore, medicine reuse has a potential and 
could be applied to reduce medicinal waste in the UK taking into consideration the safety 
and stability of the returned unused medicines, people’s uptake of the idea and agreement 
to reuse medicines in the future, pharmacist time and agreement, and whether 




1.4 Background information about the researcher 
Prior to starting the PhD study, the researcher HA was new to research involving 
qualitative methods and psychological theories. HA is a clinical pharmacist who has a 
clinical experience and was involved only in one clinical based research project during his 
study for MSc. degree in clinical pharmacy, international practice and policy. Therefore, 
HA underwent a one week training course at Kingston University about “Doing and 
Communicating Qualitative Research”. The training courses involved introduction about 
principles and practicalities of qualitative research, introductions about grounded theory, 
discourse analysis, thematic analysis, interpretative phenomenological analysis (IPA), 
qualitative interviews (individual and focus groups), and training on how to do thematic 
analysis. In addition, HA attended short courses in a relation to qualitative studies as part of 
the University of Reading Research and development Program (RRDP).  Finally, HA read 
many research papers that focused on qualitative interviews, thematic analysis and the 
application of Theory of Planned Behaviour (TPB).  
1.5 Overview of the thesis 
This chapter has provided a summary and overview about the area of study (i.e. medicinal 
waste and medicine reuse), the economic and environmental impact of medicinal waste, 
and the risk to human health, the different intervention applied to reduce medicinal waste, 
the potential for medicine reuse compared to previous interventions, and the factors the 
affect the application of medicine reuse. In addition, this chapter has set out the aims and 
objectives of the research, and detailed information about the importance of this research in 
the UK and internationally, as well as providing background information about the 
researcher HA.  
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Chapter 2 provides background information about medicinal waste, health-care waste in the 
UK National Health Service (NHS), the handling of household medicinal waste by 
pharmacist, disposal practices for medicinal waste, the impact of medicinal waste (i.e. the 
environmental, economic impact, and risk to human health), types and causes of medicinal 
waste (i.e. avoidable and non-avoidable causes), the waste hierarchy and the preventive 
strategies to reduce medicinal waste, and medicine reuse as an intervention to reduce 
medicinal waste. In addition, chapter 2 details a structured review of the different 
therapeutic classes and dosage forms of medicinal waste reported in the UK and 
Internationally. Finally, chapter 2 provides information about the gap in research about 
medicinal reuse. 
Chapter 3 provides an overview about the different psychological theories relevant to 
understanding people’s beliefs and intentions toward reusing medicines in the future, an 
overview of the common health related psychological theories (e.g. Health Belief Model, 
Protection Motivation Theory, Trans-theoretical Model of Behaviour Change and Stage of 
Change, Theory of Reasoned Action, and Theory of Planned Behaviour), assessment of the 
ability to use the TPB to predicts people’s behavioural beliefs and their intentions to reuse 
medicines in the future, and support for the application of  TPB to predict people’s 
behavioural beliefs and their intentions to reuse medicines in the future .In addition, 
chapter 3 describes the steps applied to manage the development of TPB Medication Reuse 
Questionnaire (MRQ). Finally, chapter 3 provides information about the overall 
conclusion, recommendation, and future work of the study. 
Chapter 4 describes phase 1 of the study and details the qualitative study (i.e. elicitation 
study), study compliance with ethical standard and study setting, participants recruitment 
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process, thematic analysis, and data collection and analysis. In addition, chapter 4 defines 
medicine reuse as a behaviour, and identifies behavioural, normative and control beliefs in 
a relation to medicine reuse as a behaviour. Finally, chapter 4 provides information about 
the different themes obtained inductively, then categorises these themes deductively 
according to TPB into three major categories; consequences of medicine reuse, exemplar 
and anti-exemplar individuals or groups, and expectations about medicine reuse. 
Chapter 5 describes phrase 2 of the study and details the development of Medicine Reuse 
Questionnaire (MRQ) using TBP. In addition, chapter 5 details information about the 
development of MRQ items of the indirect measures, direct measures and intentions of 
TPB, and also the background factors items.  Chapter 5 describes in details the validity (i.e. 
content validity, and Confirmatory Factory Analysis) and reliability (i.e. internal 
consistency of direct measures of TPB using Cronbach’s alpha and test retest of the indirect 
measures of TPB using Pearson correlation) process of MRQ. In addition, chapter 5 
describes the two piloting processes that result in the final version of the MRQ which was 
composed of 48 items. 
Chapter 6 describes phase 3 of the study and the final amendment of the Medicine Reuse 
Questionnaire (MRQ) before it was disseminated to a large representative sample of 
respondents drawn from around the UK to capture their perception toward reusing 
medicines in the future. In addition, chapter 6 describes the use of the online platform, the 
online panel, and the involvement of a Market Research Company in the recruitment 
process. Finally, chapter 6 describes the descriptive results of this study, the hypothesis 
testing, and the utility of TPB and its predictive power for capturing people’s beliefs and 
intentions to reuse medicines in the future. 
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Chapter 7 provides a thesis summary of the key findings of phases 1, 2 and 3, discusses the 
significance and limitations of the research, the potential impact of the research, and 
recommend future work.     
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CHAPTER 2  GENERAL INTRODUCTION AND LITERATURE 
REVIEW 
2.1 Health-care Waste in the UK National Health Service  
One way in which waste is generally thought of is as anything discarded by an individual, 
household or organisation. More formally, waste is defined by the European Waste 
Framework Directive (EWFD 2008/98/EC) as “any substance that the holder discards or is 
required to discard” (EWFD, 2008). Accordingly, the term waste encompasses a complex 
mixture of different substances, some of which are considered hazardous to people’s 
health. In addition to this, the generation, transport and disposal of waste may present 
threats to the environment and to public health, the impact of these indirect effects being 
dependent on the types and implementation of waste management options. Therefore, in 
the UK, the primary aim in the management of waste is to guarantee that it is processed, 
treated, and disposed of in a safe and cost-effective manner that does not negatively impact 
on people and the environment (Palmer, 2014).   
Waste can result from a multitude of sources. For example, health-care organisations and 
facilities produce many different types of waste as a result of their daily activities, such as 
diagnostic activities, and preventive, palliative and curative treatments. Health-care waste 
(HCW) is an umbrella term for the waste produced by research facilities, laboratories, and 
organisations that provide health-care services in addition to waste generated in a person’s 
home where health and social care is provided. HCW can include bandages, swabs, sharps, 
blood, medicines and incontinence pads (Royal College of Nursing, 2014). There are two 
main types of HCW as shown in Table 2.1 ; hazardous and non-hazardous HCW. 
Hazardous HCW is named as such because it is considered to have infectious or some other 
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properties that can cause harm to the environment and humans if it is mishandled. In 
contrast, non-hazardous HCW includes waste that does not pose any particular biological, 
chemical, radioactive or physical hazard. When HCW is a medicine or contaminated with a 
medicine it is referred to as medicinal waste (Royal College of Nursing, 2014; and World 
Health Organisation, 2011).   
Medicinal waste includes “expired, unused, spilt, and contaminated pharmaceutical 
products, drugs, vaccines, and sera that are no longer required and need to be disposed of 
appropriately” (UK Department of Health, 2013). Medicinal waste, similar to general 
HCM, can be hazardous or non-hazardous and has three main classifications (Royal 
College of Nursing, 2014):  
I. Hazardous medicines (cytotoxic or cytostatic) 
These are medicines that have one or more hazardous properties meaning they are, for 
example toxic, carcinogenic, toxic for reproduction or mutagenic, warranting classification 
as hazardous waste. Hazardous medicines include most hormonal preparations, some anti-
viral drugs and some antibiotics. Because they are classified as hazardous waste, the 
regulations state that they must be segregated from other medicines when being handled as 
waste. 
II. Non-hazardous pharmaceutically active medicines 
These are pharmaceutically active products, so while they have a pharmacological impact 
on people or the environment, they do not have any of the hazardous properties associated 
with cytotoxic or cytostatic medicines described above. Therefore, they are not considered 
to be hazardous. 
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III. Non-hazardous, non-pharmaceutically active medicines 
These are non-pharmaceutically active products, such as infusion bags containing saline or 
sugar solutions, which have no hazardous properties and also are unlikely to have a 




Table 2.1 Classifications and definitions of health-care waste 
Hazardous. Waste that can cause harm to the environment and human health if it is mismanaged. 
It can include clinical waste, infectious waste, cytotoxic and cytostatic medicines, chemicals and 
hazardous substances, radioactive diagnostics, therapeutic materials, and X-ray photos. 
Clinical waste Waste from health-care activity that 1. Contains viable micro-organisms or 
their toxins which are known or believed to cause disease in humans or other 
living organisms. 2. Contains or is contaminated with a medicine that contains 
a biologically active pharmaceutical agent. 3. Is a sharp, or a body fluid or 
other biological material (including human and animal tissue) containing or 
contaminated with a dangerous substance (based on regulations for the 
classification, packaging and labelling of dangerous substances). 
Infectious waste Waste contaminated by blood and its secondary products, cultures and 
supplies of infectious agents, waste from isolated patients, any infected thrown 
away diagnostic samples with blood and body fluids, and contaminated 




Any medicinal product that possesses any one, or more, of the following 
hazardous properties: 1. Toxic 2. Carcinogenic 3. Toxic for reproduction. 4. 
Mutagenic. This definition is wide and may include many medicines such as 
hormone-based preparations, antimicrobial substances such as 
chloramphenicol eye drops, as well as cancer-treating agents 
(chemotherapeutics and anti-neoplastic drugs). 
Non-hazardous (general waste). Waste that does not pose any particular biological, chemical, 
radioactive or physical hazard.  It includes offensive/hygiene waste, non-cytotoxic and non-




Waste that is non-infectious and not clinical, but may cause offence due to the 
presence of recognisable health care waste materials, body fluids, or odour. 
Non-hazardous 
medicinal waste 
Pharmaceutically and non-pharmaceutically active 
*Adapted from (Royal College of Nursing, 2014; and World Health Organisation, 2011). 
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2.2 The handling of household medicinal waste by pharmacies 
In the UK, if a prescribed medicine is no longer being used, then conceptually that 
medicine is considered to be waste, because it ought to be discarded rather than used, say, 
by another patient. This is because medicines that have been dispensed to patients, even if 
unused, are not currently allowed to re-enter the pharmaceutical supply chain. The Royal 
Pharmaceutical Society’s guidance for Pharmacists states that “medicines returned to a 
pharmacy from a patient's home, a nursing or residential home must not be supplied to and 
used again by any other patient and have to be destroyed”(Royal Pharmaceutical Society, 
2016) . One technical reason is uncertainty about the biochemical integrity of medicines on 
leaving the formal distribution chain; for example, storage conditions in a patient’s home 
may degrade the active ingredients. The potential for counterfeit medicines to enter the 
pharmaceutical supply chain is another concern. All of these considerations mean that, 
currently, medicines no longer being used transform, at least conceptually, into medicinal 
waste. 
Pharmacies are required to accept the return of used and unused medicinal waste from 
patients and medicinal waste returned to a pharmacy automatically necessitates 
appropriate disposal by the pharmacy (Pharmaceutical Service Negotiating Committee, 
2017). As part of this process, the Pharmaceutical Service Negotiating Committee 
recommends that pharmacy staff should ask people presenting medicinal waste to fill in an 
unwanted medicines card to guarantee that there are no items such as chemicals or products 
that may be incompatible with other products in the pharmaceutical waste bin and which 
cannot be safely disposed of. The pharmacists then (as required by NHS England or the 
waste contractor) should divide the medicinal waste into solids (including ampoules and 
36 
 
vials), liquids and aerosols (Pharmaceutical Service Negotiating Committee, 2017). Any 
household medicinal waste that is acutely toxic, carcinogenic, mutagenic or toxic for 
reproduction needs to be segregated by pharmacy staff. However, it is no longer necessary 
to segregate medicines originating in the pharmacy from those returned by households. 
Instead, the returned unused medicinal waste must be properly described with appropriate 
European Waste Catalogue (EWC) Codes and if any Controlled Drug (CD) is identified, it 
must be isolated and denatured using a CD denaturing kit before being destroyed so that it 
cannot be recovered or reused. (Pharmaceutical Service Negotiating Committee, 2017).   
The NHS England local team is responsible for arranging for a waste contractor to collect 
medicinal waste from pharmacies at regular intervals. The waste contractor usually uses 
high temperature (incineration) as a treatment process for medicinal waste. The processes 
described in this section is shown in Figure 2.1. 
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Figure 2.1 Summary of the UK processes associated with the safe disposal of 
household-generated medicinal waste  
 
Despite the existence of this formalised process for the handling and disposal of medicinal 
waste, public awareness of this service is limited. Patients do not always return their 
medicinal waste to a pharmacy, instead they may store their unused medicines at home, or 
dispose of the medicines themselves (Tong et al., 2011). This is described in more detail in 
the section that follows. 
2.3 Disposal practices for medicinal waste 
Medicinal waste that is not returned to pharmacies is either stockpiled at home or disposed 
of by patients into the household trash, or by flushing down the toilet or disposal through 
the sink (Murray et al., 2005; Bound et al., 2006; Tong et al., 2011; and Vellinga et al., 
2014). The various methods used by patients to dispose of their medicinal waste have been 
studied in the UK and around the world. A systematic review about disposal practices 
Patients return medicinal 
waste to the pharmacy
Pharmacies accept medicinal 
waste and pharmacy staff 
divide them accoording to:
1. Solids, liquids and aerosols
2. Hazardous/Non-hazardous
3. Controlled Drugs (CD)
The NHS England local team 
will arrange with a waste 
contractor to collect 
medicinal waste from 
pharmacies at regular 




relating to medicinal waste from around the world reported that patients most commonly 
dispose of their medicinal waste via the household garbage (Tong et al., 2011). Similarly, 
results from UK studies have consistently confirmed that patients most commonly dispose 
of their medicinal waste via household waste (garbage). For example, in the study by 
Bound et al. (2006), 63.2% of the people in the South East of the UK disposed of their 
medicinal waste in the household waste bin, 11.5% disposed of these via the sink or toilet, 
with only 21.8% returning their medicinal waste back to the pharmacy. Similarly, data 
from a public survey in Scotland reported that 37% of prescription only medicines and 56% 
of over the counter medicines were disposed of into the garbage, while 44% of prescription 
only medicines and 34% of over the counter medicines were flushed into the drain (Murray 
et al., 2005).  
Evidence from the above studies indicates that the majority of medicinal waste is disposed 
of improperly with only a small amount returned back to pharmacies. There is some 
evidence to show that people’s decision to dispose of their medicinal waste inappropriately, 
instead of returning them back to the community pharmacy, can be influenced by factors 
such as their knowledge and awareness of economic and environmental consequences of 
improper disposal practices. For example, Vellinga et al. (2014) investigated the effect of 
the advice given to patients in Ireland by their health-care provider on medicinal waste 
disposal practices. Before the advice was given to patients by a healthcare provider 72% of 
the respondents reported they disposed of their medicinal waste improperly; for example 
via household waste (51%), into the sink (29%) and into the toilet (14%). After advice was 
given to patients by a healthcare provider, 75% of the respondents reported they disposed 
of their medicines properly by returning them to the pharmacies. This study supports the 
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idea that people advised about medicinal waste and how to best dispose of it are more 
likely to take their medicinal waste to pharmacies rather than inappropriately disposing of 
them at home. 
2.4 Impact of medicinal waste  
Medicinal waste, as well as being disposed of inappropriately, can be accumulated at home, 
posing a risk to human health, and to the environment and it also has a financial cost too. 
Reducing medicinal waste can potentially reduce its negative financial and environmental 
impact as well as reducing the risks of accidental poisoning and medicinal abuse and other 
ill effects on human health.   
 
2.4.1 The impact of medicinal waste on human health 
Risk to human health exists if unused medicines stockpiled at home are used by others, for 
example, for self-medication. There is the risk of accidental poisoning, especially if such 
medicines are used by children. There is also a potential for medicinal abuse especially if 
the medicines are CDs or have addictive properties (Mackridge, 2005). In addition, patients 
may self-medicate for a new illness with medication previously prescribed for a different 
illness (Wu and Juurlink, 2014). For example, self-medication with antibiotics is a common 
practice in Europe, most often for a sore throat which is caused predominantly by viral 
infections. The use of antibiotics in this way has an added risk of creating bacterial 
resistance (an antibiotic-specific risk) without any potential for benefit (Grigoryan et al., 
2010).  Finally, there is the broader idea that patients who do not take their medicines as 
prescribed, creating medicinal waste, impact negatively on their own health by not treating 
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their condition (Osterberg  and Blaschke 2005) – although this is clearly a ‘cause’ of 
medicinal waste it is nonetheless associated with it.  
2.4.2 Environmental impact of medicinal waste 
The environmental risk of medicinal waste relates to contact with the environment. There is 
evidence that pharmaceuticals are found in the water environment around the world 
(Kümmerer, 2009). The likely pathways that lead to the presence of pharmaceuticals in 
water include human excretion, veterinary excretion, agriculture uses, pharmaceutical 
company waste and improper disposal of medicinal waste (Bound and Voulvoulis, 2005; 
Radhakrishna et al., 2014).  
The presence of medicinal waste in the environment is considered more difficult to control 
compared to other pollutants due to the fact that medicines are often resistant to usual 
biodegradation pathways and generally last for an undefined time in the environment 
because of, for example, long half-lives (Jones et al., 2002). The presence of medicinal 
waste in the environment can modify the physiological function of living creatures, the 
implications of which are not completely known but, for example, this has been linked to 
possible emergence of antibiotic resistant bacteria (Schwartz et al., 2003), and endocrine 
deactivating compounds (Lange et al., 2001). Data from Schwartz et al. (2003) confirmed 
the development of bacterial resistance as vancomycin resistant enterococci and beta-
lactam-hydrolysing enterobacteriaceae were cultivated from all wastewater biofilms 
examined. Moreover, in a study by Lange et al. (2001), the increased presence of 
pharmaceuticals was linked with reproductive and developmental abnormalities in various 
types of fish. For example, there is the “feminising effects” of endocrine-disrupting 
compounds, such as ethinyl estradiol on fish near wastewater treatment works. The results 
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from these studies illustrate the negative effect of the presence of medicinal waste on the 
environment. 
Despite the fact that medicinal waste is present in the water environment and with observed 
toxicological effects, the concentrations are generally at trace levels in the order of 
nanograms to micrograms per litre (Kümmerer, 2009) and below the levels thought to 
cause harm to humans in most cases (Bound et al., 2006). However, the unknown effect of 
the chronic release of medicinal waste in the environment creates uncertainty and it cannot 
be ruled out that the accumulative presence of medicinal waste in water is at levels that 
may be considered serious and pollutant to water receivers. There is yet another 
environmental impact of medicinal waste, which is less direct but also important. 
Medicinal waste can impact negatively on the environment through the “carbon footprint”. 
The carbon footprint is “the measure of the impact of individuals, organisations or 
community activities on the environment by calculating all the greenhouse gases produced 
in these activities and measuring them in the unit of carbon dioxide” (Wright et al., 2011). 
The NHS has one of the biggest carbon footprints of any organisation in Europe. Data from 
the National Audit Office (2015) reported that procurement is the largest contributor (61%) 
of the total NHS carbon footprint with pharmaceuticals (35%) as the largest component of 
procurement emissions. The majority of pharmaceuticals (80%) are linked to prescriptions 
by primary care and community services, then acute services (13%), and mental health 
services (5%) (National Audit Office, 2015). In order to have an indicative view of the 
carbon impact of particular medicines, the Association of the British Pharmaceutical 
Industry (ABPI) collaborates with the Carbon Trust to help pharmaceutical companies 
(such as AstraZeneca, GlaxoSmithKline, Janssen (J&J), Eli Lilly, and Pfizer) launch a 
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carbon foot print tool to estimate the carbon footprint for Active Pharmaceutical 
Ingredients (APIs), transport and distribution, formulation and packaging, retail and use 
phase and finally the disposal of the packaging (ABPI, 2013). This tool could potentially 
help pharmaceutical companies to provide an estimation of the carbon footprint of a range 
of medication (ABPI, 2013). But in the meantime, it is certainly acknowledged that 
pharmaceuticals, and in turn, medicinal waste, have an impact on the environment through 
carbon footprint. 
In 2014 NHS England and Public Health England produced a vision for a sustainable 
health and care system that “works within the available environmental and social resources 
protecting and improving health now and for future generations.” It aims to reduce carbon 
emissions, and minimise waste & pollution to contribute to the Climate Change Act target 
to reduce carbon emissions by 34% by 2020. Pharmaceuticals represent 16% of the entire 
health and social care system carbon footprint and reducing this figure currently relies on 
improving medicines use and reducing waste (Sustainable Development Unit, 2014).  
2.4.3 Economic impact of medicinal waste  
The number of prescribed medicines and the NHS prescription bill has increased 
substantially in the past decade. According to data from the Health and Social Care 
Information Centre published in 2016, 1,083.6 million prescription items were dispensed 
by UK CPs in 2015, with an increase of 1.8% (19.1 million items) compared to that 
dispensed in 2014 (Prescribing and Medicines Team Health and Social Care Information 
Centre, 2016). This is an increase of 50.4% (363.4 million) on the number of the item 
dispensed in 2005 (720.3 million items). The Net Ingredient Cost (NIC) of prescribing in 
2015 was £9,266.5 million increased by of 4.7 % (£414 million) from 2014. This is an 
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increase of 16.8% (£1330.0 million) in the costs from 2005, when the total cost was 
£7,936.6 million (Prescribing and Medicines Team Health and Social Care Information 
Centre, 2016). These figures shows that both the number of prescriptions and the NIC of 
prescribing, and ultimately the medicine bill, have increased significantly in the past 
decade, so it is quite important from a financial perspective too that medicines are not 
wasted and/or are used in a cost-effective manner.   
The financial impact of medicinal waste is possibly even destructive to the health-care 
economy. The general consensus in the UK is that the estimated extrapolated cost of 
medicinal waste each year is £300 million (Trueman et al., 2010). The estimated costs of 
medicinal waste in the UK was calculated based on the extrapolation of the costs of the 
medicinal waste being returned to Community Pharmacies (CPs) and General Practitioner 
(GP) surgeries which may underestimate the real value of the costs of medicinal waste as it 
did not take into account the cost of unreturned medicinal waste that were disposed of by 
patients or stockpiled at home.  
A number of other studies too from inside (six) and outside (eight) of the UK have 
estimated the costs of medicinal waste, summarised in Table 2.2. In these studies, the 
estimated costs of medicinal waste varied widely due to factors such as numbers of the 
returns made, the type and cost of medicines returned, the study duration (which ranged 
from four weeks to seven months), and the number of CPs, hospital pharmacy, and GP 
clinics involved. Studies from outside the UK involved a higher number of CPs compared 
to UK studies with the exception of the study by Mackridge and Marriott (2007). 
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In the UK the estimated extrapolated cost of medicinal waste in 2007 was in the range of 
£37-100 million per year (Hawksworth et al., 1996; Mackridge and Marriott, 2007; and 
National Audit Office Report, 2007). More recent research, mentioned above, reported that 
a figure of £300 million to be the estimated extrapolated cost of medicinal waste each year 
in the UK (Trueman et al., 2010). This is three times higher than the £100 million reported 
by the National Audit Office Report (2007). It would be fair to assume that with 
prescription volume increases, the volume of medicinal waste will increase too. This would 
suggest that the cost of medicinal waste is increasing and probably uncontrolled. Therefore, 
it is important for the NHS to investigate for more sustainable solutions of medicinal waste. 
This is in light of the financial challenges the NHS is facing; the NHS five year forward 
view estimates there to be 30 billion pounds funding gap by 2020/21 (NHS, 2014). 
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Table 2.2 Summary of research studies evaluating the economic impact of medicinal waste from different countries  
Study Study setting and duration  Study method  Country Main Findings 
Hawksworth 
et al. (1996) 
30 CPs over duration of 1 month Cross sectional 
questionnaire 
UK A total of 1,091 items were returned by 366 
patients with estimated value of £37 million 
Braybrook 
et al. (1999) 
18 pharmacies over 8 weeks Small pilot study Wales/UK The total cost of reported 1,428 items returned 
was £19,059.  
Langley et 
al. (2005) 
8 CP and 5 GPs over duration of 4 weeks Cross sectional 
observational study 
UK A total of 340 items were returned (42 to GPs 
and 298 to CPs). The total cost of returned 








UK  A total of  3,765 items  were returned by 910 





Based on previous analysis conducted by 





UK Proposed that each year an estimate of £100 
million value of unused returned medicine. 
Trueman et 
al. (2010) 
403 of the 466 items identified in the 
public survey were able to be priced. 
Costs were identified /item using British 
National Formulary (BNF). 
Public survey UK  Estimated that the annual cost of the primary 
and community care medicines wastage in UK 
NHS was around £300 million per year (£ 
250-300 million per year). 
46 
 
Study Study setting and duration  Study method  Country Main Findings 
Cameron 
(1996) 
58 CPs in Alberta (8% of provincial total) 
over duration of 8 weeks  
Self-reporting 
questionnaire   
Canada The estimated cost of the unused medicines 
returned was $60,350. The extrapolated cost 
for 750 CPs is in Alberta during the same 8 
week period was $716,400.  
Morgan 
(2001) 
Sample of 73 of Hampshire retirement 
community citizens aged 65 years or 
older. over duration of 7 months 
Cross sectional 
pilot survey 
US The total cost of 2,078 wasted medicines was 
US $ 201,100 with mean annual cost of 
wasted medication was $30.47/person (range 
= $0-$131.56).  Individual costs were modest, 
but if $30/individual demonstrate a low 
estimate of average annual cost of waste, the 
US extrapolated cost was estimated to be not 
less than $1 billion per year. 
Abou-Auda 
(2003) 
A total of 1641 families  participated 











The estimated cost of unused medicines by 
families in Saudi Arabia capital cities of 
Kuwait, Oman, Qatar, and United Arab 
Emirates (U.A.E) was $150 million.  
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Study Study setting and duration  Study method  Country Main Findings 
Coma et al. 
(2008) 
38 CPs over duration of 3 months Cross sectional 
questionnaire  
Spain The estimated cost of returned medicines was 
€8,539.9. The extrapolated cost for the 20,461 








Cairo/Egypt  The total wholesale price of returned drugs 
calculated at 10,988.84 Egyptian pounds 
(around $1,962.32 US)  
Ibrahim et 
al. (2012) 




The estimated total cost of 657 returned drugs 
to CPs was $8,348.5. 
Hassali et 
al. (2012) 
Two parts (over duration of 6 months): 
Medicine wastage in the patients’ home. 
 
Medicine wastage by the volunteer at the 
pharmacy desk.  
A descriptive study 




2) Patients returned 
their medicinal 




Malaysia  The total cost of the returned medications 
within 6 months was MYR 59,566.50 
(Malaysian ringgit) with a monthly average of 
about MYR 9,927.75. the extrapolated cost for 




Study Study setting and duration  Study method  Country Main Findings 
 
Law et al. 
(2015) 
A web-based survey (Phase I) at one 
health sciences institution between April 
and June 2011 and paper based survey 
(Phase II) planned drug take-back events 






The total cost of medicinal waste was 
$152,014.89 from both phases with the total 
extrapolated cost to US national level ranging 
from $2.4 to $5.4 billions. 
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2.5 Types and causes of medicinal waste 
There are many factors that contribute to medicinal waste and these have been described in 
the literature in different ways. These factors were described as avoidable or non-avoidable 
by Jesson et al. (2005) who derived the description from Hawksworth et al. (1996) and 
Braybrook et al. (1999) (Table 2.3). At least half of the causes of medicinal waste are 
considered unavoidable and the majority of the avoidable causes of medicinal waste are 
potentially as a consequence of poor health-care services and practices (Jesson et al., 2005). 
In addition, Trueman et al. (2010) included the concept of non-adherence, i.e. people not 
taking their medicine as intended (whether intentional or unintentional). Compliance, an 
older term, and adherence are terms used to describe medicine-taking behaviour by the 
patient. Compliance is defined as the extent to which the patient’s behaviour matches the 
prescriber’s recommendations. Adherence in turn is the extent to which the patient’s 
behaviour matches the agreed recommendations from the prescriber. Adherence is the term 
preferred by many over compliance because of its emphasis on the need for agreement 
(Horne, 2006).  
To summarise, factors that contribute to causing medicinal waste can be split into three 
types (Jesson et al., 2005; and Trueman et al., 2010): 
1. Preventable (avoidable) medicinal waste: patient stockpiles their medicines in case 
they may need to use them in the future. Or items from a repeat prescription are 
dispensed even if the patient is no longer taking them.  
2. Non-preventable (non-avoidable) medicinal waste: death of a patient, or a change in 
treatment leading to the previous medicines being no longer required.  
3. Medicinal waste related to non-compliance and/or non-adherence:  
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 Non-compliance: patient does not take medicines as prescribed. For example, 
taking incorrect doses of medicines or at irregular intervals, or not taking them at 
all.  
 Non-adherence (intentional): patient stops taking medicines. For example, due to 
adverse side effects or personal beliefs.  
 Non-adherence (unintentional): patient stops taking medicine, or fails to take at 
correct intervals. For example, due to forgetfulness.  
Table 2.3 Common causes of medicinal waste and the extent to which they are 
preventable (avoidable).  
Causes of medicinal waste Extent to which they are avoidable or 
not 
Patient death Unavoidable 
Medicines changed or stopped by the 
prescriber due to clinical reasons 
Unavoidable 
Medicine adverse reactions  Unavoidable 
Medicines passed their expiry date Avoidable 
Prescription and dispensing errors Avoidable 
Excess supply, over ordering and stockpiling Avoidable 
Patient non-compliance and non-adherence Avoidable 
* Adapted from Jesson et al. (2005), cited by (Hawksworth et al., 1996; and Braybrook et 
al., 1999) 
The factors that contribute to causing medicinal waste can be also be thought of as related 
to patients (such as patient behaviour and non-adherence), or failure of the existing 
prescribing and dispensing process (such as error in prescription order or supply). These 
factors are summarised in (Figure 2.2). It is clear that the process of prescribing, 
dispensing, and the patient as a receiver all play a part in causing and creating medicinal 
waste (Trueman et al., 2010). These are described in the sections that follow.  
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Figure 2.2 Causes of medicinal waste can occur as a result of patient factors or failure 




2.5.1 Patient death 
In the treatment of chronic conditions, the aim is to maintain the patient’s health and 
provide the best quality of life for them. This may necessitate medicines for the long term, 
and a larger number of medicines (polypharmacy) to treat comorbidities, and continuous 
modification of the prescriptions as the conditions progress (Mackridge, 2005). But if a 
patient dies, their current unused medicines and any previous medicines that have been 
stockpiled are sometimes returned to CPs or GPs as medicinal waste. Five cross sectional 
UK studies (Cook, 1996; Hawksworth et al., 1996; Langley et al., 2005; Mackridge and 








Factors related to 












consistently reported that patient death is a common reason for medicinal waste. More 
recently, a systematic review investigating the causes of medicinal waste reported patient 
death as the second most commonly cited reason for medicinal waste (West et al., 2014). 
2.5.2 Changes in the treatment prescription  
Patients can sometimes experience an adverse drug reaction or their medicines are no 
longer considered to be effective. An adjustment to the dose, or stopping or changing the 
treatment may therefore be necessary to fulfil the required patient outcome. When 
medicines are prescribed for long durations such as three months, larger amounts of unused 
medicines could potentially accumulate as a result of treatment being changed (Jesson et 
al., 2005; and Mackridge and Marriott, 2007). This is because, for example, if a 3-month 
quantity is prescribed, dispensed, but then changed half-way through the 3-month period, 
there is scope for a large quantity to be wasted. 
Changing the treatment is a considerable cause of medicines being returned unused by 
patients. It is reported as a common cause of medicinal waste in many UK studies (Cook, 
1996; Hawksworth et al., 1996; Langley et al., 2005; Mackridge and Marriott, 2007; and 
Coma et al., 2008). A recent systematic review investigating the causative factors of 
medicinal waste by West et al. (2014), reported medicine being changed as the most 
commonly cited reason for medicinal waste. 
2.5.3 Patient non-adherence 
Patient non-adherence is another of the most commonly cited reason for medicinal waste. 
A report by York Health Economics Consortium (YHEC) and the School of Pharmacy, 
University of London (Trueman et al., 2010), comprehensively discussed the issues of 
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compliance and adherence, linking them to medicinal waste. In this report they divided the 
causes of medicinal waste into intentional non-adherence (such as beliefs and side effects), 
unintentional non-adherence (such as omission, forgetfulness), and factors not related to 
adherence (such as patient death, medicines passed beyond the expiry date, or medicine 
prescription changed). Data from Trueman et al. (2010) illustrated that a dislike of taking 
medicines, previous experience and/or anticipation of future adverse side effects (cited 
Benson and Britten, 2003; and Elliott et al., 2007), inconvenience of medicine taking (cited 
Eatock and Baker, 2007), belief that medicines are ineffective (cited Jesson et al., 2005), 
depression (cited Bambauer et al., 2007), and lack of professional support for appropriate 
medicine use (cited Bultman and Svarstad, 2000) can all result in patient non-adherence, 
therefore generating medicinal waste.  Moreover, non-adherence differs according to 
medicine type and medical condition. For example, non-compliance is more likely to 
happen with preventive medicines rather than those used for symptomatic relief (cited 
Piette et al., 2006) and with chronic conditions (over 70% of prescriptions in the UK were 
via repeat prescription) more than acute conditions (Trueman et al. (2010). 
2.5.4 Excess supply of medicines 
Medicines are often prescribed in conditions where there is no clinical need or in an 
amount which is excessive for the needs of the patient, resulting in excess supply of 
medicines and therefore, medicinal waste. This poor prescribing and dispensing practice is 
referred to as system failure rather than patient factors (Trueman et al., 2010). Excess 
supply of medicines was reported as a cause of medicinal waste but less commonly 




2.5.5 Error in prescribing or dispensing processes 
Although it is less usual for errors to occur in the prescribing and dispensing process, errors 
are still made in small numbers resulting in patients receiving improper medicines 
(Mackridge, 2005). Dispensing errors occur in relation to a range of elements including 
strength of medicine, medicine type, medicine quantity, dosage form and package labelling 
(Chua et al., 2003). The overall quantities of improper dispensed medicines are relatively 
small. In the study by Mackridge and Marriott (2007), they accounted for less than 1% of 
medicines returned to CPs and GPs for disposal.  
2.5.6 Other causes of medicinal waste 
In the literature, other less common causes of medicinal waste were also reported such as 
patient unsure why medicines are prescribed (Braund et al., 2008; and Braund et al., 2009), 
unclear instructions (Abahussain et al., 2006; Braund et al., 2008; Braund et al., 2009; El-
Hamamsy, 2011; and Ibrahim et al., 2012), and unknown causes of medicinal waste (Coma 
et al., 2008; and El-Hamamsy, 2011). 
The above causes of medicinal waste can lead to either therapeutic effect loss and/or 
material waste. Therapeutic loss happens when the effects of the medicines are reduced by 
the patient’s failure to take medicines as prescribed. Non-adherence can lead to therapeutic 
loss when medicines are taken, but not as prescribed.  
The next section examines ways in which the problem of medicines waste has been tackled 




2.6 The waste hierarchy and preventive strategies to reduce medicinal waste  
To reduce medicinal waste, one approach is to prevent waste in the first place. Preventing 
waste is at the top of the Waste Hierarchy, a grading system which “ranks waste 
management options according to what is best for the environment” (EWFD, 2008; and UK 
Department of Health, 2013), with ‘prepare for reuse’, ‘recycle’, ‘other recovery’ and 
‘disposal’ all following ‘prevention’ (the preferred choice) in decreasing order of 
preference (Figure 2.3).  
Figure 2.3 Waste hierarchy, adapted from (EWFD, 2008; and UK Department of 
Health, 2013). 
 
A number of strategies have been considered to reduce the generation of medicinal waste 
as the ‘prevention’ or ‘minimisation’ levels. Most of these strategies focused on improving 
patient adherence such as Medicines Use Reviews (MURs), and the use of Monitored 















supply, introducing small prescription charges, and medicinal waste campaigns (Jesson et 
al., 2005; and Trueman et al., 2010).  
2.6.1 Medicines Use Reviews  
The Pharmaceutical Services Negotiating Committee (PSNC) describes MURs as a process 
which covers a variety of interventions undertaken by an accredited pharmacist who runs 
structured adherence-centred reviews with patients taking multiple medicines for long-term 
conditions. The MUR was first introduced in 2005 to help identify and resolve problems in 
medicine taking to improve medicines adherence and stop the supply of unnecessary 
treatments, which theoretically, has the potential to decrease medicinal waste and produce 
financial savings for the NHS (Jesson et al., 2005; and Trueman et al., 2010). There is 
however a lack of data relating to the cost-effectiveness of this practice, which may 
indicate its limited success. A study from the School of Pharmacy, University of East 
Anglia by Wright (2016), described the problems related to MURs to be largely derived 
from insufficient training of the pharmacists, service introduction and targeting, and lack of 
support from GPs with negative GP perceptions about the value of MURs which may result 
in non-implementation of recommendations and reduced cost effectiveness of the service. 
In a contrast, Trueman et al. (2010) argued that with better targeting of MURs to the most 
vulnerable patients, MURs could prove highly effective. Nonetheless, it is reasonable to 






2.6.2 Monitored dosage systems (MDS)  
Elderly patients with long-term chronic conditions in particular are thought to be more 
vulnerable to medicines non-adherence. Evidence suggests that physical or organisational 
difficulties lead to the generation of medicinal waste in this population in particular 
(Beckman et al., 2005). A practice whereby medicines are dispensed by pharmacists into 
multi-compartments labelled clearly with patient and medication details, is increasingly 
used in care homes to aid and simplify the administration of medicines for such patients 
(Trueman et al., 2010). Monitored dosage systems (MDSs) or sometimes referred to as 
multi-compartment medicine devices, or even multi-compartment compliance aids are in 
theory used to aid adherence (Trueman et al., 2010). Two available examples of MDS were 
described in a study by Barber et al. (2009); the cassette MDS which contains multiple 
medicines in one compartment and blister MDS which contain only one dose of medicine 
in each compartment.  
Although the idea is that well targeted use of MDSs could increase cost-effectiveness, 
improve medicine taking, enhance adherence, and thus achieve better desired medicinal 
outcomes, there is uncertainty about this because of a lack of cost-effectiveness data 
especially in patients who have a poor adherence record (Brunenberg et al., 2007). 
Moreover, this system could be responsible for a fair proportion of medicinal waste itself. 
For example, when a prescription is changed, all items already supplied in such devices 
have to be thrown away (Trueman et al., 2010). In addition, MDSs are limited to solid 
dosage forms and do not take into account other dosage forms, such as liquids or inhalers, 
which account for over 40% of doses administered in care homes (Barber et al., 2009).  
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2.6.3 New Medicine Service (NMS) 
The New Medicines Service (NMS), a newer CP service developed from the MUR, 
provides support for patients who are newly prescribed a medicine for a long-term 
condition such as asthma, COPD, type 2 diabetes or hypertension, or who are taking 
anticoagulant therapy or anti-platelets. Patients with a chronic condition who require a 
change of dose or formulation of a current medicine do not count and are not eligible for 
the NMS.  The NMS concentrates on specific patient groups and conditions, and consists of 
three stages; patient engagement, intervention, and follow up (Figure 2.4). 
The NMS is similar in its aims to the MUR, in that it aims to help improve patients 
adherence to medicines with a potential to reduce medicinal waste. Although the NMS is 
cost effective and increases the number of patients who are adherent to their medicines by 
around 10% (Elliott et al., 2014), there is a lack of data that link this intervention directly to 
reducing medicinal waste. 
Figure 2.4 Standard care pathway of patients receiving the NMS from a community 







GP (in most 
cases) refer 



















Refer to GP to 
resolve medicine 
related issues, if any 
Refer to GP to 
resolve medicine 
related issues, if any  
Patients agreed to adhere 
to new medicine or CPs to 
resolve medicine-related 
issues, if any 
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2.6.4 Limiting prescription to 28 days’ supply 
Limiting prescription duration to 28 days can contribute to reducing the generation of 
medicinal waste (Trueman et al., 2010; cited Hawksworth et al., 1996). A UK study by 
Hawksworth et al. (1996) calculated the volumes of medicinal waste returned to CPs and 
found that it was reduced by a third when the repeat prescription duration was shortened to 
28 days only.  Although this study identified an opportunity to reduce medicinal waste, it 
did not take into consideration other consequences associated with shortening prescription 
duration such as the added dispensing cost (pharmacy charges), the added time spent by the 
pharmacists to prepare the prescription, which is perhaps diverting pharmacists away from 
other more useful activities, the added patient travel costs, and the inconvenience the 
patient may experience (ordering monthly prescriptions and having these dispensed) which 
may increase the risk of the patient becoming non-adherent to the treatment (Domino et al., 
2004). In the study by Domino et al. (2004), the increase in patients’ travel costs and the 
additional dispensing fees paid to pharmacies in USA was included in considering the 
benefits of reducing the length of prescriptions. This study suggests supported the idea that 
prescription durations up to three months may be a better option.  
In addition, evidence from an Italian study found that shortening prescription durations in 
hypertensive patients reduced adherence rates in those who had previously been taking 
their medicines appropriately (Atella et al., 2006). The effect on adherence was also 
noticed in the UK report by Trueman et al. (2010), where the application of 28 days 
prescribing in some circumstances reduce patient adherence to their medicines. More 
recently, a research by Davies and Taylor (2013), showed that by imposing the 28 days 
prescription, an extra £150 million in dispensing fees a year is added to the NHS costs in 
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addition to the loss of disease control as a result of non-adherence. The authors of this 
study added that the extra £150 million is considered far more than any possible saving that 
can be generated by imposing the 28 day prescription. In general, there is no consistent 
evidence in the literature which shows a reduction in medicinal waste due to limiting 
prescribing to 28 days. 
2.6.5 Adding extra prescription charges 
The idea of adding extra prescription charges is that when patients have to pay more 
prescription charges for their medicines, they would value their medicines more and this 
would be a nudge to reduce medicinal waste. This may not be true as the increase in 
prescription charges does not always have beneficial effects on reducing medicinal waste 
(Donyai, 2014). Instead it may negatively affect patient adherence by disheartening 
patients from taking their medicines which may lead to unfavourable health consequences. 
In addition, the concept of adding charges to medicines may not affect rich patients, instead 
it may add pressure on patients who cannot afford their medicines (Trueman et al., 2010). 
Currently, there is no data from the UK that support the idea of adding prescription charges 
to reduce medicinal waste.  
2.7 Medicinal waste management strategy and medicines reuse  
Historically, the UK medicinal waste management strategies that have occurred in CPs 
such as disposal of medicinal waste and intermittent medicines take-back campaigns 
remain at the foot of the waste hierarchy, i.e. at ‘disposal’ (see Figure 2.3) (EWFD, 2008; 
and UK Department of Health, 2013). As described in the previous section though, a range 
of waste management strategies in the UK operate at a higher level in the waste hierarchy 
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and these include MURs, MDS, educational campaigns, and limiting prescription to 28 
days. These attempts to address the avoidable causes of medicinal waste such as non-
adherence, excess supply and stockpiling, and prescription and dispensing errors (Jesson et 
al., 2005; and Trueman et al., 2010). The evaluation of these preventive strategies is limited 
and there is a distinctive lack of evidence about the effectiveness of these preventive 
strategies in addressing medicinal waste (Trueman et al., 2010; and West et al., 2014). In 
addition, these preventive strategies failed to address medicinal waste generated due to 
unavoidable causes (e.g. medicine adverse reaction, prescriptions being changed or 
stopped, and patient death) which are considered more common causes of medicinal waste 
(West et al., 2014) and are estimated to account for more than 50% of primary care 
medicinal waste (Trueman et al., 2010). To address the problems of current waste 
management practice, unused medicinal waste, especially those produced as a result of 
unavoidable causes could in theory be redistributed to other patients (Jesson et al., 2005; 
and Trueman et al., 2010). The redistribution of the returned unused medicines to other 
patient is known as medicines reuse, an idea that is on the third tier of the waste hierarchy 
(see Figure 2.3). 
Medicine reuse, the third tier in the Waste Hierarchy could have a positive financial impact 
(Mackridge and Marriott, 2007) as well as a potential to provide more sustainable use of 
returned unused medicinal waste, while reducing the environmental impact of current 
disposal practices (Daughton, 2003).   
2.7.1 Medicine reuse as an intervention to reduce medicinal waste in the UK 
Medicine reuse remains largely unexplored in the UK because unused medicines are not 
currently permitted to be redistributed to other patient.  In the UK if a prescribed medicine 
62 
 
is no longer being used, then conceptually that medicine is waste because it ought to be 
discarded rather than used by another patient. One technical reason is uncertainty about the 
stability and safety of the returned unused medicines (Mackridge and Marriott, 2007). 
In 2007, a UK study by Mackridge and Marriott (2007) investigated returned unused 
medicines in primary care and showed that a considerable amount of these returns were 
unopened and within the expiry date, and probably suitable for reuse. Findings from this 
study are consistent with results from a Swedish study that looked at medicines returned to 
pharmacies of which a good amount remained unopened and had not expired (Ekedahl, 
2003). The evidence from these studies highlights the potential for medicines reuse. 
Moreover, patients returning their medicines to pharmacies often voice a wish for these to 
be reused by others. In fact, an NHS sustainability survey carried out by Ipsos MORI in 
2011 reported half of the respondents were likely to accept re-issued medicines returned to 
pharmacies (NHS Sustainable Development Unit, 2011). There is precedence for medicines 
reuse in other countries. For example, in the United States unused medicines are collected 
and redistributed to patients who are less able to afford the cost of medicines (National 
Conference of State Legislatures, 2012).  
The application of medicines reuse in the UK depends on many factors such as safety and 
stability of returned unused medicines, pharmacist time and agreement to help redistribute 
the returned unused medicines, and people’s uptake and agreement to reuse returned 
unused medicines. Stability and safety is a major concern. In fact, there are characteristics 
that may allow or preclude medicines reuse such as the physical and chemical features, and 
dosage forms (Al-Siyabi and Al-Riyami, 2007). These characteristics could be qualitatively 
assessed by pharmacists to determine if the medicine is suitable for reuse. Only oral solid 
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dosage forms are considered potentially suitable (Al-Siyabi and Al-Riyami, 2007). 
Examples of medicine characteristics and dosage forms for medicines reuse are shown in 
Table 2.4. 
In theory, a formal, quality-assured system for collecting and reusing unused medicines 
could provide an effective solution for the problem of medicinal waste in the UK, 
considering medicines reuse has the potential to address both preventable and non-
preventable causes of medicinal waste, which current waste management strategies do not 
address. 
Table 2.4 Examples of medicine characteristics the preclude or allow medicines reuse 
Reusable medicines Non-reusable medicines  
Medicines intact, and solid oral dosage 
form 
Ampoules and injectable medicines, 
suspensions, suppositories, and 
compounded or reconstituted medicines 
Medicines in multi-dose sealed 
containers from which no doses have 
been withdrawn 
Medicines that require refrigeration e.g. 
insulin 
Medicines with an expiry date >6 
months 
Medicines with an expiry date <6 months 
Solid dosage form sealed by 
manufacturer 
Misbranded or adulterated medicines 
Medicines which are stored correctly, 
with their integrity, packaging or 
labelling not compromised 
Medicines which are stored incorrectly, 
and/or with integrity, packaging or 
labelling compromised (e.g. through 
environmental damage such as water 
damage, crushing, broken seal, torn or 
marked label) 
*Adapted from Al-Siyabi and Al-Riyami (2007). 
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2.8 Toward medicines reuse: structured review of the different therapeutic classes, 
and dosage forms of medicinal waste reported in the UK and internationally 
Knowing information about the different therapeutic classes and dosage forms of medicinal 
waste can help understand more if these medicines can be reused. For example, it is helpful 
to know if medicines being returned are solid (thus have the potential to be reused), liquid, 
injectable or other dosage forms. And whether these medicines are over the counter 
(cheaper / not critical to NHS costs) or other therapeutic classes that could be more relevant 
in terms of cost effectiveness.  Despite a thorough literature review on the causes medicinal 
waste (West et al., 2014), financial and environmental impact of medicinal waste (Trueman 
et al., 2010), disposal practices of medicinal waste (Tong et al., 2011), and the management 
strategies of medicinal waste, only a few studies have reported the type and therapeutic 
classes and dosage forms of unused or returned medicinal waste. In this section, a 
structured review rather than a systematic review of the literature was conducted to report 
the key findings from the literature on medicinal waste in terms of the most common 
therapeutic classes of medicinal waste that are returned by patients and their dosage forms. 
The result from this review was presented at the “Sustainability and You” annual 
symposium in Brighton (22/06/2016) under the title “Toward medicines reuse: a structured 
review of the different classes and dosage forms of wasted medicines reported in the UK 
and internationally”. 
2.8.1 Aim  
To review and summarise the findings from the literature about the different therapeutic 




2.8.2 Methodology and search strategy 
A search strategy of electronic databases was carried out over a period of one month in 
May 2015 (the search strategy was reviewed and updated on July 2017 through which one 
study was added) to identify reports and studies published in English and related to 
therapeutic classes and dosage forms of  medicinal waste. Electronic databases searched 
included; PubMed/Medline, Cochrane library, Grey literature (open grey and British 
library), National Audit Office (NAO), International Journal of Pharmacy practice (IJPP), 
and NICE evidence. The bibliographies of retrieved references were also searched. 
The search used Boolean combinations of a list of terms that included; types of unused 
medicines OR classes of unused medicines OR dosage forms of unused medicines OR 
types of medicinal waste OR classes of medicinal waste OR dosage forms of medicinal 
waste OR types of unused drugs OR classes of unused drugs OR dosage forms of unused 
drugs OR types of drug waste OR classes of drug waste OR dosage forms of drug waste. 
The inclusion criteria was to select studies that reported the therapeutic classes and dosage 
forms of the returned medicinal waste, either dispensed by a prescription or purchased over 
the counter (OTC), or a medicine sample that had expired (or had no clear expiry date) or 
was never fully consumed (or not being used at all), and those limited to the English 
language. The exclusion criteria was for studies that were not published in English, and 
studies that did not described medicinal waste, instead described medical waste, medical 
devices waste, clinical tissue waste. 
A list of 2,428 candidate studies was generated as a result from searching the electronic 
databases. Study selection was carried out initially by screening all the study titles and 
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abstracts, and then by fully screening the candidate forty two studies against structured 
review inclusion and exclusion criteria through which thirty one studies were finally 
included (Figure 2.5).  
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Figure 2.5 Literature search scope shown using the PRISMA flow chart, adapted 
from The PRISMA Group (2009)  
Records identified through 
database searching  
(n = 2,428) 
Records after duplicates removed  
(n = 2,412) 
Records screened  
(n = 2,412) 
Records excluded  
(n =2,371) 
Full-text articles 
assessed for eligibility  
(n = 42) 
Full-text articles 
excluded  
(n = 11) 
Studies included  


































Data obtained from the retrieved studies included demographic information of the 
participants, the types and dosage forms of medicinal waste, study settings and sample size, 
and the time duration of the collection of the returned medicines which varied from 4 week 
up to 12 months all summarised in Appendix 1 and Appendix 2.  
A total of thirty one studies published between 2002 and 2015 and comprising data from 
different countries from around the world (Australia, Austria, Egypt, Ghana, India, Jordan, 
Kuwait, Malaysia, Mexico, New Zealand, Oman, Qatar, Saudi Arabia, Spain, Taiwan, 
Tanzania, Thailand, United Arab Emirates, United Kingdom, United States of America) 
were reviewed.  
In most of these studies, medicinal waste was returned by patients to CPs, GP clinics, 
hospitals, or sometimes collected via medicine take back and medicinal waste campaigns. 
However, four studies, two from India (Gupta et al., 2011; and Aditya and Singh, 2013), 
one from Malaysia (Ali and Ibrahim, 2009), and one from Ghana (Aboagye and Kyei, 
2014), used a survey to collect information about the therapeutic classes and dosage forms 
of medicinal waste without the need of face to face or telephone contact with the 
participants to collect information about the returned medicinal waste. The methodologies 
used and the targeted populations are summarised in Appendix 1. 
2.8.3.1 Demographics of the participants 
Gender was not reported in the majority of the studies. Seven studies (23% of the retrieved 
studies) described the gender of the participants, and it was not clear if there is a gender 
differences associated with the return of medicinal waste. For example, in the studies from 
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Egypt, the number of people who returned their medicinal waste happened to be more male 
than female. Data from the seven studies that described gender reported that medicinal 
waste were more commonly associated with females in three studies (Wongpoowarak et 
al., 2004; Coma et al., 2008; and Kagashe et al., 2014) and more commonly with males in 
three studies (Gupta et al., 2011; Ibrahim et al., 2012; and Aboagye and Kyei, 2014). 
Moreover, one study from Malaysia out of seven (Ali and Ibrahim, 2009) was with female 
students only (Appendix 1). 
Age of participants was described in 15 studies out of 31 (48%). The age profile of the 
participants varied in these studies, and the range was up to 81 years.  Only seven studies 
out of the 15 found a noticeable connection between the mean number of the returned items 
per patient and their age. The majority of medicinal waste was reported to be collected 
from participants with the age range of 60-80 years (Langley et al., 2005; Braund et al., 
2008; Braund et al., 2009; Guirguis, 2010; and Ibrahim et al., 2012). This may simply 
indicate that this age group has more need for medicines or may be more diligent in 
returning them when no longer needed.  Two studies (Aditya and Singh, 2013; and 
Aboagye and Kyei, 2014) found that the majority of medicinal waste were reported to be 
collected from participant’s age range 20-40. The reason is that these studies were among 
students in which the age range will most likely be 20-40 years. It is difficult to generalize 
that the age range of 60-80 years was associated with more medicinal waste as age data 
was absent from the majority of the studies (52%). 
2.8.3.2 Dosage forms of returned medicinal waste 
Dosage forms of the returned medicinal waste were investigated in 18 studies out of the 31 
(58%) (Appendix 2). The dosage forms reported were oral solid dosage forms (tablets, 
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capsules, granules, powders, and lozenges), liquids (syrups, injections, eye drops, 
suspensions, emulsions, and lotions), semisolids (ointments, creams, gel, paste and 
suppositories), and others such as inhalers, sprays, patches, strips, and chewing gum. Oral 
dosage forms were the most common reported dosage form in eleven studies out of 18 
(61%) with percentages ranging from 40.6%−95.6% of all medicinal waste. Moreover, 
tablets were reported to be the commonest of the oral dosage forms. 
One study from Oman by Al-Siyabi and Al-Riyami (2007) reported that during handling of 
the dosage forms most of them appeared in a suitable condition for reuse and were still in 
their original container. However, some changed in colour, consistency and odour and were 
not suitable for reuse. Results from a UK study by Mackridge and Marriott (2007) were 
consistent with the Omani study in which many of the returned medicinal waste were 
reported to be in a condition suitable for reuse as assessed by a pharmacist. Findings from 
the Omani and the UK study are important considering unused medicines are sometimes 
arranged to be sent for reuse in developing countries and such considerations are also 
important for implementing medicines reuse in the UK in the future.  
2.8.3.3 Therapeutic category of the returned medicinal waste 
With the exception of two studies (Braund et al., 2009; and Kagashe et al., 2014) in which 
only prescribed medicines were included in their analysis, the majority of the studies 
include both prescribed and over the counter medicines in the analysis. Moreover, only 
three studies (Garey et al., 2004; El-Hamamsy, 2011; and Gracia-Vásquez et al., 2015) 
included medicine samples in addition to prescribed and over the counter medicines. 
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The majority of the studies (28 out of the total 31) reported the returned medicinal waste by 
therapeutic category and these were included in the current analysis. The remaining three 
studies reporting the medicinal waste individually, by generic or brand name were 
excluded from the analysis of reporting the medicinal waste by therapeutic categorisation 
(Appendix 2).  
The therapeutic categorisation systems used were not the same in all studies. Seven studies 
used British National Formulary (BNF) categories (Langley et al., 2005; Al-Siyabi and Al-
Riyami, 2007; Mackridge and Marriott, 2007; Bradley, 2009; Trueman et al., 2010; El-
Hamamsy, 2011; and Ibrahim et al., 2012). Five studies used the Anatomical Therapeutic 
Chemical Coding (ATC) of the World Health Organisation (WHO) (Abahussain et al., 
2006; Coma et al., 2008; James et al., 2009; Abushanab et al., 2013; Vogler et al., 2014). 
Other ways of therapeutic categorisation included national coding such as the Saudi 
National Formulary (SNF) (Abou-Auda, 2003), Monthly Index of Medical Specialities 
online (MIMS) (Wongpoowarak et al., 2004). The remaining studies used disease and class 
of medicine classification such as diabetes/anti-diabetic. As a result, the returned medicinal 
waste were classified using many different therapeutic categories such as cardiovascular 
system (CVS), central nervous system (CNS), alimentary tract/gastrointestinal tract (GIT), 
respiratory system, musculoskeletal system and joint disease, analgesics and antipyretics, 
non-steroidal anti-inflammatory drugs (NSAIDs), endocrine system, malignant disease and 
anticancer medicines, nutrition and blood, vitamins and minerals gynaecology and 
medicines for urinary tract infection (UTI), antibiotics, medicine for Ear, Nose, and 
Oropharynx and skin medicine. 
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Eight studies out of the 28 (29%) reported that cardiovascular system (CVS) medicines 
were the most common therapeutic category of returned medicinal waste (Langley et al., 
2005; Al-Siyabi and Al-Riyami, 2007; Mackridge and Marriott, 2007; Bradley, 2009; 
Guirguis, 2010; Trueman et al., 2010; Ibrahim et al., 2012; and Vogler et al., 2014). Central 
nervous system (CNS) medicines was reported in four studies out of the 28 (14%) as the 
most common therapeutic category of returned medicinal waste (Braund et al., 2008; 
Braund et al., 2009; James et al., 2009; and Al-Azzam et al., 2012). Other therapeutic 
categories of returned medicinal waste were also reported to be the most common 
therapeutic class but in less number of studies. 
The different therapeutic categorisation systems used in reporting medicinal waste make 
the interpretation of results difficult. For example, one study from India combined 
analgesics with NSAID in one therapeutic category, while three studies from USA, Mexico 
and Thailand described analgesics and antipyretics as one category, and musculoskeletal 
and joint disease medicine as another category. In addition, the number of studies that 
investigated medicinal waste by therapeutic categorisation was reported more from some 
countries compared to others. For example, 8 studies out of twenty eight (29%) were 
reported from two countries UK (4 studies) and New Zealand (4 studies). This makes 
reporting of the results by the number of studies less representative worldwide.  
In order to smoothly report the results from this structured review, firstly, all the different 
therapeutic categories were re-classified according to the BNF categorisation system and 
reported by country (Figure 2.6). For example, NSAIDs were re-classified under 
musculoskeletal system medicines (BNF Chapter 10), analgesic and antipyretics were re-
classified under CNS medicines (BNF Chapter 4), and alimentary tract system medicines 
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were re-classified under gastrointestinal system medicines (BNF Chapter 1). Secondly, in 
countries where more than one report was found such as UK, New Zealand, Jordan, and 
Egypt, the sum of all returns of medicinal waste were calculated and reported by country. 
Figure 2.6 shows the results of the common therapeutic categories of the returned 
medicinal waste reported by country, and after re-classification according to the BNF 
categorisation system. In the UK, results showed that CVS medicines were the most 
common therapeutic class of medicinal waste. A possible explanation is that CVS 
medicines is one of the commonly prescribed medicines comprising approximately 20% of 
all the medicines prescribed in the UK because of the prevalence of cardiovascular disease 
in the UK. Moreover, CVS medicines are one of the commonly amended classes of 
medicine because of frequent changes in the doses and drugs necessitated by updated 
guidelines (Langley et al., 2005).  CNS medicines were the second most common 
therapeutic class of the medicinal waste in the UK. Other therapeutic categories of 
medicinal waste such as gastro intestinal and respiratory medicines were also reported but 
less commonly in the UK. Similar results to the UK were reported from countries such as 
Australia, Austria, Mexico, and Oman in which CVS medicines were the most common 
therapeutic class of medicinal waste. Moreover, in Mexico, Australia and Austria, 
musculoskeletal system medicines were also common and came in second place. 
In New Zealand, results showed that CNS medicines were the most common therapeutic 
class of medicinal waste. The reason behind having CNS medicines the commonest 
medicinal waste is that paracetamol was the most common individual returned item as 
waste. Other therapeutic categories of medicinal waste such as gastrointestinal, 
cardiovascular and musculoskeletal system medicines were reported in New Zealand but 
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less commonly. In Jordan, results were similar to New Zealand, in which CNS medicines 
were the most common therapeutic class of medicinal waste and paracetamol was the most 
common individual tablet returned as waste (Braund et al., 2007). The reason of having 
CNS medicines as the commonest category of medicinal waste in Jordan is that analgesics 
are commonly used as self-medication for headache which is a generally common 
discomfort in Jordan (Al-Azzam et al., 2012). Other therapeutic categories of medicinal 
waste such as gastrointestinal, anti-infective, musculoskeletal system medicines were 
reported in Jordan but less commonly. 
In Spain, results showed that both gastrointestinal system (215 items, 18.3%) and CNS 
medicines (214 items, 18.2 %) were the most common therapeutic classes of medicinal 
waste. While in Saudi Arabia, results showed that both respiratory system (16.8%) and 
CNS medicines (16.4%) were the most common therapeutic classes of medicinal waste. 
In Egypt, anti-infective medicines were the most common therapeutic class of medicinal 
waste. The reason for antibiotics to be a commonly reported medicinal waste in Egypt was 
explained as antibiotics are available without prescription and also not completing the 
course of antibiotic treatment as symptoms resolve. Other therapeutic categories of 
medicinal waste such as CVS, and gastrointestinal system medicines were reported in 
Egypt but less commonly. Similar result to Egypt came from Tanzania, in which anti-
infective medicines were the most common therapeutic class of medicinal waste. Other 




Results from USA, Thailand, and India showed that musculoskeletal system medicines 
were the most common therapeutic class of medicinal waste. The reason is that NSAID 
was the most common group of the medicinal waste reported in these countries.  
Finally, result from Malaysia showed that vitamins and minerals were reported as the most 
common therapeutic category of medicinal waste.  In this study, all participants were 




Figure 2.6 The common therapeutic categories of medicinal waste reported from different countries in the world, re-classified 
according to BNF categorisation system.






















4 Central nervous system
5 Infections
6 Endocrine system
7 Obstetrics, gynaecology, and urinary-tract
disorders
8 Malignant disease and immunosuppression
9 Nutrition and blood
10 Musculoskeletal and joint diseases
11 Eye
12 Ear, nose, and oropharynx
13 Skin
14 Immunological products and vaccines
15 Anaesthesia




Despite extensive literature on medicinal waste, none of the literature reviews to date have 
specifically focussed on the therapeutic classes and the dosage forms of the returned 
medicinal waste. This structured review provides good insight on the different therapeutic 
categories and dosage forms of the returned medicinal waste from different countries 
around the world. The principal finding was that CVS medicines were reported as the 
commonest returned medicinal waste, certainly in the UK. It could be argued that the 
therapeutic category of medicinal waste could be as important as the quantity of the 
returned medicinal waste in terms of financial value. To clarify more, in the study by 
Braund et al. (2009), the volume of medicinal waste from respiratory system medicines 
were about the half (8%) of the medicinal waste of the CNS medicines (19%), but the cost 
of the medicinal waste in the respiratory group was 20% compared to 17% in the CNS 
medicines. This illustrates the financial implications of knowing the therapeutic 
categorisation of medicinal waste. 
This structured review reported the results of the commonly returned medicinal waste from 
different countries around the world. However, these results should be interrupted 
carefully. Firstly, findings are applicable to medicinal waste that were returned by patients 
only and not taking into consideration that the majority of medicinal waste were reported to 
be disposed of into household garbage or via the sink or stockpiled at home (James et al., 
2009). Secondly, the small sample size and the small number of returns of medicinal waste 
in about one third of the studies made these studies less representative. Finally, results from 
this structured review cannot be generalised. For example, results from Egypt and Tanzania 
of having antibiotics as the most common therapeutic category of medicinal waste cannot 
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be generalised to other countries where antibiotics are only available under a prescription 
such as UK or USA. Moreover, results from the Malaysian study which reported that 
vitamins and minerals were the most common therapeutic category of medicinal waste is 
impossible to generalize to the whole population as this was among only female Malaysian 
students.  
This structured review has some other limitations which should also be acknowledged. 
Firstly, it included results from reports, thesis, audit, and grey literature (British library, and 
open grey), and there is a risk that some studies were not included as a result of not 
performing a systematic review. Secondly, the search strategy was restricted to studies that 
were published in the English language only. Thirdly, the reasons behind accumulation of 
the returned medicinal waste from each therapeutic category were not clearly evidenced. 
Some studies provided possible explanations that may be applicable only to the country 
from which data was obtained, and it may not be applicable to generalise these 
explanations. Finally, information about what motivates people to return their medicinal 
waste and if they returned certain type of medicinal waste over others were not investigated 
and remain unknown.  
2.8.5 Conclusion 
This structured review identified a limited number of studies from the literature which 
investigated the different therapeutic classes and the dosage forms of medicinal waste that 
were returned by patient to the CPs. Although there was variability between the levels of 
medicinal waste reported in different countries, findings from the UK were relatively 
consistent. In the UK, cardiovascular medicines were the category of the returned 
medicine most associated with waste. People’s behaviour and the factors that could 
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determine people’s decisions to return their medicinal waste or stockpiled them at home or 
disposed of them into the landfill or water system were not investigated. In addition, no 
formal research study has examined the general public’s views about medicines reuse and 
whether they are willing to reuse medicines returned to CPs in the future. This review 
could provide the basis for a feasibility study investigating tablets prescribed for 
cardiovascular conditions as candidates for medicines reuse which could be the initial step 
for implementing medicines reuse before it is extended to other therapeutic categories of 
medicine in the future. But before such a study could even be planned, there is also a gap in 
the literature in that there are no qualitative studies that have investigated people’s beliefs 
about medicines reuse and whether they would even consider reusing medicines in the 
future.   
2.9 Gap in research about medicines reuse 
Medicine reuse remain largely unexplored because unused medicines are not currently 
allowed to be re-dispensed to another patient in the UK, instead, medicines returned to a 
pharmacy are automatically considered to be waste that requires appropriate disposal. The 
main reason is that stability and safety of medicines cannot be ensured once medicines 
leave the formal distribution chain (i.e. are given out to patients). There is an opportunity to 
check some elements relating to the safety and stability of returned unused medicines using 
a unique identifier (a 2-dimension barcode) and an anti-tampering device which are yet to 
be introduced but on the horizon. The European Commission agreed in 2016 these two 
safety features are to be placed on the packaging of most human medicines to prevent the 
entry of falsified medication into the supply chain (European Medicines Agency, 2016). In 
the UK, manufacturers will be required to place the safety features on the packaging of 
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most prescription medicines and certain non-prescription medicines no later than 9 
February 2019 (European Medicines Agency, 2016). The two safety measures can 
potentially be used to evaluate if any returned unused medicines can be suitable to be 
reused by checking their authenticity. 
As stated previously, the implementation of medicines reuse in the UK would rely heavily 
on guaranteeing the safety and stability of the returned medicines, people’s uptake of this 
idea, and pharmacist’s views (time and agreement) about the possibility of implementing 
medicines reuse in the future. Moreover, the pharmaceutical company involvement would 
also be needed. This is because there are other features that might need to be investigated 
and added to product packaging in order to help verify the physico-chemical integrity of 
unused returned medicines. For example, it is possible to add a label that is sensitive to 
temperature which can indicate the storage temperature under which the medication has 
been kept while in the patient’s charge. Pharmaceutical companies may also need to be 
involved in repackaging any returned unused medicines. To move toward medicines reuse 
in the UK, areas that need to be explored are people’s and pharmacist’s views about 
medicines reuse, and whether and how the pharmaceutical industry can contribute to 
guaranteeing storage conditions and/or repacking the returned unused medicines.  
There has been little work carried out previously at examining perceptions about medicines 
reuse in the UK, apart from a study that examined whether pharmacists from one Health 
Board in South East Wales could come to some consensus on the barriers and potential 
solutions towards medicines reuse (McRae et al., 2016b). The results showed that 
pharmacists would be willing to redistribute medicines if certain criteria were met such as 
81 
 
being solid dosage forms with a tamper evident seal. The public’s views about medicines 
reuse have not been investigated in the UK and this provided the basis for the current work.  
To date, no formal research study has examined the general public’s views about and their 
openness to the idea of medicines reuse. It is important to develop an understanding of 
what the public thinks about medicines reuse if the idea is to be pursued in the future. This 
thesis sets out to capture people’s views about reusing medicines in the future using a 
psychological theory as its framework. The work in this thesis uses the Theory of Planned 
behaviour (TPB) as its psychological framework to address the feasibility of medicines 
reuse from the perspective of the general public. The next chapter explains the rationale for 
underpinning this work using a psychological theory and it details TPB as well as its 




CHAPTER 3 OVERVIEW OF PSYCHOLOGICAL 
THEORIES RELEVANT TO UNDERSTANDING PEOPLE’S 
BELIEFS AND INTENTIONS TOWARD REUSING MEDICINES 
3.1 Introduction 
There are several factors that can influence people’s beliefs toward and intentions for 
conducting any behaviour such as reusing medicines. These factors can include potential 
advantages and disadvantages of performing the behaviour (i.e. medicines reuse), but also 
views about the safety and storage conditions of the retuned unused medicines, and a social 
pressure or normative belief about the behaviour. However, understanding these factors 
and the approaches that potentially can change people’s intentions to reuse medicines is not 
straightforward. Psychological theory can be applied to help underpin the understanding of 
these factors. Such an approach provides a structured framework that can be used to 
formally design a questionnaire to capture people’s beliefs and intentions toward reusing 
medicines. More importantly, it can be used in order to understand which elements of 
belief would need to be modified (e.g. through an intervention) before the behaviour takes 
place. 
3.2 Psychological theories to understand people’s beliefs and intentions  
Human behaviour, how it is defined and the methods by which it might be studied, depends 
on the disciplines and interests of the researchers, with one discipline being psychology 
(Morris et al., 2012). Psychological theory can provide a generalizable organising 
framework for studying health-related behaviour (Michie et al., 2005). This is because as 
well as providing a means through which behaviour can be understood, health psychology 
theories provide a mechanism for influencing and changing people’s behaviour. 
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Thus the application of a framework to study people’s cognitive and behavioural responses 
to health-related issues could enable researchers and others to predict people’s health 
behaviours, and in turn, attempt to change them (Godin et al., 2008). This will be detailed 
later in this chapter. However, in the meantime, there are many different and overlapping 
psychological theories and models available in the literature that can be applied or have 
been already applied to study health-related behaviours which are important to review and 
consider (Armitage and Conner, 2001; Taylor et al., 2006; and Ogden, 2012). In addition, 
lack of guidance on how to choose the most suitable theory for a particular research interest 
makes the selection of the relevant theory not straightforward (Michie et al., 2005; and 
Michie, 2008).  One potential approach to improve the selection of a theory across relevant 
disciplines is to consider those psychological theories that could be of a potential use in 
informing public health questions, and then to narrow down the range of these theories to a 
specific health domain or topic. The identification of the range of theories could help select 
a relevant theory that can address the particular behaviour, population and context of the 
research question (Davis et al., 2015).   
There are many psychological theories and models attempting to explain the relationship 
between people’s thoughts, beliefs, decisions and behaviours, however, not all are helpful 
or in fact evidenced based (Donyai, 2012). The next section provides an overview of a 
number of health related social cognitive theories that are commonly and more frequently 
used (Armitage and Conner, 2000; Taylor et al., 2006; and Ogden, 2012). These include; 
the Health Belief model (HBM), Protection Motivation Theory (PMT), Trans-Theoretical 
Model of Health Behaviour Change (TTM/SoC), Theory of Reasoned Action (TRA), and 
Theory of Planned Behaviour (TPB). The purpose is to review these theories and outline a 
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rationale for the theory that was selected for this thesis. Note that although the majority of 
the theories outlined below focus on behaviours that relate directly to health, e.g. smoking 
cessation, there is precedence of applying these theories to other behaviours such as those 
relating to the environment and waste reduction. The main focus of the next sections 
therefore is to outline the theories but then argue for the external validity of the TPB to this 
study. 
3.3 Overview of common health related social cognitive theories 
3.3.1 Health Belief Model (HBM) 
The Health Belief Model (HBM) is one of the earliest health models developed by a group 
of psychologist in the 1950s who attempted to predict the preventive health behaviours and 
the behavioural response to treatment in acutely and chronically ill patients (Rosenstock, 
1974). Over recent years, the HBM has been used to improve many health-related 
interventions by predicting a wide variety of health-related behaviours (Carpenter, 2010; 
Ogden, 2012). Although the current thesis does not focus on a particular health condition or 
a behaviour that can directly impact on health, nonetheless this theory is reviewed because 
of its prevalence in health psychology research. The core beliefs of HBM constructs consist 
of; perceived susceptibility including a person’s perception regarding risk of health 
behaviour (e.g. susceptibility to illness); perceived severity of the threat to health behaviour 
(e.g. severity of the illness); perceived benefits from the behaviour (e.g. stopping smoking 
will save money and reduce my illness); perceived barriers towards behaviour or the costs 
involved in performing the behaviour (e.g. stopping smoking will make me irritable); cues 
to actions which might be internal (e.g. family member illness) or external (e.g. television 
news and reports); and demographics and socio-economic values (e.g. age, ethnicity, 
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education and income) (Taylor et al., 2006; Ogden, 2012). Each of the individual 
constructs or when combined together can be used to predict the likelihood that the 
behaviour will occur.  
The HBM has received many criticisms. Firstly, HBM has a weak predictive power in most 
areas of health-related behaviour (Armitage and Conner, 2000; Taylor et al., 2006). This is 
mainly related to the factors such as poor construct definition, and lack of other core 
psychological factors including environmental or economic issues that might also have an 
impact on clinical practice behaviours (Armitage and Conner, 2000; Taylor et al., 2006). In 
addition, variables such as intentions to carry out a specific behaviour, and the influence of 
social pressure, that can be highly predictive of behaviour are both neglected from HBM 
(Conner, 2010). Secondly, HBM does not have clear guidelines regarding how variables 
might be combined and operationalised, especially the constructs of benefits and barriers 
(Armitage and Conner, 2000). Although there is a lot of conflict in the literature around the 
use of HBM, studies have used this model or different aspects of  the model’s constructs to 
predict health related behaviours such as taking part in screening for hypertension, 
screening for cervical cancer, genetic screening, exercise behaviour, decreased alcohol use, 
changes in diet and smoking cessation (Taylor et al., 2006; Ogden, 2012). 
3.3.2 Protection Motivation Theory (PMT) 
The Protection Motivation Theory (PMT) is considered a revised version and expansion to 
HBM which includes additional constructs. According to PMT, the main determinant to 
carry out a health-related behaviour is protection motivation or intention to perform the 
behaviour, and the behaviour change may be achieved by engaging with an individual’s 
fears (Munro et al., 2007).  Protection motivation is determined by threat appraisal and the 
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coping appraisal process. Threat appraisal is referred to as a cognitive process the 
individual uses to assess the level of threat (including severity, susceptibility, and fear), 
while coping appraisal process refers to the individual’s assessment of their ability to carry 
out risk preventive behaviour which influences the protection motivation (including 
response effectiveness and self-efficacy) (Janmaimool, 2017). Together, the outcome of the 
appraisal processes is classified into either adaptive (adopting of health behaviour) or 
maladaptive responses (avoidance or denial of health threat) (Conner, 2010; Ogden, 2012).   
The PMT has been successfully applied to predict a number of health behaviours and is 
less widely criticised compared to HBM (Norman et al., 2005). However, a lot of HBM 
criticism could still be applied to PMT. For example, PMT generally considers that 
individuals are a rational information processor (except fear constructs which does include 
an element of irrationality). Moreover, PMT does not account for habitual behaviours (e.g. 
brushing teeth), and does not include a role for social (e.g. what others do) and 
environmental factors (e.g. opportunities to exercise or eat properly at work) (Ogden, 
2012). 
3.3.3 Trans-Theoretical Model of Behaviour Change or Stages of change 
(TTM/SoC) 
The TTM/SoC is a more complicated model compared to TRA, and TPB (both described 
below), and HBM, and PMT (both described above) and the only one that was designed 
directly to potentially facilitate behavioural change (Taylor et al., 2006).  TTM/SoC is a 
widely used cognitive model which divides individuals into five stages that demonstrate 
different levels of motivational willingness (to change their behaviour). These stages were 
first developed in relation to smoking and include; pre-contemplation (e.g. I am happy 
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being a smoker and intend to continue), contemplation (e.g. recently, I have been coughing 
a lot, maybe I should think about stopping smoking), preparation (I will buy fewer 
cigarettes), action (e.g. I have stopped smoking), and maintenance (e.g. I have stopped 
smoking for five months now) (Morris et al., 2012; Ogden, 2012). In some versions of the 
TTM/SoC, the final stage, termination, is added. In this stage the new behaviour is seen as 
being fully determined after a period of five or more years. (Taylor et al., 2006).  
The transition between stages is controlled by self-efficacy and decisional balance 
constructs. Self-efficacy (which is also included in HBM and TPB) is expected to increase 
as individuals move toward action and maintenance stages. Decisional balance measures 
the individual’s relative balancing of advantages and disadvantages of changes which 
combine to form a decision. This balance between advantages and disadvantages depends 
mainly on which stage of change the individual is in (Prochaska and Velicer, 1997). There 
are many criticisms regarding the complexity of the TTM/SoC model, how distinctive the 
stages are, and whether the individual should move through each stage. Moreover, changes 
between stages can occur so quickly which makes the stages less valuable (Ogden, 2012). 
Consequently, the TTM/SoC model is less clear on how individuals change or the reasons 
some change more efficiently than others (Morris et al., 2012).   
Another criticism of the TTM/SoC model is that the effectiveness of a stage based 
intervention differs based on the behaviour (West, 2005). Moreover, the fact that the stages 
in TTM/SoC are bound to a particular time interval is understood to be deceptive. As a 
result West (2005) proposed that a more coherent definition of the stages in TTM/SoC 
model is required. The criticism of TTM/SoC is mainly regarding the standardisation and 
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the consistency of the use of the TTM/SoC model which has also been raised recently by 
Friman et al. (2017). 
3.3.4 Theory of reasoned action (TRA) and Theory of planned behaviour (TPB) 
The TRA was developed by Fishbein and Ajzen in 1967 to examine the relationship 
between beliefs, attitudes, intentions and behaviour (Fisbein and Ajzen, 1975). The TRA 
assumes that individual’s intention to perform a behaviour is the most proximal antecedent 
of that behaviour. Individuals’ intentions are acknowledged by their attitudes toward 
performing the behaviour and the subjective norms relating to behavioural performance. 
Therefore, the TRA is an important model in which the individual is positioned within the 
social context (Ogden, 2012). TRA combines two sets of belief variables, the behavioural 
attitudes and the subjective norm as a requirement for individual’s intention to perform a 
behaviour (Figure 3.1). The TRA was expanded by Icek Ajzen to develop TPB.  





In TPB, Icek Ajzen attempted to evolve and extend TRA by adding the perceived 
behavioural control (PBC) construct. PBC is a construct describing the factors that control 
the individual’s decision to carry out the behaviour. In addition, PBC is considered a 










behaviour (Ajzen, 2002). Intention to perform the behaviour is the key determinant of 
behaviour in TPB. Intention potentially is the best predictor of behaviour (Armitage and 
Conner, 2001). According to TPB, the stronger the intentions to engage in the behaviour, 
the more likely the behaviour will be performed (Ajzen, 1991). 
The TPB proposes a framework in which cognitions (i.e. behavioural, normative, and 
control beliefs) and broader constructs (i.e., attitude toward the behaviour, subjective norm, 
perceived behavioural control, and intention) influence behaviour (Steinmetz et al., 2016) 
(Figure 3.2). The TPB proposes a framework to describe how human action is guided, 
suggests that intentions should be conceptualized as plans of action in pursuit of 
behavioural goals, and highlights behavioural intentions as an outcome of a combination of 
several beliefs, that is, the combination of attitude, subjective norms, and PBC (Francis et 
al., 2004; Ogden, 2012). To clarify this, if TPB is applied to alcohol use, then the TPB 
would make the following predictions: if a person believes that decreasing their alcohol 
intake would make their life better and would be useful to their health (i.e. attitude toward 
the behaviour) and believes that important people in their life would like them to decrease 
alcohol intake (i.e. subjective norm), and in addition believes that they have the ability of 
drinking less amount of alcohol due to their past behaviour and evaluation of internal and 
external factors (i.e. PBC), then this will predict high intention to decrease their alcohol 
intake. Moreover, the PBC can predict behaviour without the effect of intention. For 
instance and relating to exercise, if PBC reflects actual behaviour; a belief that a person 
would not be able to exercise, because they are physically not able to, would be a better 
predictor of their exercising than their high intention to exercise (Ogden, 2012).  
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Figure 3.2 Theory of Planned Behaviour Model (TPB) with background factors 
(Ajzen, 2017) 
 
3.4 Assessment of the ability to use TPB to predict people’s behavioural beliefs 
and their intentions to reuse medicines in the future  
3.4.1 TPB compared to TRA, HBM, PMT, and TTM/SoC 
TPB, TRA, HBM, PMT, TTM/SoC are special models that have in common a number of 
constructs that concentrate on individual behaviour and behaviour changes (Armitage and 
Conner, 2000; and Morris et al., 2012; Rosenstock, 1974). Although the majority of these 
constructs have originated from a common basis and share similar or overlapping 
characteristics, some of these constructs are unique to a particular theory and different from 
other theories (Armitage and Christian, 2003; Noar and Zimmerman, 2005; and Donyai, 
2012). For example, the perceived threat construct of HBM described as perceived 
seriousness and perceived susceptibility is different from all other constructs in TRA, TPB, 
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and TTM/SoC. Moreover, the HBM includes objective demographics and cue to action 
construct that are not included in TRA, TPB, and TTM/SoC which can be seen as a 
potential advantage (Taylor et al., 2006). However, the evidence identified in practice in 
the review by Taylor et al. (2006) indicated that the HBM has not normally been used 
effectively to take advantage of having objective demographics and cue to action constructs 
as a potential strength (Taylor et al., 2006). The HBM is more health behaviour focused 
compared to TRA and the TPB, which are designed to be more applicable at greater levels 
of generalisation. Thus, TRA and the TPB can be applied outside as well as inside the 
health discipline (Ajzen, 2002).  
The TRA and the TPB have in a common identical attitudinal and social norm constructs. 
In addition, the TPB contains a PBC construct relating to control related beliefs and self-
efficacy (Ajzen, 2002). The TRA and the TPB have less, but more accurately defined 
constructs, and are mathematically better specified than the HBM and the TTM/SoC. This 
promotes the adequacy and consistency of the use of TRA and TPB (Taylor et al., 2006). 
The TPB is more appropriate to predicting behaviour and has been widely used inside and 
outside health-related research (Armitage and Conner, 2001; Ajzen, 2002; Taylor et al., 
2006; and Morris et al., 2012). There is meta-analytical and systematic review evidence 
that the predictive performance of both the TRA and the TPB is superior to that of the 
HBM. Moreover, the additional constructs contained in the TPB allow it to have a greater 
predictive percentage of overall behavioural variance than the TRA (Taylor et al., 2006). 
The available evidence in the review by Taylor et al. (2006) suggests that the application of 
TPB in countries like USA and UK can predict around 20-30% of observed variance of 
health behaviours.  Moreover, there is a strong correlation between behaviour and both the 
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attitudes towards the behaviour and PBC constructs of TPB. However, the correlation 
between behaviour and subjective norms is less and sometimes referred to as a weak 
correlation (Morris et al., 2012). The issue of the weak correlation was argued by Armitage 
and Conner (2001) to be probably methodological as a small number of studies that 
measured subjective norms fairly reported strong relationships with behaviour (Morris et 
al., 2012).  
3.4.2 Support for the application of TPB to predicts people’s behaviour and 
intention towards reusing medicines  
TPB is a framework which has been widely applied in a variety of domains for predicting 
and explaining behaviour, and increasingly for conducting behaviour change interventions 
(Ajzen, 1991; Perkins et al., 2007; and Steinmetz et al., 2016). There have been several 
reviews and meta-analyses which describe the generalisability of TPB use in different 
behavioural domains and its effectiveness to predict a range of health behaviours (Armitage 
and Conner, 2001; Taylor et al., 2006; and Ogden, 2012). The generalisability of TPB-
based effective interventions is reviewed in the recent meta-analysis by Steinmetz et al. 
(2016) and summarised into eight behavioural domains; alcohol and drugs, adherence to 
medical regimens, hygiene, nutrition, physical activity, sexual behaviour, traffic, and work 
and school behaviour. These domains involved studies that were concerned with reducing 
alcohol consumption (Hagger et al., 2012; Armitage et al., 2014), smoking cessation 
(Bledsoe, 2006; Topa and Moriano, 2010), predicting adherence to medicines (Abraham et 
al., 1999; Chisholm et al., 2007), promoting hand hygiene (Yardley et al., 2011), nutrition 
related intervention such as promoting whole grain foods by dieticians (Chase et al., 2003) 
and food safety (Milton and Mullan, 2012), physical activity (Hagger et al., 2002) and 
weight control (Schifter and Ajzen, 1985; McConnon et al., 2012), sexual behaviour related 
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interventions such as promoting safer sex practices (Armitage and Talibudeen, 2010; Booth 
et al., 2014; and Asare, 2015), traffic related interventions such promoting school-age 
cyclists to wear safety helmets (Quine et al., 2001), and  promoting driver’s compliance 
with speed limits (Elliott and Armitage, 2009), and work related interventions such as 
promoting work health and safety (Sheeran and Silverman, 2003). In addition to the above 
domains, TPB-based interventions have been applied in other domains such as environment 
and sustainability (Stern, 2005; Koger and Winter, 2011; and De Leeuw et al., 2015), reuse 
(Sumaedi et al., 2016), recycling (Davis and Morgan, 2008; Pakpour et al., 2014) and 
intention to donate to charity (Van der Linden, 2011). These are examples of studies which 
applied TBP in different domains that reflect the generalisability of TBP.    
The effectiveness of TPB-based interventions in predicting behavioural changes were 
reviewed in a number of studies and meta-analyses. For example, in the quantitative meta-
analysis review of 185 independent studies published up to the end of 1997, Armitage and 
Conner (2001) found that across all behaviours, the average multiple correlation of 
intention and PBC was 0.52 with behaviour accounting for 27% of the variance, and the 
average multiple correlation of attitude, subjective norm and PBC with intention was 0.63 
accounting for 39% of the variance. Moreover, when the behaviour measures were self-
reports, the TPB accounted for 11% more of the overall variance than when the behaviour 
were externally observed. Finally, in the study by Armitage and Conner (2001), the 
correlation between subjective norms and behavioural intention was found to be weaker 




Ajzen (1991), conducted a review of 16 studies involving the TPB to examine the 
effectiveness of TPB-based interventions in predicting behavioural changes and found that 
attitude, subjective norm and PBC accounted for a significant amount (20% to 78%) of 
variance in behavioural intention. The multiple correlations between behavioural intention 
and its three predictors (i.e. attitude, subjective norm and PBC) ranged from (0.43 to 0.94), 
with an average correlation of 0.71. Moreover, Ajzen (1991) added that PBC together with 
intention were significant predictors of behaviour, with the average multiple correlation 
being 0.51.  
Finally, in a review by Godin and Kok (1996) of 56 studies, the variance in behavioural 
intention explained by TPB constructs was 40.9% and PBC was a significant predictor in 
85.5% of health related studies, followed by attitude (81.5%) and subjective norm (74.4%). 
PBC contributed a mean additional 13% of variance to the prediction of behavioural 
intentions, over and above the attitude and subjective norm, and 12% to the prediction of 
behaviour. The PBC figures reported by Godin and Kok (1996) were higher than those 
reported by Armitage and Conner (2001). Subjective norm was a strong predictor of the 
behaviour in the study by Godin and Kok (1996) compared to the Armitage and Conner 
(2001) study, which was reported to be a weak predictor of the behaviour.  
These reviews and meta-analyses support the empirical applicability and popularity of 
TPB, and demonstrated that TPB is quite a successful model in explaining and predicting 
behavioural intentions and actual behaviours. In this thesis, TPB is applied to understand 




3.5 Aims of the research 
This thesis aimed to capture people’s beliefs and intentions towards reusing medicines that 
are returned to pharmacies by using TPB as its underpinning framework. Medicine reuse 
relates to the idea that unused prescribed medicines returned by one patient to a pharmacy 
can be re-dispensed and therefore reused by another patient as a strategy for reducing 
medicinal waste in the UK. The objectives were first (i.e. phase one) to use interviews to 
define medicines reuse as a behaviour; and identify behavioural, normative, and control 
beliefs about medicines reuse. Then (i.e. phase two), to construct, validate, pilot and 
develop a questionnaire which captures representative views about medicines reuse in the 
UK and people’s intentions and willingness to reuse medicine in the future. The final part 
of this thesis (i.e. phase three) focuses on overall conclusions, recommendations and 
explaining future work that can arise from the findings of this study. 
3.6 Rationale of the research design 
This is a mixed method study design using qualitative interviews to define the behaviour 
(i.e. medicine reuse), identify normative, behavioural, and control beliefs about the 
behaviour, and develop items of the indirect measures of TPB, and then use the developed 
Medicine Reuse Questionnaire (MRQ) to quantitatively capture people’s beliefs and 
intentions to reuse medicine in the future. The mixed methods design of having a 
qualitative-quantitative approach was determined by the use of TPB which requires first 
performing the elicitation qualitative study, then applying the developed questionnaire (i.e. 
MRQ) quantitatively (Francis et al., 2004; and Ajzen, 2006). 
During the qualitative study, the face to face interviews as a data collection method was 
chosen over a focus group approach. The reason behind choosing face to face interview is 
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that first TPB is about individual not group opinions, and second there was a risk of people 
leading each other during the focus groups which would affect the results of this research, 
for example by failing to capture the breadth of possible themes (Ajzen, 1991; Ajzen, 2011; 
and Ajzen, 2017). In addition, the decision to apply thematic analysis (TA) was influenced 
by simplicity and theoretical freedom of TA and its ability to provide rich and detailed 
themes. In addition, TA allow for the application of inductive, deductive and mixed 
inductive-deductive approach (Braun and Clarke, 2006). Other options were not used either 
because of complexity of having many different types that were again not directly relevant 
to this work (e.g. light and full grounded theory) or not being applicable to this study (e.g. 
discourse analysis) (Goulding, 2017). Finally, the semi-structured face to face interview 
was chosen as a data collection method over full in-depth unstructured interview first 
because of the use of TPB which requires a deductive approach of mapping themes against 
pre-existing concepts, and secondly, because the purpose of this study was to develop and 
construct the MRQ, necessitating a structured approach.   
There are many psychological theories and models attempting to explain the relationship 
between people’s thoughts, beliefs behaviours, however, not all are helpful (i.e. some have 
been criticised in terms of effectiveness and their predictive power, and less clear construct 
development and unclear guidelines about the how to measure the behaviour or the intention toward 
the behaviour compared to TPB) or in fact some are thought not to be evidenced based. The 
Health Belief model (HBM), Protection Motivation Theory (PMT), Trans-Theoretical 
Model of Health Behaviour Change (TTM/SoC), Theory of Reasoned Action (TRA), and 
Theory of Planned Behaviour (TPB) were reviewed in this chapter and the effectiveness and 
superiority of the TPB over other theories was clearly illustrated. To summarise more, TPB has 
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more accurately defined constructs, and is mathematically better specified than the HBM 
and the TTM/SoC. In addition, TPB is more appropriate to predicting behaviour (i.e. the 
effectiveness and predictive power) and has been widely used inside and outside health-
related research (i.e. the generalisability of TPB include application to; alcohol and drugs, 
adherence to medical regimens, hygiene, nutrition, physical activity, sexual behaviour, 
traffic, and work and school behaviour). Finally TPB has unique concepts which can 
predict performing the behaviour (i.e. people are able to perform the behaviour or not) 
without the need to know their intention. This is important, for example people may intend 
to do exercises (i.e. intention construct) but actually not perform the behaviour (i.e. 
exercise), simply because they are not able physically to do exercise while actually 
intending to do so (i.e. PBC). 
3.7 Steps applied to manage the development of a TPB Medication Reuse 
Questionnaire (MRQ) and thesis outline 
3.7.1 Defining the behaviour of interest and selecting the population  
When TPB as a psychological framework was applied, certain steps were followed to 
enhance the validity of the research. These steps were according to recommendations made 
by Ajzen (2006) and Francis et al. (2010). First, a formal definition of the behaviour under 
investigation was defined. The TACT principle was used, by which the behaviour was 
defined according to target, action, context, and time. For example, for the behaviour 
“capturing people’s beliefs and intention to reuse medication that are returned to 
pharmacies by another patient” the target is people, the action is to capture people’s beliefs 
and intentions to reuse medication, the context is reusing medication that are returned to 
pharmacies by another patient, and the time is in the future. A sample of population of 
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interest for an elicitation (qualitative study) study was determined. The sample size for the 
elicitation study was aimed to be between 15−20 participants.  
3.7.2 Completing the elicitation Study 
An elicitation study was used to develop the indirect measures (behavioural beliefs, 
normative beliefs, and control beliefs) for all the predictor constructs of TPB (attitude, 
subjective norms, and PBC). A sample of 19 participants was interviewed face to face and 
the data were analysed using thematic analysis. Themes obtained from the elicitation study 
were classified according to the TPB constructs (Chapter 3) and were used to develop the 
questions related to the indirect measures of the TPB.  
3.7.3 Developing the Medication Reuse Questionnaire (MRQ) 
The MRQ questions were of three types; first the questions developed from the elicitation 
study which were related to the indirect measures of TPB, second, the question related to 
the direct measures of TPB, and third, the questions related to the background factors that 
are important and related to medicines reuse. All the MRQ questions were developed 
according to Ajzen (2006); and Francis et al. (2004) guidelines. 
3.7.4 Piloting and validation of the MRQ 
The participants of the elicitation study were re-invited for a face to face interview to 
review and comment on the items of the draft MRQ.  Content validity was applied by 
asking cognitive questions (Chapter 4) and also some general questions at the end of the 
interview such as are any items difficult to answer or ambiguous; does the questionnaire 
feel too repetitive; does it feel too long; does it feel superficial; and are there any annoying 
features of the wording or formatting?  
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Reliability testing was applied including internal consistency for the direct measures of 
TPB and test-retest reliability for the indirect measures of the TPB. Finally, Confirmatory 
Factory Analysis (CFA) was applied to the MRQ (Chapter 4) to confirm that the questions 
measuring each construct are considered indicators of the same latent variable; and the 
TPB model in which the attitude, subjective norm, PBC, and intention items are treated as 
assessing separate constructs is superior to a model in which all questions are considered to 
measure the same underlying construct (Ajzen, 2017).  
3.7.5 The use of the MRQ 
Following the elicitation study (Chapter 3), MRQ items was created, reviewed and 
underwent validity and reliability test (Chapter 4). The MRQ was then developed and made 
available online using the Qualtrics online platform. An online panel was used to recruit 
participants in collaboration with a market research panel company called Research Now®. 
The MRQ was used to capture the representative views about people’s beliefs and 
willingness to reuse medicine in the future. These data were used in order to report on the 
beliefs and also to illustrate the predictive properties of the different elements of the MRQ 
(Chapter 5). 
3.7.6 Overall conclusions, recommendations and future work 
Having developed and used the MRQ and reported on the findings, the final element of this 
thesis (Chapter 6) reflects on the findings and produces recommendations for extending 
this work into the future.  
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CHAPTER 4 IDENTIFYING BELIEFS ABOUT MEDICATION 
REUSE: QUALITATIVE ELICITATION STUDY  
4.1 Introduction 
As outlined in the introduction to this thesis, in the UK unused prescribed medicines are 
treated as waste and should be returned to a pharmacy for disposal but people are more 
likely to dispose of their medicines inappropriately than return them to pharmacies. A 
sustainable system for addressing medicinal waste is needed. One solution in theory is to 
reuse certain returned prescribed medicines but this is not currently permitted in the UK 
and people’s beliefs about medicines reuse remain unexplored. In this chapter, the aim was 
to capture people’s beliefs about medicines reuse and to map the determinants of people’s 
intentions to take part in medicines reuse behaviour. The research question was ‘what are 
the behavioural determinants of medicines reuse?’ The objectives were to define medicines 
reuse as a behaviour and identify beliefs about this behaviour using qualitative interviews 
and the Theory of Planned Behaviour (TPB) (Francis et al., 2004; Ajzen, 2006).   
Thematic analysis (TA) of the interviews was carried out because it provides a way of 
organising qualitative interview data in the form of themes: recurrent topics, ideas or 
statements identified across the corpus of data. However, TA also received a lot of 
criticisms in past based on the absence of clear and precise guidelines on how researchers 
analysing their data (Braun and Clarke, 2006). In order to avoid this, and to have a clear 
demarcated TA, a step by step approach as described by Braun and Clarke (2006), was 
followed using a series of six phases of analysing the data. TA is judged to be highly 
suitable approach to this research because of its theoretical freedom which means it is 
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flexible and useful in providing rich, detailed and complex data. Moreover, its flexibility 
also allows inductive, deductive, and mixed inductive-deductive approach.  
In this chapter, a mixed inductive-deductive approach was used. Themes obtained 
inductively using TA were mapped against a theoretical framework (i.e. TPB was used to 
identify themes) within a deductive approach (Braun and Clarke, 2006). That is, the 
identification of themes in was guided by the theoretical framework of the TPB. The 
ontology that underpins thematic analysis values humans as ‘sense making’ individuals 
who can reflect on their experiences and produce meanings through the use of language.  
The TPB makes a distinction between behaviour and behavioural intentions on the basis 
that what people intend to do is more predictable than what they will actually do (Ajzen, 
2006). This is particularly pertinent to this research since medicines reuse in the UK is not 
yet a reality According to TPB, behavioural intentions are a function of three determinants: 
firstly, the person’s attitude in terms of likely consequences of the behaviour (behavioural 
beliefs), that is the individual’s positive or negative evaluation of taking part in the 
behaviour, creating a favourable or unfavourable attitude towards the behaviour; secondly, 
the person’s beliefs about the normative expectations of other people (normative beliefs), 
that is social pressure to take part or not take part in the particular behaviour, creating a 
perceived social pressure or subjective norm; thirdly, the individual’s beliefs about the 
existence of factors that may enable or obstruct taking part in the behaviour (control 
beliefs), that is whether the person has control over the behaviour, creating a belief about 
perceived behavioural control. The combination of these three factors leads to the 
formation of an individual’s behavioural intention, which is thought to be the immediate 
antecedent of the behaviour according to the TPB. With a sufficient degree of actual 
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control over the behaviour, the model expects that people would carry out their intentions 
when the opportunity arises (Figure 3.1).   
Figure 4.1 Schematic representation of the theory of planned behaviour, adapted 
from Ajzen (2006), showing the relationship between the determinants of behaviour 








The findings of this chapter were accepted to be published on 20th June 2017, in the 
International Journal of Pharmacy Practice (IJPP) under the title “How do people 
conceptualise the reuse of medicines? An interview study”.  
This chapter (i.e. the qualitative elicitation study) is referred to as phase 1 of the larger 
study. In this phase people were recruited and interviewed using face to face semi-
structured interviews to capture their beliefs about medicine reuse as a behaviour. This is 


























4.2 Aims and objectives 
The aim of phase 1 of the study was to: 
a)  Define medicine reuse as a behaviour, identify themes, and categorising these themes 
to behavioural, normative, and control beliefs about medicine reuse.  
The objective of phase 1 described in this chapter was to: 
a)  Use thematic analysis to capture themes relating to people’s beliefs about medicines 
reuse, and then use the Theory of Planned Behaviour (TPB) as a tool to categorise 
these themes into behavioural, normative, and control beliefs about medicines reuse.  
4.3 Methods 
4.3.1 Compliance with ethical standards 
This study was approved by the University of Reading’s Research Ethics Committee 
through the School Exemptions process (reference number 30/15) on 6/5/2015 (Appendix 
3). Information letters (Appendix 4) were sent to the participants who showed an interest to 
participate in this study and written consent (Appendix 5) from each participant was 
obtained before the interviews. 
4.3.2  Setting and participants recruitment 
Participants were recruited in spring 2016 through an advertisement placed in the 
university’s community newsletter circulated biannually to local residents. The university’s 
community newsletter is often used to recruit participants to research projects because it 
reaches 15,000 local households. The advert (Appendix 6) used for this study sought 
English-speaking adults with an interest in the concept of medicines reuse and willingness 
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to participate in a qualitative study by attending an interview at the university campus. 
Medicines reuse was defined as “the idea that medication returned by one patient can be 
dispensed by a pharmacist to another patient” (instead of disposal as waste – which is what 
currently takes place). Participants either contacted the research team directly or were 
introduced to the research team via already-recruited participants via email. A balanced 
number of men and women were interviewed, and there was also good representation 
across different age bands meaning that recruitment continued until data saturation using 
convenience sampling. Data saturation was guided by an initial desired sample size (n = 
20) determined by PD and HA according to the TPB methodology (Ajzen, 2006) which 
was modified down when no additional themes were identified after interviewing the 15th 
participant (Francis et al., 2010). After this time point, four more people were interviewed 
but three additional people who contacted the research team expressing an interest were 
turned away. 
4.3.3 Data collection 
A semi-structured interview schedule (Appendix 7) based on the TPB and focussing on 
behavioural beliefs, normative beliefs and control beliefs in relation to medicines reuse was 
constructed and used in the interviews (Ajzen, 2006). 
Fifteen participants were interviewed by both the PhD supervisor (PD) and (HA) (the PhD 
student) in attendance, after which the remaining four participants were interviewed by HA 
alone. Written consent was obtained, and the interviews, which lasted around 40 min, were 
audio-recorded. Participants were recruited until no more new and significant concepts 
emerged (i.e. sampling saturation). 
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4.3.4 Data analysis 
Interviews were transcribed verbatim, password-protected and anonymised/de-identified by 
‘The Transcription Agency’, a university-approved supplier. HA reviewed all transcripts to 
confirm that names or other information that might identify the participants had been 
removed, and also ensured data integrity by cross-checking the transcripts against the 
interview recordings, in consultation with PD. The interview transcripts were analysed 
manually, and then the NVivo 10 software (QSR International Pty Ltd. Version 10, 2012) 
was used to visualise theme connections and to construct the initial and then the final 
thematic maps. The thematic analysis process was carried out by HA according to the six 
phases described by Braun and Clarke (2006) and was reviewed by PD. The recordings 
were listened to several times to guarantee the precision of the transcription process and the 
transcribed data were read and re-read, before the primary ideas were noted down. This 
repeated process of reading is the primary phase of analysis which ensures familiarisation 
with the data and data immersion. Following the primary phase, coding was introduced. 
During the coding process, attention was distributed equally to the corpus of transcribed 
data to identify all of the interesting concepts, and the data were systemically organised 
into meaningful sets. These codes were then combined to form the wider unit of analysis 
called the theme or sub-theme. This third phase of analysis involves searching for themes 
and the analysis is refocused on broader level (theme level) coding and incorporating the 
different relevant codes into themes or potential themes (Appendix 8, summary of the 
thematic coding process and analysis). A thematic map was used to describe the 
relationship between the emerging themes and sub-themes as shown in the (Figure 4.2). 
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The fourth phase of analysis involved reviewing the themes. At this point refinement of 
themes occurred at two levels; level one included reviewing the coded data extracts by 
reading all the collated extracts against each theme to ensure a coherent pattern and to 
discard or rework themes that did not fit to the dataset. Reviewing the dataset at this stage 
also ensured that no data were missed at an earlier stage. The thematic map that emerged 
was then considered to be a precise reflection of the meaning evident in the entire dataset 
(Figure 4.3). Phase five of the analysis was about defining and labelling the themes and 
capturing the story within individual themes and how it fitted the overall story in the 
dataset. The sixth and the final phase of analysis consisted of producing the current 
manuscript and selecting examples of data extracts to explain elements of the themes and 
relating this back to the research question. Themes obtained from the process of thematic 
analysis were categorised according to the TPB to define behavioural beliefs, normative 
beliefs and control beliefs about the reuse of unused prescribed medicines.  
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Figure 4.3 Developed thematic map showing three major themes (oval shapes) and their sub-themes before the data were 
















































































From 22 participants who contacted the research team, a total of nineteen were recruited 
(11 female), including one couple who were interviewed jointly. Two participants were 
British Asian and 17 were white British. Participant age groups were 40-49 (n=3), 50-59 
(n=2), 60-69 (n=8) and >70 (n=6). 
Three major categories were identified and labelled: “Consequences of medicines reuse” 
(relating to behavioural beliefs), “Exemplar and anti-exemplar individuals and groups” 
(relating to normative beliefs), and “Expectations about returned medicines” (relating to 
control beliefs). The compositional structure of these categories is described in tables (3.1, 
3.2, and 3.3).  
Participants interviewed in this study were generally in favour of the idea of medicines 
reuse in that they felt the NHS should move to a system whereby unused prescribed 
medicines would be reused instead of being discarded. This system of reusing prescribed 
medicines would not be obligatory, with patients opting in or out, and the whole process 
regulated to prevent misuse. The following quotes illustrate this point: 
“Medicine reuse should be regulated and monitored by NHS to avoid the risk of 
having black market, this include pharmacist selling the collected medicines online, 
and also counterfeit medicines that patient bought online should not put back the 
shelf (if returned) and this will be assured during a quality check by the 
pharmacist.” (P17, female, >70 age group) 
“I think the majority of people because of the trust they have in the health service, if 
it was standard practice for the health service then they may well accept it.  The 
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difficulty would be if you made it look as though it was a practice carried out by 
pharmacists, they might object.  It would have to be seen to be something that’s 
done by the health service, OK, rather than by the pharmacy, the pharmacy only 
acting as an agent for the health service.” (P15, male, 50-59 age group)  
4.4.1 Consequences of medicines reuse 
This category encapsulates participants’ understanding of the advantages and 
disadvantages of medicines reuse if ever implemented (see Table 4.1). 
4.4.1.1 Potential advantages of medicines reuse 
Both economic and environmental advantages of reusing medicines were discussed. Some 
perceived that reusing unused medicines would save money for the NHS and reduce 
manufacturing costs by cutting medicinal waste. The following quotes exemplify this point: 
“Mainly I would say economy, because it does seem wasteful that these things cost 
a lot of money to research and develop and produce, then package and transport, 
then being wasted, so it is a question of economy.” (P2, male, >70 age group). 
 “I would say the main advantage of reusing medicines is saving on cost, in this 
country masses of drugs are wasted. When you have been prescribed something and 
did not need much of it, and then you think what an awful waste?  Surely it would 
be better to return it and somebody else able to use it.” (P5, Male, 60-69 age 
group) 
“I think medicine reuse would be an efficient thing to do financially and 
environmentally, because if you are reusing you are not having to produce as much, 
and also you are reducing waste.” (P7, female, 60-69 age group) 
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In addition, medicines reuse was thought more applicable for expensive medicines 
especially if logistical costs of reuse processes were to dwarf the monetary value of cheaper 
medicines; logistical costs were conceptualised in different ways. For example if medicines 
reuse processes could not happen in a pharmacy because of competing priorities or lack of 
storage space, a formal, costly system for collecting and despatching unused medicines to, 
say, a clinical centre might be needed; there technicians could work to check, repackage, 
and prepare the medicines for reuse, which would carry a cost. The following quote 
illustrates the former point: 
“Generic medicines, maybe they are so cheap that a packet of aspirin cost maybe 
16p or something, but maybe some of the more expensive medicines that is 
definitely worth reusing.” (P3, male, 40-49 age group) 
Medicines reuse was thought to reduce the proportion of medicines thrown into household 
bins and encourage people to return unused medicines to a pharmacy, thus helping reduce 
negative environmental effects arising from medicines reaching landfill or the water 
supply. Some felt knowing returned medicines were destined for disposal under the current 
system acted as a disincentive for returning unused medicines to a pharmacy. For example: 
“Most people just dispose of their medicines in the bin, and probably only a 
minority of people actually take the medicines back to the pharmacy. A lot of these 
medicines contain chemicals which probably make their way into the water and 
could pollute water supply. Oestrogen for example could make its way into the 
water supply. I don’t know whether these chemicals break down within a period of 
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time and become inert, or whether they continue to be active and modify the 
environment.” (P3, male, 40-49 age group) 
“I do believe there’s an enormous amount of medicine wasted, and sometimes I 
wonder what happens to these wasted medicines as it would be awful to wash it down 
the water works, all these drugs and chemicals would harm health in another sort of 
way. And I have always wondered why if they’re intact they’re not reused.” (P11, 
female, 40-49 age group)  
“People Flush medicines down the loo or just put it in the rubbish bin.  Dreadful.  
When Hormones such as oral contraceptives flushed down the loo, it was linked to 
low sperm count in men” (P16, female, 40-49 age group).  
“I think one of the reasons people put medicines down the loo is because they know 
if they take the medicine back to the pharmacist he is going to destroy them anyway 
so they think, why I should make the effort with this, pointless. They don't understand 
the damage they might be doing so I think there would be an environmental benefit.” 
(P15, male, 50-59 age group)  
Medicines reuse was thought to reduce the overall carbon footprint of medicines by 
impacting on manufacturing and transport of new medicines. For example: 
“So what I'm describing I think are people who are more aware, shall I say, of a 
bigger picture, they’re not thinking just personally, they’re thinking what can I do, 
does it save the environment, if one less packet of pills has to be made that's one less 
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energy, that’s less transport, it’s all the good reasons, not just money.” (P2, male, 
>70) 
4.4.1.2 Potential disadvantages of medicines reuse 
Participants identified a range of issues with reusing medicines that had been in the hands 
of other people. The proper storage of unused medicines in terms of the temperature, 
humidity, or cleanliness of the storage environment was one concern. Linked to this was 
the impact on the safety of unused medicines. Safety was conceptualised as inadvertent 
contamination or deliberate tampering. For example: 
“I think my concerns about medicine reuse would be the hygiene aspects of the 
returned medicine as I want to know if it was stored in a clean place, and that I wasn’t 
going to get any kind of infection or problem with it.” (P1, female, 60-69 age group) 
“I think the main issue of reusing medicines would be the risk.  I suppose some 
medications have to be stored at certain temperatures, like insulin. Also you would 
have to be assured that the medicine had not been tampered with.” (P4, female, 60-
69 age group) 
“The thing that would concern me about reusing medicines is if the drugs had become 
contaminated somehow, so there would have to be a very thorough check to make 
sure something has not been contaminated in some way.” (P5, male, 60-69 age 
group) 
In addition, the risk of medication errors was highlighted in terms of errors introduced by 
patients and the risk of returning counterfeit medicines. The risk of errors made by 
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pharmacists was also a concern such as redistributing the wrong medicine to a patient and 
accepting counterfeit medicines. For example: 
“There could be a risk of medication error being made, for example if somebody 
put a medication back in the wrong box and returned it.  There have to be very 
strict rules on checking the returned medicines.” (P6, male, >70 age group) 
“I suppose there is a slight risk of a wrong drug getting into a wrong packet or 
being placed in the wrong place somewhere, so being mis-prescribed but I think it 
is quite small because pharmacists are so careful when the check what they give 
you.” (P17, female, >70 age group) 
Participants’ recognition of the advantages of medicines reuse was juxtaposed with 
assertions about a need for quality and safety assurances. Pharmacists were trusted to carry 
out quality and safety checks, but participants worried if pharmacists had the time to devote 





Table 4.1 The compositional structure of category 1: “Consequences of medicines 
reuse” 
Consequences of medicines reuse 
Participants’ attitudes towards medicines reuse involved an evaluation of the benefits 
and the risks associated with the distribution of returned medicines to other patients: 
Potential advantages of medicines reuse 
A) Economic impact on the NHS 
- Direct monetary savings for the NHS 
- Reduction in manufacturing expenditure 
- Cost-benefit of reusing cheaper medicines 
B) Environmental effects 
- Reduction in negative environmental effects of medicines disposed inappropriately 
- Reduction of the carbon footprint. 
Potential disadvantages of medicines reuse 
A) Poor quality medication  
- Temperature of storage  
- Humidity of storage environment 
- Cleanliness of the storage environment 
B) Harmful medication 
- Deliberate or malicious tampering with returned medicines  
- Medicines as a source of infection if contaminated  
C) Incorrect medication 
- Errors introduced by patients 
- Errors introduced by pharmacists 
- Risk posed by accepting counterfeit medicines 
4.4.2 Exemplar and anti-exemplar individuals and groups 
This category encapsulates participants’ understanding of individuals or groups of people 
who would partake or particularly engage with and promote medicines reuse (exemplar 
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individuals and groups) and those who would not (anti-exemplar individuals and groups) if 
a scheme were to be implemented in the future (see Table 4.2). 
4.4.2.1 Individuals or group of people who might approve of medicines reuse 
Those subscribing to the ideology of the ‘Green movement’ were considered to support 
medicines reuse, with spouses and partners, relatives and friends who think green, 
environmentalists and members of the Green Party, identified as people who might 
encourage medicines reuse. For example: 
“I'm a dyed in the wool Conservative, but I think the Green Party for example 
would be positive about medicine reuse and may campaign for it.” (P2, male, >70 
age group) 
“I think people part of the Green movement will approve medicine reuse.”(P3, 
male, 40-49 age group) 
“I think my husband and some friends, I think people who thinks green would 
support it.  I would have thought most environmentalists would support it because 
the other things is, a lot of this stuff does end up in the water somehow or other, and 
affects wildlife.” (P17, female, >70 age group) 
4.4.2.2 Individuals or groups of people who might disapprove of medicines reuse 
Pharmaceutical companies and their employees (or others with an interest in these 
companies) were considered among the group that would disapprove of medicines reuse 
because of a potential to reduce financial profits. For example: 
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“I think drug manufacturers may think that medicine reuse is a bad idea, because 
they are making an absolute fortune out of the NHS.” (P6, male, >70 age group) 
“I wonder if people working in pharmaceuticals would not frown upon it in some 
way if their profits are being affected.” (P11, female, 40-49 age group) 
“I’m very suspicious of the pharmaceutical companies as they like to produce more 
drugs and they make more money, so really I’m very suspicious because they are 
enormous conglomerates. It’s to their benefit because they make a lot of money, 
absolutely.” (P18, male, >70 age group) 
Longstanding taxpayers were another group who might disapprove of medicines reuse 
because of a sense of entitlement to receive ‘the genuine medicine’. For example: 
“Getting access to the NHS services is at the cost of the UK taxpayer. I think 
because it’s so ingrained in this country, the NHS and the prescription process, that 
people almost feel that it is now like an entitlement to have the genuine medicine at 
a fixed cost, and that kind of thing.”(P1, female, 60-69 age group) 
Participants on the whole believed that people, especially mothers, may not approve of 
medicines reuse for their children, with babies particularly seen as a ‘very special group’. 
For example: 
“I think mothers are probably very cautious for their offspring, and wants the best 
for her child, there's a kind of feeling because it’s brand new, off the shelf, it’s 
purer, it’s safer, there’s no element of risk.” (P2, male, >70 age group) 
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“I think people might be resistant for example with drugs that are for babies.  I 
think that might be seen as a very special group.” (Participant 7, female, 60-69 age 
group) 
Participants had contradicting thoughts regarding the stance taken by ‘the elderly’. Some 
thought older people would support reusing medicines because they were brought up not to 
waste things as a result of a natural aversion to waste stemming from experiencing 
shortages around the Second World War; this was compared to a younger generation who 
might dislike using ‘second hand medicines’. For example: 
“I think particularly amongst the older generation would probably be more 
susceptible to saying, yeah medicine reuse is good idea, because we were brought 
up not to waste things.  I do not know if youngsters think about that kind of thing as 
much because there is a surplus of everything these days but there was not when we 
grew up so we don’t, we still don’t waste things, we still mend things.” (P17, 
female, >70 age group) 
“…I think older people, the make do and mend generation who experienced 
shortages after Second World War, who are fast becoming rare and rarer” (P14, 
male, 60-69 age group) 
Others thought that the elderly might in fact disapprove of medicines reuse if they have a 




“Elderly people, I think might think that you shouldn’t do that when it comes to 
elderly people, people with maybe cancer, and these kind of very serious disease.” 
(P7, female, 60-69 age group) 
Table 4.2 The compositional structure of category 2: “Exemplar and anti-exemplar 
individuals and groups” 
Exemplar and anti-exemplar individual 
The groups of individuals or people whom the participants thought would or would 
not engage with and approve of medicines reuse.  
Individuals or groups of people who might approve of medicines reuse 
A) The Green movement 
- Spouses and partners, relatives and friends who ‘think green’ 
- Environmentalists 
- The Green Party, the political organisation 
B) The elderly  
- Those with a dislike of waste and an affinity for frugality  
Individuals or groups of people who might disapprove of medicines reuse 
A) Pharmaceutical companies  
- Employees  
- Beneficiaries  
B) Taxpayers  
- UK Taxpayers with a sense of entitlement 
C) Vulnerable patients (those making a decision for them) 
- Babies  
- Children 
D) The elderly  
- Cautious individuals worried about safety 
- Terminally ill patients 
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4.4.3 Expectations about returned medicines 
This category encapsulates participants’ understanding of factors that may facilitate or 
impede the workability of medicines reuse as a formal process and is expressed in terms of 
the participants’ expectations about returned medicines (see Table 4.3). 
4.4.3.1 Physical characteristics of returned medicines 
It was clear that not all returned medicines were considered as suitable for medicines reuse. 
There was general agreement that reused medicines should be those originally packaged in 
sealed or in blister-pack containers, be unopened, comprise of oral solid dosage forms only, 
be a genuine medicine (not a counterfeit), and have more than 6 months of shelf-life 
remaining. In contrast, returned medicines that have a broken seal, have been opened, 
liquids and injectable medicines, controlled drugs, medicines with less than 6 months of 
shelf-life remaining, and medicines obtained from mistrusted or online sources would be 
excluded from the reuse process. For example: 
“I don’t think medicine in a liquid form can be reused, someone might introduce 
something such as foreign body. This apply to gel and cream which is maybe easier 
to inject or get something in it, whereas in a blister pack you can tell whether it is 
been tampered with or not.” (P7, female, 60-69 age group) 
“If the returned medicine has only six months life left then it may not be put back on 
the shelf to give it to some people.”(P9, female, >70 age group) 
“I can understand why opened packets have to be destroyed, as there is too high a 
risk of being tampered with. But there should be a way of reusing those unopened 
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medicines, and those still within date, I do not know what would need to be put in 
place, but it just seems wrong to bin them.” (P10, male, 60-69 age group) 
4.4.3.2 The quality assurance of returned medicines 
In addition to physically checking returned medicines, there should be stringent quality and 
safety checks by the pharmacist, to confirm suitability for reuse. The checking process 
would involve the pharmacist confirming storage conditions and discounting any risk of 
product degradation, contamination or infection. The pharmacist would check that the 
product had not been tampered with, maliciously or accidentally, damaged, bought from an 
online source, and was not a counterfeit.  For example: 
“I would be quite happy to reuse medicines as long as I know that the safeguards 
have been put in place that the returned medicines has not been tampered with.” 
(P4, female, 60-69 age group) 
“I think another key thing is temperature control, I think most people would have a 
medicine cabinet in the bathroom, and that always amuses me because you have got 
the humidity and the heat of showers and baths.  So I think whenever people buy 
medicine cabinets there should be an instruction saying don’t use them in a 
bathroom.” (P5, Male, 60-69 age group) 
“So all returned medicine have to be checked, I suppose there is a slight risk of 
having counterfeit medicines from untrusted sources include those bought online 
getting into pharmacy shelf.” (P17, female, >70 age group) 
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4.4.3.3 The logistics of medicines reuse 
The medicines reuse processes including the collection and the redistribution of returned 
medicines were considered in depth by the participants. Medicines could potentially be 
returned to pharmacies (CPs, pharmacies within the GP clinics, and hospital pharmacies) 
and assessed ‘on-site’. Pharmacists were considered to be the professional group qualified 
to quality assure the suitability of returned medicines for reuse purposes. Potential 
challenges to an on-site system were the pharmacist’s availability for collecting and 
checking returned medicines, space within a pharmacy to enable processing and storage of 
returned medicines, and whether the process of returning medicines would be slick and 
rapid for patients (which was preferred to having to queue). For example: 
“As all returned medicine have to be checked.  So this could be a disadvantage in 
terms of pharmacists’ time because they are very busy in chemists, aren’t 
they?  Very busy pharmacists.” (P17, female, >70 age group) 
“Pharmacist may not have the room to put back medicines into the shelf , I am 
thinking of our pharmacy, it is small, and maybe there is no enough space in the 
pharmacy for the returned medicines.” (P6, male, >70 age group) 
Because of these challenges some of the participants proposed an alternative model 
whereby medicines would be dropped off in a specified area within a pharmacy without the 
need to speak to any staff. Those medicines would be despatched to a clinical centre where 
a pharmacist or trained technician completes a quality check in an ‘off-site’ model. An 
additional idea was to repackage returned medicines before returning them to pharmacies 
for reuse. However, the costs associated with having an off-site system were highlighted as 
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potentially prohibitive. Some participants thought that pharmaceutical companies should be 
obliged to support medicines reuse processes financially or even help in the repackaging 
process. For example: 
“I think the pharmaceutical companies will have to collaborate to help in medicine 
reuse process, I know this is terrible thing, because they’re all in competition, but it 
would be good if they could have some way of collaborating whereby the pooled, 
they all put money into these centres to fund it as almost like a, not exactly a 
charity, but like a community investment type idea.” (P7, female, 60-69 age group) 
“Medicines have labels on them, so one assumes that if you gave them back to the 
pharmacy, for example, he would then have to send them back to the supplier, the 
supplier would have to send them back to the manufacturer, the manufacturer 
would then have to repackage them, and then they have to come all the way back 
down the chain.” (P12, female, 60-69 age group) 
Incentives were thought to encourage patients to return unused medicines instead of unsafe 
disposal practices. Incentives could include a point’s reward system to encourage 
medicines return or a discount to be offered on any medicines reused. 
“I would have a knowledge of my pharmacist because I go to the same place and 
they know what medication I’m on and if somebody has changed their medication 
or whatever and so returns some tablets and the pharmacist know that I take those.  
So pharmacist can probably say here we are Mr. X, here is those returned tablet 
and they are 50 pence instead of £1 or whatever it is.  So that sort of thing.” (P14, 
male, 60-69 age group) 
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Table 4.3. The compositional structure of category 3: “Expectations about returned 
medicines”. 
Expectations about returned medicines 
Factors that may facilitate or impede the workability of medicines reuse for individuals. 
Physical characteristics of returned medicines  
A) Original packaging of the medicine  
- Medicines sealed by the manufacturer potentially suitable to be reused 
- Medicines in blister packaging potentially suitable to be reused 
B) Whether the packaging had been opened or not 
- Only unopened and sealed medicines to be reused  
- Medicines not sealed or with a broken seal not to be reused 
C) Remaining shelf life of medication 
- Medicines should have more than six months of shelf-life if to be reused 
D) Pharmaceutical presentation (formulation) of the product 
- Solid oral dosage forms potentially suitable to be reused 
- Liquid, creams and gels, and injections not to be reused 
The quality assurance of returned medicines 
A) Storage conditions 
- Temperature and humidity of storage environment and risk of degraded product 
- Cleanliness of the storage environment and risk of spread of infection 
B) Tampered product  
- Malicious damage to the product to be ruled out 
- Accidental damage to the product to be ruled out 
C) Counterfeit medicines 
- Medicines bought from untrusted sources including online sources not to be reused 
The logistics of medicines reuse  
A) Collection and redistribution of returned medicine ‘on-site’ within a pharmacy 
setting  
- Efficiency of system for returning medicines 
- Space for collection, processing and storage of returned medicines 
- Pharmacists’ time availability to conduct quality assurance of returned medicines 
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Expectations about returned medicines 
Factors that may facilitate or impede the workability of medicines reuse for individuals. 
 
B) Collection and redistribution of returned medicines ‘off-site’   
- Collection spots within pharmacies  
- Clinical centres responsible for processing medicines for reuse 
- Pharmaceutical companies to be involved in funding and supporting reuse processes 
C) Incentives for taking part in medicines reuse 
- Points reward system to encourage the return of medicines 
- Discount on medicines to encourage the reuse of medicines 
4.4.4 Medicines reuse definition 
According to the results from TA and relating to TPB, a working definition of medicines 
reuse as a behaviour coalesced as: “Accepting prescribed medication with more than 6 
months of shelf-life remaining that, as verified by a pharmacist, had been kept untampered 
for less than three months, under normal storage conditions and in an original sealed 
blister pack, by another patient before being returned to a community pharmacy”. People 
taking part in medicines reuse behaviour were seen as “Adult patients prescribed 
medication for a chronic (not terminal) condition with the capacity to consent”. 
4.5 Discussion 
This chapter described phase 1 of the larger study the results of which are briefly 
summarised here. A working definition of medicines reuse as a behaviour was produced. In 
addition, people’s ideas about the advantages and disadvantages of medicines reuse, who 
might approve or disapprove of medicines reuse, and factors that would impede or facilitate 
medicines reuse were mapped systematically using thematic analysis. The principle 
findings were; the potential for medicines reuse to impact positively on the deleterious 
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economic and environmental impact of medicines waste were juxtaposed against a range of 
stability and safety risks identified with reusing returned medicines. While participants had 
trust in pharmacists’ competence to quality assure returned medicines, they expressed 
concerns about their availability and access to sufficient storage space to support medicines 
reuse processes. Environmentalists and the Green Party were seen as the main proponents 
of medicines reuse behaviour with drug manufacturers and beneficiaries, some taxpayers, 
and those caring for children seen as the main opponents – there were contradictory views 
about the stance of the elderly. The physical characteristics of reused medicines, and 
quality assurance and logistics of medicines reuse processes were considered as factors that 
enabled or obstructed engagement in medicines reuse. 
During the qualitative study, the face to face interview approach was chosen over focus 
groups. The reason behind choosing face to face interviews is that, first TPB is about 
individual intentions and not that of a group of people and their opinions, and second there 
was a risk of people leading each other during focus groups which will affect the results of 
this research (Ajzen, 1991; Ajzen, 2011; and Ajzen, 2017). In addition, semi-structured 
face to face interview was chosen over full in-depth unstructured interviews, first because 
of the use of TPB which requires a deductive approach mapping people’s answers to the 
theory’s framework, secondly, because of the purpose of this study which was to develop 
and construct the MRQ which in turn required the mapping described above to be 
completed.  
One of the strengths of the current study is the application of TA to summarise key themes 
and to formalise views that the general public hold about medicines reuse, which had only 
been reported anecdotally and not appropriately investigated until now. The decision to 
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apply thematic analysis (TA) was influenced by simplicity and theoretical freedom of TA 
and its ability of providing rich and detailed themes, but also because TA allow for 
inductive, deductive and mixed inductive-deductive approaches (Braun and Clarke, 2006). 
Other options were not used because they would have introduced unnecessary complexity. 
For example grounded theory would have generated more theory rather than mapping to 
the TPB) (Goulding, 2017). 
Themes obtained in this study have defined what people understand by medicines reuse 
behaviour as well as behavioural, normative and control beliefs. These are the domains that 
according to the TPB are relevant for predicting whether people intend to reuse medicines 
(Ajzen, 2006). This psychologically driven approach is another strength of the current 
study which provides a mechanism for measuring people’s intentions to engage in 
medicines reuse behaviour, with a further potential for this approach to be useful in 
wanting to change people’s intentions in the future. However, the views are not likely to be 
representative of the general UK population, firstly because thematic analysis was 
completed with a small sample of nineteen participants and secondly, because the sample 
was a self-selected sub-group of the local population who responded to a call to discuss 
medicines reuse. 
There has been little work done previously at examining perceptions about medicines reuse 
in the UK apart from a study that used a modified Delphi design to examine whether 
pharmacists from one Health Board in South East Wales could come to some consensus on 
the barriers and potential solutions towards medicines reuse (McRae et al., 2016a). The 
results showed that pharmacists would be willing to redistribute medicines if certain 
criteria were met such as being solid dosage forms with a tamper evident seal. Results from 
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our study showed that participants also referred to sealed blister packs as the type of 
product that would be a part of medicines reuse. Other criteria expressed by pharmacists in 
the study by McRae et al. (2016a) included liability protection for pharmacists taking part 
in medicines reuse, guidance from the professional regulator, that reused medicines must 
be supplied in new packaging, that technologies would need to be developed to indicate 
inappropriate storage, and that there must be public engagement on medicine redistribution. 
Accordingly, this is the first study in the UK that has captured the general public’s views 
and intentions toward reusing medicines that are returned to pharmacies. The work in this 
thesis was completed independently of the above study by McRae et al. (2016a), and 
addresses the feasibility of medicines reuse from the perspective of the general public, 
without whose approval medicines reuse could not become a reality. 
Based on the results from TA (i.e. this elicitation study), the next steps are to develop and 
test a formal questionnaire that can capture systematically nationwide views of medicines 
reuse and people’s intentions to reuse medicines in the future. Therefore the next phase (i.e. 
phase 2) of this study focussed on the construction and validation of a medicines reuse 
questionnaire, described in the next chapter.   
4.6 Conclusion 
This study suggests that people could potentially agree to reuse medicines that are returned 
to pharmacies if their concerns about safety and quality of the returned medicines are 
addressed, the physical characteristics of medicines are satisfactory, and the medicines 
reuse process is well defined and managed. This is a qualitative study with a small number 
of participants recruited from one local area in the UK meaning that the results are not 
necessarily generalizable. However, the mixed inductive deductive approach strengthens 
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the themes generated as TBP’s deductive categorisation of the themes enhanced the 
interpretative power of thematic analysis. The themes generated will enable a structured 
questionnaire to be developed for quantifying broader, nationwide views (i.e. views drawn 
from respondents from around the UK) about medicines reuse and people’s intention to 















CHAPTER 5 DEVELOPMENT OF THE MEDICINES REUSE 
QUESTIONNAIRE: CONSTRUCTION, VALIDATION, AND PILOTING  
5.1 Introduction 
There was no existing questionnaire in the literature that could be used to measure people’s 
beliefs and intentions toward reusing medicines. The Medicines Reuse Questionnaire 
(MRQ) was developed specifically to address the research objectives of this thesis. The 
research method was first to categorise themes obtained from the elicitation study (i.e. 
qualitative interviews) against the indirect measures of the TPB (behavioural beliefs, 
normative beliefs, and control beliefs) in order to develop the MRQ items of the indirect 
measures. Items of the direct measures (attitude toward the behaviour, subjective norms, 
and perceived behavioural control) and intention, and the background factor items were 
developed according to the recommendation by Ajzen (2006) and Francis et al. (2004). The 
details about the construction and development of the MRQ are described in the next 
section. 
5.2 Aims and objectives 
The aims of phase 2 of the study were to: 
a) Construct the MRQ items using both direct and indirect measures including 
background factors that are related to the behaviour (i.e. medicines reuse behaviour).  
b) To standardised the MRQ items using pilot tests. 
The objectives of phase 2 described in this chapter were: 
b) To use the TPB framework as a tool to develop the MRQ items. 




An amendment to ethical application (reference number 30/15) was submitted to the 
University Reading’s Research Ethics Committee and was approved on 10/02/2017. The 
amendment contained information about the use of online platforms (e.g. Bristol online 
and Qualtrics), recruitment of University of Reading staff and students via university 
internal email system (chapter 4), and online recruitment using Market Research 
Company, online panel and online platform (chapter 5). 
MRQ items were first constructed, then underwent validation and pilot testing including; 
content validity (CV) and confirmatory Factory Analysis (CFA), reliability testing using 
internal consistency of direct measures (Cronbach’s alpha), and test re-test (Pearson 
correlation). The validity and reliability testing is described in the next sections of this 
chapter. 
5.4 Construction and development of MRQ using TPB framework 
In total, the MRQ (first version – v1) consisted of 50 items (Appendix 9).  Twelve items 
relating to the direct measures and 3 items relating to intention construct were developed 
according to the recommendation by Ajzen (2006) and Francis et al. (2004). Twenty eight 
items relating to indirect measures and 7 items asking information about demographics 
were developed according to the results from the elicitation study. The numbers of items 
that were developed for each construct are presented in Figure 5.1.  The MRQ has two 
parts. Items in the main part were developed using a 7-point Likert scale for responses and 
focussed on reusing sealed, returned blister-pack medication. Items in the section focussing 
on background factor were developed using multiple choice responses and included 
demographics information such as age, gender, religion, ethnicity, the level of education. 
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5.4.1 Developing the MRQ items of the indirect measures of TPB  
The items in the indirect measures were developed using a 1 to 7 unipolar Likert scale for 
behavioural beliefs, motivation to comply and control belief. For outcome evaluation, 
normative belief, and power of control factor, the unipolar Likert scale was recoded into 
bipolar (-3 to +3) Likert scale as recommended by Francis et al. (2004) and Ajzen (2006). 
The recoding allowed items developed to be measured using a weighting process involving 
one unipolar and one bipolar scale. The method of multiplying scores on a unipolar scale 
by scores on a bipolar scale was used to calculate and make the composite score 
interpretable (Francis et al., 2004; Ajzen, 2006).  Table 5.1, Table 5.2, and Table 5.3 
describe how the composite score was calculated for indirect measures of attitude, 








and if taking 
medicines or 
not) 
= 7 items 
Behavioural 
beliefs = 5 items 
X 
Outcome 




beliefs = 4 items 
X 
Motivation to 
comply = 4 
items 
 
Control beliefs = 
5 items  
X 
Power of control 




= 4 items  
Subjective  
Norms  




= 4 items 
133 
 
Table 5.1 Calculating the composite score of attitude (indirect measures) by multiplying scores on a unipolar scale of 
behavioural beliefs items by scores on a bipolar scale of outcomes evaluation items. 
Behavioural beliefs items Outcomes evaluation items 
a. I think for me to contribute toward reducing the harmful 
effects of medication on the environment is: 
extremely bad 1   2   3   4   5   6   7 extremely good 
f. Reusing sealed, returned blister-pack medication will help me contribute toward 
reducing the harmful effects of medication on the environment is: 
definitely disagree -3   -2   -1   0   1   2   3 definitely agree 
b. I think for me to contribute toward reducing the NHS drug 
expenditure is: 
extremely bad 1   2   3   4   5   6   7 extremely good 
g. Reusing sealed, returned blister-pack medication will help me contribute toward 
reducing NHS drug expenditure: 
definitely disagree -3   -2   -1   0   1   2   3 definitely agree 
c. I think for me to receive low quality medication is: 
extremely bad 1   2   3   4   5   6   7 extremely good 
h. Reusing sealed, returned blister-pack medication will result in me receiving low 
quality medication: definitely disagree -3   -2     -1   0   1   2   3 definitely agree 
d. I think for me to receive unsafe medication is: 
extremely bad 1   2   3   4   5   6   7 extremely good  
i. Reusing sealed, returned blister-pack medication will result in me receiving unsafe 
medication: definitely disagree -3   -2   -1   0   1   2   3 definitely agree 
e. I think for me to receive incorrect medication is: 
extremely bad 1   2   3   4   5   6   7 extremely good  
j. Reusing sealed, returned blister-pack medication will result in me receiving 
incorrect medication: definitely disagree -3   -2   -1   0   1   2   3 definitely agree 
For each behavioural belief, the belief score on the extremely bad - extremely good scale is multiplied by the relevant outcome evaluation score on 
the definitely disagree - definitely agree scale.  
Total attitude (indirect measurement) score = (a x f) + (b x g) + (c x h) + (d x i) + (e x j).  
For example, if the participants responded by choosing the bold numbers as above then, 
Total attitude (A) = (7 x 3) + (6 x 2) + (2 x -2) + (1 x -3) + (1 x -3)  
Total (A) = +23. Because there are 5 items, the possible range of total scores is (7 x ±3) x 5 = -105 to +105 
Total A score = +23 reflects a weak positive attitude toward reusing medicine.   
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Table 5.2 Calculating the composite score of subjective norm (indirect measures) by multiplying scores on a unipolar scale of 
motivation to comply items by scores on a bipolar scale of normative beliefs items. 
Normative belief items Motivation to comply items 
a. Environmentalists would believe that I should reuse sealed, 
returned blister-pack medication: 
definitely disagree -3   -2   -1   0   1   2   3 definitely agree 
e. Generally speaking, how much do you want to do what 
environmentalists believe you should do? 
Not at all 1   2   3   4   5   6   7 very much 
b. The pharmaceutical industry would believe that I should reuse 
sealed, returned blister-pack medication: 
definitely disagree  -3    -2   -1   0   1   2   3 definitely agree 
f. Generally speaking, how much do you want to do what pharmaceutical 
industry believes you should do? 
Not at all 1   2   3   4   5   6   7 very much 
c. My close friends would believe that I should reuse sealed, returned 
blister-pack medication: 
definitely disagree  -3    -2   -1   0   1   2   3 definitely agree 
g. Generally speaking, how much do you want to do what close friends 
believe you should do? 
Not at all 1   2   3   4   5   6   7 very much 
d. My family would believe that I should reuse sealed, returned 
blister-pack medication: 
definitely disagree  -3    -2   -1   0   1   2   3 definitely agree  
h. Generally speaking, how much do you want to do what your family 
believes you should do? 
 Not at all 1   2   3   4   5   6   7 very much 
For each normative belief, the belief score on the definitely disagree - definitely agree scale is multiplied by the relevant motivation to comply 
score on the Not at all - very much scale.  
Total subjective norm (indirect measurement) score = (a x e) + (b x f) + (c x g) + (d x h).  
For example, if the participants responded by choosing the bold numbers as above then, 
Total subjective norm (SN) = (7 x 3) + (-1 x 1) + (2 x 6) + (3 x 7)  
Total (SN) = +53, Because there are 5 items, the possible range of total scores is (7 x ±3) x 4 = -84 to +84 
Total A score = +53 reflects moderate positive subjective norm toward reusing medicine.   
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Table 5.3 Calculating the composite score of PBC (indirect measures) by multiplying scores on a unipolar scale of control 
beliefs items by scores on a bipolar scale of power of control factors items.  
Control beliefs items Power of control factors items 
a. I expect that any medication offered to me for reuse will 
be in the original, sealed, blister-packaging: 
definitely no 1   2   3   4   5   6   7 definitely yes 
f. It would make it easier for me to reuse medication if I could see that it was in the 
original, sealed, blister-packaging: 
strongly disagree -3   -2   -1   0   1   2   3 strongly agree 
b. I expect to see evidence that any medication offered to 
me for reuse would have been quality-checked: 
definitely no 1   2   3   4   5   6   7 definitely yes 
g. It would make it easier for me to reuse medication if I could see that it had been 
quality-checked: 
strongly disagree -3   -2   -1   0   1   2   3 strongly agree 
c. I expect to see evidence that any medication offered to 
me for reuse would have been safety-checked: 
definitely no 1   2   3   4   5   6   7 definitely yes 
h. It would make it easier for me to reuse medication if I could see that it had been 
safety-checked: 
strongly disagree -3   -2   -1   0   1   2   3 strongly agree 
d. I expect that any medication offered to me for reuse will 
have more than six months of shelf-life remaining: 
definitely no 1   2   3   4   5   6   7 definitely yes 
i. It would make it easier for me to reuse medication if I could see that it had more 
than six months of shelf-life remaining: 
strongly disagree -3   -2   -1   0   1   2   3 strongly agree 
e. I expect to be offered some form of reward for reusing 
medication: definitely no 1   2   3   4   5   6   7 definitely yes 
j. It would make it easier for me to reuse medication if I were offered some form of 
reward: strongly disagree -3   -2   -1   0   1   2   3 strongly agree 
For each control belief, the belief score on the definitely no - definitely yes scale is multiplied by the relevant power of control factor score on the strongly 
disagree - strongly agree scale.  
Total Perceived behavioural Control (indirect measurement) score = (a x f) + (b x g) + (c x h) + (d x i) + (e x j).  
For example, if the participants responded by choosing the bold numbers as above then, 
Total Perceived behavioural Control (PBC) =  (6 x 2) + (7 x 3)  + (7 x 3) + (5 x 1) + (4 x 0)   
Total (PBC) = +59, Because there are 5 items, the possible range of total scores is (7 x ±3) x 5 = -105 to +105 
Total PBC score = +59 reflects moderate positive PBC toward reusing medicine.   
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Positive scores reflect that the participants have more favourable attitudes; social pressure 
to perform the behaviour (i.e. medicines reuse); and control factors that make medicines 
reuse more likely to happen. Negative scores reflect that the participants have less 
favourable attitudes; less social pressure to perform the behaviour; and control factors that 
make medicines reuse less likely to happen. 
In total, 28 items were developed; 10 items for the indirect attitude construct (5 items for 
behavioural beliefs and 5 items for outcome evaluation), 8 items for the indirect subjective 
norm construct (4 items for normative beliefs and 4 items for motivation to comply), and 
10 items for the indirect PBC (5 items for control beliefs and 5 items for power of control 
factor).  
5.4.2 Developing the MRQ items of the direct measures of TPB  
The items in the direct measures were developed using a 1 to 7 unipolar Likert scale. The 
endpoints of the attitude items were constructed using bipolar adjectives described as a pair 
of opposites (e.g. good-bad, harmful-beneficial; satisfying-dissatisfying; worthless-
worthwhile). The attitude items included both instrumental (whether reusing medication 
achieves something e.g. worthless-worthwhile) and experiential items (how it would feel to 
reuse medication e.g. satisfying-dissatisfying, good-bad). The mixing of positive and 
negative endpoints are described in Table 5.4, and was used to reduce the risk of having 
response set, or having a tendency to answer the MRQ items in the likely manner 
neglecting their content. Although the idea of mixing positive and negative endpoint is to 
force respondents to think about their response, there is no guarantee that the respondents 
will fully observe the questions when answering. Moreover, overusing this technique (i.e. 
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mixing of positive and negative endpoint) for many question may end up that the 
respondents feel that they need to interrupt their completion of the questionnaire and so 
they may not complete the questionnaire or may not notice the differences leading to 
unwanted errors and incorrect responses. In this research, there was no overuse of mixing 
negative and positive endpoints, instead only a few questions were developed using mixing 
of positive and negative endpoint as recommended by Francis et al. (2004) and Ajzen 
(2006).  
Table 5.4 Calculating the mean of the item scores to give an overall attitude score 
Attitude 
a. Reusing medication in the future is: 
Harmful 1   2   3   4   5   6   7 beneficial 
b. Reusing medication in the future is: 
good 1   2   3   4   5   6   7 bad……………..negative endpoint 
c. Reusing medication in the future is: 
satisfying (for me) 1   2   3   4   5   6   7 dissatisfying (for me) ……………..negative endpoint  
d. Reusing medication in the future is: 
worthless 1   2   3   4   5   6   7 worthwhile 
Attitude items used a mix of positive (a and d) and negative endpoints (b and c). 
Items with negative endpoints (b and c), were recoded so that the higher number reflects the 
positive attitude to the target behaviour. For example, an answer of 7 becomes a score of 1, five 
become a score of 3, and 4 remains 4. 
The mean of the item scores is calculated to give an overall attitude score. 





The endpoints of the items in subjective norms (the perceived social pressure to perform 
the behaviour or not) construct were developed using items referring to the opinion of 
important people in general. Items using the response format that completed an otherwise 
incomplete sentence (I should/I should not) were arranged so that the end of the scale was a 
negative endpoint (e.g. most people who are important to me would think that I should / I 
should not reuse medication in the future). However, items using the response format 
(strongly disagree/strongly agree) of a complete sentence were arranged so that the end of 
the scale was a positive endpoints. For example, most people who are important to me 
would want me to reuse medication in the future (Table 5.5).  
Table 5.5 calculating the mean of the item scores to give an overall subjective norm 
score  
Subjective norm 
a. I would feel under social pressure to reuse medication in the future: 
strongly disagree 1   2   3   4   5   6   7 strongly agree 
b. Most people who are important to me would want me to reuse medication in the future: 
strongly disagree 1   2   3   4   5   6   7 strongly agree 
c. It would be expected of me to reuse medication in the future: 
strongly disagree 1   2   3   4   5   6   7 strongly agree  
d. Most people who are important to me would think that ------------- reuse medication in the 
future: 
I should 1   2   3   4   5   6   7  I should not……………..negative endpoint 
Subjective norm items used a mix of positive (a, b, and c) and negative endpoint (d). 
Items with negative endpoints (d), were recoded so that the higher number reflect the positive 
subjective norm to reuse medicines in the future. For example, an answer of 7 becomes a score of 
1, 5 becomes a score of 3, and 4 remains 4. 
The mean of the item scores is calculated to give an overall subjective norm score.  




The end points of PBC were developed using the internal (self-efficacy) and the external 
(controllability) dimensional control to reflect participant’s confidence to reuse medication.  
Items representing self-efficacy measured whether participants felt confident about being 
able to reuse medication using a mix of negative (possible/impossible) and positive 
(strongly disagree/strongly agree) endpoints. For example, ‘for me to reuse medication in 
the future is’, and ‘I am confident that I could reuse medication in the future if I wanted to’, 
respectively. Items representing controllability measured whether participants felt that 
reusing medication is up to them or beyond their control using positive (strongly 
disagree/strongly agree) endpoints. For example, the decision to reuse medication in the 
future is beyond my control (Table 5.6).  
Table 5.6 Calculating the mean of the item scores to give an overall PBC score  
PBC 
Self-efficacy Controllability 
a. I am confident that I could reuse medication 
in the future if I wanted to: strongly disagree 1   
2   3   4   5   6   7 strongly agree  
c. The decision to reuse medication in 
the future is beyond my control: 
strongly disagree 1   2   3   4   5   6   7 
strongly agree 
b. For me to reuse medication in the future is: 
possible 1   2   3   4   5   6   7 impossible 
……………..negative endpoint 
d. Whether I reuse medication or not in 
the future is entirely up to me: 
strongly disagree 1   2   3   4   5   6   7 
strongly agree  
PBC items used a mix of positive (a, c, and d) and negative endpoint (b). 
Items with negative endpoints (b), were recoded so that the higher number reflect the 
positive PBC to reuse medicines in the future. For example, an answer of 7 become a 
score of 1, 5 become a score of 3, and 4 remains 4. 
The mean of the item scores is calculated to give an overall PBC score.  
Mean = (4 + 6 (after recoding) + 7 + 7) / 4 = 6     
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The composite scores for all variables in the direct measures (attitude, subjective norm, and 
perceived behavioural control) were calculated based on the mean of the items. In total, 12 
items were developed according to the recommendation by Ajzen (2006) and Francis et al. 
(2004). 
5.4.3 Developing the MRQ items of the intention construct 
A generalised intention method was used to measure participant’s intentions towards 
reusing medicines in the future. The decision to choose the generalised intention method 
was guided by the fact that this method allowed to develop three items using 1 to 7 
unipolar Likert scale in which internal consistency can be demonstrated, therefore, the 
items developed using this method make sense to measure reusing medicine as a behaviour. 
In addition, the generalised intention method is the most commonly used method in TPB 
literature where most research has been about participant’s own health-related behaviour 
such as would be for medication reuse (Francis et al., 2004). The Intention performance 
method, which is used to observe the actual behaviour, was not used in this study as 
medicines reuse is not allowed in the UK and the actual behaviour (i.e. medicines reuse) 
cannot be measured. Therefore, intention performance was not used. Also, it was decided 
not to use the intention simulation method. Although intention simulation appeared to be a 
valid measure to simulate the actual behaviour, it is very time consuming and sometimes 
misleading if it is not constructed carefully. 
The composite scores for the three variables of intention were calculated based on the mean 
of the items. The three items developed to measure intention towards reusing medication 
were according to the recommendations by Ajzen (2006) and Francis et al. (2004) and 
using positive (strongly disagree / strongly agree) endpoints (Table 5.7). 
141 
 
Table 5.7 Calculating the mean of the item scores to give an overall intention score  
  Intention  
a. I expect to reuse medication in the future: 
 strongly disagree 1   2   3   4   5   6   7 strongly agree 
b. I want to reuse medication in the future: 
strongly disagree 1   2   3   4   5   6   7 strongly agree 
c. I intend to reuse medication in the future: 
strongly disagree 1   2   3   4   5   6   7 strongly agree  
Intention items used positive (strongly disagree - strongly agree) endpoints. 
The mean of the item scores is calculated to give an overall intention score. 
Mean = (4 + 6 + 7 ) / 3 = 5.7     
 
5.4.4 Developing the MRQ background factors items  
In TPB, the information regarding the determinants of the behaviour is included in a 
person’s behavioural, normative and control beliefs. However, TPB does not specify the 
roots of these beliefs. Instead, Ajzen linked the possible background factors that may have 
an effect and would influence the behaviour to construct of TPB. These background factors 
include information about people that is related to the behaviour; for example, and relating 
to medicines reuse; information about people’s long-term condition and whether they were 
using medicines or not, were included in the MRQ. In addition, demographic variables 
such as age, gender, ethnicity, religion, and the level of education were also included in the 
MRQ as background factors (Ajzen, 2011).  
In this thesis, background factor items were developed and added to the MRQ. These 
factors were expected to influence people’s intention to reuse medicines in the future 
indirectly by their effect on the proximal determinants of TPB. 
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5.5 Developing the MRQ 
The first draft (v1) of the MRQ (Appendix 9) included a set of items which assessed the 
three direct measures (predictor variables) of the intention (attitude construct, subjective 
norm construct, and perceived behavioural control construct), the belief-based items of the 
same three predictor variables developed from the elicitation study (behavioural belief 
construct, normative belief construct, and control belief construct), items assessing 
behavioural intention construct, and the background items that are related to medicines 
reuse as behaviour. The MRQ items were developed in line with Ajzen (2006) and Francis 
et al. (2004) guidelines and were piloted using validity and reliability tests as described in 
the next sections. 
5.6 Validity and reliability of the MRQ  
Validity and reliability are important concepts of the questionnaire measuring accuracy and 
consistency, respectively. Reliability is generally necessary for validity but it doesn’t 
guarantee validity. Although both reliability and validity are considered separate concepts, 
in fact, they are related to each other. To clarify this more, the relationship between validity 
and reliability can be shown by the 4 different scenarios as below (Golafshani, 2003): 
1. Reliable and not valid, the questionnaire measures the variable consistently but it 
doesn’t measure what it is supposed to measure. 
2. Valid but not reliable, the questionnaire measures what it is meant to measure but 
it is unstable/inconsistent. 
3.  Neither reliable nor valid, the questionnaire is inconsistent / unstable and does 
not measure what it is meant to measure. 
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4.  Both Reliable and valid, the questionnaire is consistent / stable and measures 
what it is meant to measure. 
For example, with reference to Figure 5.2 if the concept of medicines reuse were measured 
perfectly by the MRQ for a person, then it is like hitting the centre of the target. If not, 
then, it is like missing the centre. The more you are off target for that person, the further 
you are from the centre (Figure 5.2). To clarify more, first, if the hits are on the target 
consistently but missing the centre of the target then the MRQ is measuring consistently the 
wrong value for the participants (i.e. the MRQ is reliable and not valid). Second, if the hits 
are randomly spread across the target, but rarely hit the centre of the target, then the MRQ 
is getting the right answer for the group, but not very well for individuals (i.e. the MRQ is 
valid but not reliable). Third, if the hits are spread across the target and you are 
consistently missing the centre, the MRQ is neither reliable nor valid. Finally, if the hits 
are consistently on the centre of the target, then the MRQ achieved the “Robin Hood” 
scenario meaning that the MRQ is both reliable and valid. (Trochim, 2006).  In this thesis, 
the aim was to develop the MRQ that is both reliable and valid, the “Robin Hood” 
scenario. 
Figure 5.2 The relationship between validity and reliability, adapted from Trochim 




5.6.1 Validity of the MRQ 
5.6.1.1 Content validity of the MRQ items 
Content Validity (CV) is the degree to which items in the questionnaire can fully cover, 
assess or measure the construct of interest in the questionnaire, meaning that these items 
must relate to the construct being measured (Shaughnessy and Zechmeister, 1985; 
Bolarinwa, 2015). To determine the validity of the MRQ, CV was explored by interviewing 
11 of our experts panel (the response rate of our panel of expert was 58%, 11 out of 19 
participant experts attended the cognitive interviewing). This was conducted using the 4-
stage process of cognitive interviewing and asking CV questions about 1) understanding, 2) 
remembering, 3) judging and 4) relevance of each item on the MRQ. Respondents 
indicated their agreement or disagreement with each CV question on a 4-point Likert scale 
(4 = strong agreement, 1 = strong disagreement).    
The cognitive interviewing questions were adapted from Tourangeau (1984), who 
identified a 4 stage process to explain how information is stored, retrieved, and organized 
by respondents to answer the questionnaire items. The 4 stage process applied to the MRQ 
were comprehension of each question (understanding of the question); retrieval of relevant 
information from memory (remembering the answer to the question); relevance and 
judgment of the information needed and formation of the response (Willis, 2015). The CV 





Table 5.8 The four CV questions which were used to assess each item in the MRQ 
using 4-point response scale 
CV Questions for each item in the MRQ Agreement or disagreement level 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
Q1. I understand what this question says     
Q2. I would be able to remember the 
information needed in order to answer this 
question 
    
Q3. I would be able to decide which response to 
choose 
    
Q4. This question is relevant to measuring 
people beliefs about  the concept of medicine 
reuse 
    
 
A Content Validity Index (CVI) was calculated for each item on the scale (I-CVI) as well 
as for the overall scale (S-CVI). According to recommendations by Polit et al. (2007), the 
MRQ scale to have an excellent content validity, should be composed of items with (I-CVI) 
of 0.78 or higher and an S-CVI/Ave of 0.90 or higher.  The (I-CVI) of the MRQ was 
determined by calculating the proportion of the 11 experts who would have to give a rating 
of 3 or 4 to each of the four CV questions for each item. A minimum of 0.81 (I-CVI) was 
considered an acceptable value for an overall rating, which meant that 9 experts out of 11 
would give a rating of 3 or 4 of the four CV questions. In addition, the (S-CVI/ Ave) and 
the (S-CVI/ UA) was also calculated to be 0.97 and 0.74 respectively. Definitions of CV 
terms are described in Figure 5.3. 
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Figure 5.3 Definitions of content validity terms.  
I-CVI, item-level content validity index; S-CVI, scale-level content validity index; S-
CVI/UA, scale-level content validity index, universal agreement calculation method; S-
CVI/Ave, scale-level content validity index, averaging calculation method. Adapted from 
(Polit and Beck, 2006) 
 
All 50 MRQ items were assessed as relevant for measuring people’s intentions to 
participate in medicines reuse (I-CVI for responses to CV Q4 ≥0.83 for all 50 items). 
Agreement was also reached about remembering necessary information and making 
judgment needed for completing all MRQ items (I-CVI for responses to CV Q2 and 
3 ≥0.83 for all 50 items). Regarding understanding what the question said, only 3 out of 11 
panel members could not clearly understand 3 items (item 11, 12, and 37) out of 50 (was 
not clear in terms of their wording) and made recommendations on rephrasing (I-CVI for 
responses to CV Q1 item 11 and 12 were 0.73, and CV Q1 item 37 was 0.64). These three 
items were reworded as described in Table 5.9. 
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Table 5.9 Rewording item 11, 12, and 37 according to CV results  
 
5.6.1.2 Data screening and construct validity  
A principal component analysis (PCA) was conducted with orthogonal rotation (varimax) 
using Statistical Package for Social Sciences (SPSS) software version 23. Data screening 
for multicollinearity (variables that are highly correlated) and singularity (variables that are 
perfectly correlated) was performed. The R matrix (or the correlation matrix) table, an 
SPSS output produced using the coefficient and significant levels options is shown in 
Appendix 10. The upper half of the table included the Pearson correlations coefficients 
between all pairs of the MRQ items. The lower half of the table contained the one-tail 
significance of these coefficients. The idea of the R matrix is that in order to run factor 
analysis, the variables should not have perfect correlation, instead it should have fair 
correlation. To clarify this more, the R matrix is used to check the relationship patterns. 
The R matrix output of the MRQ was scanned for any variables with correlation over 0.3, 
Items before CV Items after CV 
11. Environmentalists think that I 
should 1   2   3  4   5  6  7 I should not 
accept sealed, returned blister-pack 
medication  
11. Environmentalists would believe that I 
should 1   2   3  4   5  6  7 I should not reuse  
sealed, returned blister-pack medication  
12. Pharmaceutical industry think that 
I should 1   2   3  4   5  6  7 I should 
not accept sealed, returned blister-pack 
medication 
12. Pharmaceutical industry would believe that 
I should 1   2   3  4   5  6  7 I should not reuse  
sealed, returned blister-pack medication 
37. What is your gender? 
a. Male   b. Female    
37. What is your gender? 




then, correlation coefficients were scanned themselves for any value greater than 0.9 which 
may indicate that a problem could arise as a result of the multicollinearity. Although there 
was a possible risk of multicollinearity between control factors 2 and 3, and attitude 2 and 
4 (as they have correlation of more than 0.3 and the correlation coefficients for themselves 
are > 0.9), the determinant for the R matrix was 6.124 E-17 (0.0006124). The determinant 
value confirmed that the multicollinearity is not a problem as it is greater than the 
necessary value of 0.00001 (Field, 2009). 
The sampling adequacy for factor analysis was verified by the Kaiser–Meyer–Olkin 
(KMO) measure (i.e. factor analysis is appropriate for this data). The result of the KMO 
was 0.735 (good) for the multiple items, and all KMO values for individual items were > 
0.59 (after checking the anti-image correlation matrix output), which is well above the 
acceptable limit of 0.5 (Field, 2009). Kaiser recommends a bare minimum of 0.5 for both 
multiple and individual items, and that values between 0.5 and 0.7 are mediocre, values 
between 0.7 and 0.8 are good, values between 0.8 and 0.9 are great and values above 0.9 
are superb (Field, 2009; cited Hutcheson and Sofroniou, 1999).  
The Bartlett’s measure tests the null hypothesis that the original correlation matrix is an 
identity matrix. A significant Bartlett’s test (p <0.05), means that the R matrix is not an 
identity matrix and there is some relationships between the variables. In factor analysis, 
the value of Bartlett’s test should be significant, meaning that it is important to have some 
relationships between variables. For the MRQ, the value of Bartlett’s test of sphericity χ² 
(253) was = 1287.947, p <0.001, indicating that correlations between items were 




Table 5.10 Results of Kaiser–Meyer–Olkin (KMO) and Bartlett's Test from (SPSS 
output) 
The results of PCA, Bartlett’s test, and KMO, showed that multicollinearity is not a 
problem, sufficient correlations exist, and there is sampling adequacy for factor analysis, 
respectively. As a result Confirmatory Factor Analysis (CFA) was performed. 
CFA is a statistical test (method) used to help verify the factor structure of a set of the 
observed variables. CFA is theory driven, that is, the analysis is driven by the theoretical 
model to measure relationships between the observed and unobserved variables (Schreiber 
et al., 2006). When applying CFA, the theoretical model is used to estimate population 
covariance matrix that is compared with observed covariance matrix. The aim is to 
minimise the difference between estimated and the observed covariance matrices 
(Schreiber et al., 2006). CFA was performed using a sample of 46 participants using 
Analysis of a Moment Structures (Amos) SPSS software. The factor loadings for each item 
of the indirect and direct measures are shown in Table 5.11 and Table 5.12, respectively.  
Items with low factor loading were either deleted (Control belief item number 5 as it is 
very low) or rephrased (normative belief item number 1 and 2, control belief item number 
4, subjective norm item number 1 and 3, perceived behavioural control item number 3 and 
Kaiser-Meyer-Olkin Measure of Sampling Adequacy 0.735 




 df 406 
 Sig. 0.000 
Kaiser-Meyer-Olkin Measure of Sampling Adequacy 0.735 




 df 406 
 Sig. 0.000 
150 
 
4, although the factor loading is low and below the required 0.5, but it was decided to 
rephrase and to give these items another opportunity as their low factor loadings maybe due 
to small sample size).   
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Table 5.11 Shows the factor loadings for the indirect measure of the MRQ item using 
Amos SPSS 
MRQ items (indirect measures) Construct Factor 
loading 
1. I think for me to contribute toward reducing the harmful 
effects of medication on the environment is * Reusing 
sealed, returned blister-pack medication will help me 
contribute toward reducing the harmful effects of 




2. I think for me to contribute toward reducing the NHS 
drug expenditure is * Reusing sealed, returned blister-
pack medication will help me contribute toward 




3. I think for me to receive low quality medication is * 
Reusing sealed, returned blister-pack medication will 
result in me receiving low quality medication  
Behavioural 
belief 0.760 
4. I think for me to receive unsafe medication is * Reusing 
sealed, returned blister-pack medication will result in 
me receiving unsafe medication  
Behavioural 
belief 0.889 
5. I think for me to receive incorrect medication is * 
Reusing sealed, returned blister-pack medication will 
result in me receiving incorrect medication  
Behavioural 
belief 0.801 
Environmentalists would believe that I should reuse sealed, 
returned blister-pack medication * Generally speaking, how 
much do you want to do what environmentalists believe 




The pharmaceutical industry would believe that I should 
reuse sealed, returned blister-pack medication * Generally 
speaking, how much do you want to do what the 






MRQ items (indirect measures) Construct Factor 
loading 
1. My close friends would believe that I should reuse 
sealed, returned blister-pack medication * Generally 
speaking, how much do you want to do what close 




2. My family would believe that I should reuse sealed, 
returned blister-pack medication * Generally speaking, 
how much do you want to do what your family believes 




1. I expect that any medication offered to me for reuse 
will be in the original, sealed, blister-packaging * It 
would make it easier for me to reuse medication if I 





2. I expect to see evidence that any medication offered to 
me for reuse would have been quality-checked * It 
would make it easier for me to reuse medication if I 




3. I expect to see evidence that any medication offered to 
me for reuse would have been safety-checked * It 
would make it easier for me to reuse medication if I 
could see that it had been safety-checked  
 
0.923 
4. I expect that any medication offered to me for reuse 
will have more than six months of shelf-life remaining 
* It would make it easier for me to reuse medication if I 





5. I expect to be offered some form of reward for reusing 
medication * It would make it easier for me to reuse 





Table 5.12 Shows the factor loadings for the direct measure and intention of the MRQ 
item using Amos SPSS  
MRQ items (direct measure and intention) Construct Factor 
loading 








Reusing medication in the future is satisfying (for me) 1   2   3   
4   5   6   7 dissatisfying (for me) 
Attitude 
0.724 




I would feel under social pressure to reuse medication in the 




Most people who are important to me would want me to reuse 




It would be expected of me to reuse medication in the future 




Most people who are important to me would think that ---------
---- reuse medication in the future  I should 1   2   3   4   5   6   
7  I should not  
Subjective 
norm 0.779 
I am confident that I could reuse medication in the future if I 






For me to reuse medication in the future is possible 1   2   3   4   













MRQ items (direct measure and intention) Construct Factor 
loading 






I expect to reuse medication in the future strongly disagree 1   
2   3   4   5   6   7 strongly agree 
Intention 
0.889 
I want to reuse medication in the future strongly disagree 1   2   
3   4   5   6   7 strongly agree 
Intention 
0.970 
I intend to reuse medication in the future strongly disagree 1   




5.6.2 Reliability testing of the MRQ items 
Reliability is the ability of the questionnaire to produces the same results (constant results) 
under the same conditions over repeated observations, or referred sometimes as the 
stability or the consistency of the scores of the questionnaire items over time or across 
raters (Francis et al., 2004; Bolarinwa, 2015). Two methods were used to measure the 
reliability of the MRQ items. Cronbach’s alpha coefficient as a measure of internal 
consistency of the items in the direct measures of TPB and Pearson correlation as a 
measure of test-retest reliability of indirect measures of TPB (Francis et al., 2004; Ajzen, 
2006). 
5.6.2.1 Reliability of direct measures of TPB (internal consistency) 
The reliability of direct measures were calculated using Cronbach’s alpha (α) coefficient to 
determine the internal consistency of direct measures of the MRQ constructs. The alpha (α) 
coefficient is an estimate of reliability based on the average of correlations between all 
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items in the scale. It is the current standard statistic for assessing the reliability of a scale 
composed of multiple items and it is the most appropriate reliability measure to use for 
Likert and semantic differential scales because these methods assume that the items are 
parallel sample measures of the same attitude content domain. The alpha (α) coefficient 
depends not only on the correlation between items but also on the number of items, 
therefore, longer scales tend to have a higher (α) coefficient value. As a result, the alpha (α) 
coefficient should be carefully interpreted for large scale questionnaires (Field, 2009). 
The alpha (α) coefficient value ranges from 0 to 1 providing the overall evaluation of the 
measure’s reliability. If all items are entirely independent (not correlated, or share no 
covariance) from one another then α = zero. If all items have high correlation or share high 
covariance then α will reach 1 (as the number of the items in the scale reach infinity). The 
alpha (α) values of <0.5 are usually not acceptable, with the minimum acceptable value to 
be in the range between 0.65 to 0.8  (Goforth, 2016).  
The alpha (α) coefficient of the direct measures and intention construct was 0.904. The 
highest alpha (α) coefficient value was reported with intention 0.954 and attitude 0.935 
constructs and lowest with perceived behavioural control constructs 0.303. Moreover, the 
alpha (α) coefficient value of the subjective norm construct was also within the acceptable 
range (0.706). The alpha (α) coefficient value of the PBC was not accepted as it was below 
0.5,  but improved first by deleting PBC item 4 (as the α value increased from 0.303 into 
0.562), and then further improved by further deleting PBC items 3 as the α value further 
increased from 0.562 into 0.830 (Table 5.13). As a result, PBC items 3 and 4 were reworded 
to have new PBC 3 and 4 items. 
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Table 5.13 The internal consistency (Cronbach’s alpha) of the direct measures of the 
MRQ constructs 





N of Items 
Direct measures construct and intention 0.904 0.918 15 
Attitude 0.935 0.944 4 
Subjective norm 0.706 0.714 4 
Perceived behavioural control (PBC) 
PBC if PBC item 4 deleted (Whether I 
reuse medication or not in the future is 
entirely up to me), PBC if PBC item 3 
(The decision to reuse medication in 
the future is beyond my control) 
further deleted (i.e. both PBC item 3 





Intention  0.954 0.955 3 
 
5.6.2.2 Test re-test reliability of indirect measures (temporal stability) 
For the reliability assessment of indirect measures, it was not appropriate to use an internal 
consistency criterion (Cronbach’s alpha), because different accessible beliefs may well be 
inconsistent with each other (i.e. people can logically hold both positive and negative 
beliefs about the same behaviour). To clarify more, a person may believe that the referral 
of patients with back pain will assure the patients and also that an x-ray will expose these 
patients to unnecessary radiation. A GP may be highly motivated to comply with the 
expectations of professional colleagues but not at all motivated to comply with the 
expectations of patients. Consequently, the removal of some of these beliefs from the 
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overall measures on the basis of low or negative correlations is not logical (Francis et al., 
2004; Ajzen, 2006). As a result, test-retest reliability which is sometimes referred to a 
temporal stability was used to measure the reliability of indirect measure of the MRQ 
constructs (table 4.14).  Test-retest reliability examined the ability of the indirect measures 
of the MRQ items to produce consistent results when the same MRQ items were tested at 
two different points of time (the time interval was at least two weeks) by a administering 
the MRQ to the same participant twice. Only 24 (52%) participants completed the MRQ 
twice (i.e. for the first time T1 and after two weeks T2) out of 46 who were invited to do so 
via the University email system.   
Of the total 28 MRQ items of the indirect measures, 22 had correlations that met the 
threshold for reliability (> 0.5). The Pearson correlation of the remaining 6 MRQ items 
(normative belief item number 1 and 2, motivation to comply item number 1 and 2, control 
belief item number 5 and power of control factor item number 5) was < 0.5. The low 
correlation of these items may affect the reliability of these items to capture people’s belief 
about reusing medicines. This provided the rationale for removing some of the questions as 




Table 5.14. Test re-test reliability of the indirect measures of the MRQ items (Pearson 
correlation) 
MRQ Item Pearson 
correlation 
Behavioural Belief 1 (I think for me to contribute toward reducing the 
harmful effects of medication on the environment is) 
0.622 
Behavioural Belief 2 (I think for me to contribute toward reducing the 
NHS drug expenditure is) 
0.579 
Behavioural Belief 3 (I think for me to receive low quality medication is) 0.686 
Behavioural Belief 4 (I think for me to receive unsafe medication is 0.649 
Behavioural Belief 5 (I think for me to receive incorrect medication is) 0.750 
Outcome evaluation 1 (Reusing sealed, returned blister-pack medication 
will help me contribute toward reducing the harmful effects of medication 
on the environment)  
0.523 
Outcome evaluation 2 (Reusing sealed, returned blister-pack medication 
will help me contribute toward reducing NHS drug expenditure)  
0.642 
Outcome evaluation 3 (Reusing sealed, returned blister-pack medication 
will result in me receiving low quality medication) 
0.540 
Outcome evaluation 4 (Reusing sealed, returned blister-pack medication 
will result in me receiving unsafe medication) 
0.685 
Outcome evaluation 5 (Reusing sealed, returned blister-pack medication 
will result in me receiving incorrect medication) 
0.506 
Normative belief 1 (Environmentalists would believe that I should reuse 
sealed, returned blister-pack medication) 
0.216 
Normative belief 2 (The pharmaceutical industry would believe that I 
should reuse sealed, returned blister-pack medication)  
0.438 
Normative belief 3 (My close friends would believe that I should reuse 
sealed, returned blister-pack medication)  
0.663 
Normative belief 4 (My family would believe that I should reuse sealed, 




MRQ Item Pearson 
correlation 
Motivation to comply1 (Generally speaking, how much do you want to do 
what environmentalists believe you should do?) 
0.388 
Motivation to comply 2 (Generally speaking, how much do you want to do 
what the pharmaceutical industry believes you should do?) 
0.381 
Motivation to comply 3 (Generally speaking, how much do you want to do 
what your close friends believe you should do?) 
0.571 
Motivation to comply 4 (Generally speaking, how much do you want to do 
what your family believes you should do?) 
0.517 
Control belief 1 (I expect that any medication offered to me for reuse will 
be in the original, sealed, blister packaging) 
0.624 
Control belief 2 (I expect to see evidence that any medication offered to 
me for reuse would have been quality-checked) 
0.586 
Control belief 3 (I expect to see evidence that any medication offered to 
me for reuse would have been safety-checked) 
0.596 
Control belief 4 (I expect that any medication offered to me for reuse will 
have more than six months of shelf-life remaining)  
0.539 
Control belief 5 (I expect to be offered some form of reward for reusing 
medication) 
0.419 
Power of control factor 1 (It would make it easier for me to reuse 
medication if I could see that it was in the original, sealed, blister 
packaging)  
0.579 
Power of control factor 2 (It would make it easier for me to reuse 
medication if I could see that it had been quality-checked) 
0.530 
Power of control factor 3 (It would make it easier for me to reuse 
medication if I could see that it had been safety-checked) 
0.558 
Power of control factor 4 (It would make it easier for me to reuse 





MRQ Item Pearson 
correlation 
Power of control factor 5 (It would make it easier for me to reuse 
medication if I were offered some form of reward) 
0.480 
 
5.7 Results summary  
The MRQ items were developed following the standard construction procedures described 
by the Ajzen (2006) and Francis et al. (2004) guidelines. These procedures briefly required 
first an elicitation study to define the behaviour (i.e. medicines reuse) and population of 
interest, and to develop the items of indirect measures of TPB (refer to Chapter 4). Then, 
items of the direct measures of TPB, and the background factors that are related to 
medicines reuse behaviour were also developed. Standard scaling procedures were applied 
using a 7 point Likert scale for both direct and indirect measure items and a multiple choice 
format for background factor items. The item endpoints of the 7 point Likert scale included 
a mix of positive and negative end points. The first MRQ draft was developed and 
composed of 50 items. This draft was piloted and subjected to validity and reliability tests. 
These tests included content validity (which was explored by cognitive interviewing of 11 
participant’s and before administering the MRQ). Then, MRQ was administered to 46 
participants and further testing was applied (CFA, alpha coefficient and Pearson 
correlation).   
As a result of the piloting of the draft MRQ, two items were deleted from the MRQ and not 
replaced. These items were from indirect measures and relating to providing a rewarding 
system that may encourage people to reuse medicines in the future (i.e. control factor item; 
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I expect to be offered some form of reward for reusing medication, and power of control 
factor item; It would make it easier for me to reuse medication if I were offered some form 
of reward). The deletion of these items was based on results from CFA where the factor 
loading was very low (0.026) and test re-test reliability (Pearson correlation) was below 
0.5. Moreover, some participants commented that the reward system is not affecting their 
decision to reuse medicine or not.  
Four items from indirect measures were deleted but replaced and reworded. Those items 
were 2 normative belief items (environmentalists would believe that I should reuse sealed, 
returned blister-pack medication, and the pharmaceutical industry would believe that I 
should reuse sealed, returned blister-pack medication), and 2 motivation to comply items 
(generally speaking, how much do you want to do what environmentalists believe you 
should do?, and generally speaking, how much do you want to do what the pharmaceutical 
industry believes you should do?). The deletion of these items was based on results from 
CFA where the factor loading was low (0.358 and 0.356, respectively) and test re-test 
reliability (Pearson correlation) was below 0.5. These deleted items were from indirect 
measures, which means it was developed from the elicitation study. Therefore, it was 
important to contact our expert panel from the elicitation study and asked their opinion 
(who signed a consent form and agreed to be further contacted) before replacing these four 
items.  
As result, an email was sent to them with a question asking about other people who may 
influence their decision to reuse medicines other than environmentalist and people from the 
pharmaceutical industry. The reply came from 10 participants out of 19 who commented 
that pharmacist and doctors would affect their decisions. As a  results, the deleted items 
162 
 
were replaced by four items; 2 normative belief item items (my doctor would believe that I 
should reuse sealed, returned blister-pack medication, and my pharmacist would believe 
that I should reuse sealed, returned blister-pack medication), and 2 motivation to comply 
items (generally speaking, how much do you want to do what your doctor believes you 
should do?, and generally speaking, how much do you want to do what your pharmacist 
believes you should do?).  
One item from subjective norm (I would feel under social pressure to reuse medication in 
the future) was reworded into most people whose opinions I value, would approve of my 
decision to reuse medication in the future as the factor loading was low. Finally, two items 
from PBC construct (the decision to reuse medication in the future is beyond my control, 
and whether I reuse medication or not in the future is entirely up to me) were also reworded 
into the decision to reuse medication in the future is within my control, and whether or not 
I reuse medication in the future is completely up to me as their factor loadings were below 
0.5. Although the factor loadings were very low for these two items, it was decided to 
reword these items and give them another chance instead of only deleting them at this stage 
as these items were measuring the controllability of the behaviour. Therefore, it was 
important to make sure that the very low factor loading is not due to poor construction or 
wording of these two items. 
Based on the results of the piloting and refinement processes described above, the second 
draft (v2) of the MRQ (Appendix 11) was developed. The second draft MRQ was 
composed of 48 items and underwent further piloting by sending the MRQ to another 46 
participants and the data analysed using CFA, and internal consistency (direct measures 
and intention construct) in order to ensure that the newly developed or reworded items 
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were valid. The result of the second piloting based on the factor loading from CFA indirect 
and direct measures (Table 5.15 and Table 5.16, respectively), showed good factor for 
loading with the exception of two items from PBC construct which measure the 
controllability of medicines reuse behaviour. The factor loadings for those two items was 
low and negatively loaded as well. Moreover, internal consistency of the PBC was also 
below 0.5. Those two items were measuring the controllability of the medicines reuse 
behaviour and were given a chance in the first piloting by rewording them, but were 
deleted in the second piloting. Therefore, the remaining PBC items included in third 
version of MRQ measured only self-efficacy of the medicines reuse behaviour.  
Table 5.15 Showed factor loading of the indirect measures of the second MRQ version  
MRQ items (indirect measures) Construct Factor 
loading 
I think for me to contribute toward reducing the harmful 
effects of medication on the environment is x Reusing 
sealed, returned blister-pack medication will help me 
contribute toward reducing the harmful effects of 




I think for me to contribute toward reducing the NHS drug 
expenditure is x Reusing sealed, returned blister-pack 
medication will help me contribute toward reducing NHS 




I think for me to receive low quality medication is x 
Reusing sealed, returned blister-pack medication will result 
in me receiving low quality medication  
Behavioural 
belief 0.777 
I think for me to receive unsafe medication is x Reusing 
sealed, returned blister-pack medication will result in me 





MRQ items (indirect measures) Construct Factor 
loading 
I think for me to receive incorrect medication is x Reusing 
sealed, returned blister-pack medication will result in me 
receiving incorrect medication  
Behavioural 
belief 0.913 
My doctor would believe that I should reuse sealed, 
returned blister-pack medication x Generally speaking, how 
much do you want to do what your doctor believes you 




My pharmacist would believe that I should reuse sealed, 
returned blister-pack medication x Generally speaking, how 
much do you want to do what your pharmacist believes you 




My close friends would believe that I should reuse sealed, 
returned blister-pack medication x Generally speaking, how 
much do you want to do what close friends believe you 




My family would believe that I should reuse sealed, 
returned blister-pack medication x Generally speaking, how 
much do you want to do what your family believes you 




I expect that any medication offered to me for reuse will be 
in the original, sealed, blister-packaging x It would make it 
easier for me to reuse medication if I could see that it was 




I expect to see evidence that any medication offered to me 
for reuse would have been quality-checked x It would make 
it easier for me to reuse medication if I could see that it had 




I expect to see evidence that any medication offered to me 






MRQ items (indirect measures) Construct Factor 
loading 
it easier for me to reuse medication if I could see that it had 
been safety-checked 
I expect that any medication offered to me for reuse will 
have more than six months of shelf-life remaining x It 
would make it easier for me to reuse medication if I could 







Table 5.16 Showed factor loading of the direct measures and intention of the second 
MRQ version 
MRQ items (direct measures and intention) Construct Factor 
loading 
Reusing medication in the future is Harmful 1   2   3   4   5   6   
7 beneficial  
Attitude 
0.934 




Reusing medication in the future is satisfying (for me) 1   2   3   
4   5   6   7 dissatisfying (for me) 
Attitude 
0.845 




Most people whose opinions I value, would approve of my 
decision to reuse medication in the future strongly disagree 1   2   
3   4   5   6   7 strongly agree 
Subjective 
norm 0.759 
Most people who are important to me would want me to reuse 




It would be expected of me to reuse medication in the future 




Most people who are important to me would think that -----------




I am confident that I could reuse medication in the future if I 





For me to reuse medication in the future is possible 1   2   3   4   







MRQ items (direct measures and intention) Construct Factor 
loading 
The decision to reuse medication in the future is within my 





Whether or not I reuse medication in the future is completely up 





I expect to reuse medication in the future strongly disagree 1   2   
3   4   5   6   7 strongly agree 
Intention 
0.949 
I want to reuse medication in the future strongly disagree 1   2   
3   4   5   6   7 strongly agree 
Intention 
0.956 
I intend to reuse medication in the future strongly disagree 1   2   




The alpha (α) coefficient values were consistent and actually improved compared to the 
previous piloting (Table 5.17). The alpha (α) coefficient value of the direct measures and 
intention construct was 0.931 in the second piloting which showed an improvement in term 
of internal consistency between the items in the direct measures and intention construct 
compared to the previous piloting (0.904). The internal consistency of attitude slightly 
improved as the alpha (α) coefficient values slightly increased from 0.935 in the first 
piloting to 0.954 in the second piloting. The subjective norm and the PBC internal 
consistency showed an improvement as the alpha (α) coefficient values of the subjective 
norm increased from 0.706 in the first piloting to 0.818 in the second piloting and alpha (α) 
coefficient values of PBC increased from 0.303 in the first piloting to 0.425 in the second 
piloting. However, the alpha (α) coefficient values of PBC is far from the acceptable value. 
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Hence two PBC items that measured controllability of reusing medicines were deleted. The 
intention construct internal consistency was the same as the alpha (α) coefficient value in 
the first piloting.  
Table 5.17 Alpha (α) coefficient values of the direct measure and intention construct 
of the second MRQ version 





N of Items 
Direct measures construct and intention 0.931 0.930 15 
Attitude 0.954 0.956 4 
Subjective norm 0.818 0.820 4 
Perceived behavioural control (PBC) 0.425 0.425 4 
Intention  0.953 0.954 3 
 
The third version (v3) of the MRQ were composed of 46 items (Appendix 12) and was 
ready to be used to capture national views, beliefs and willingness of people to reuse 
medicines in the future.   
5.8 Discussion 
This chapter described phase 2 of the larger study the results of which are briefly 
summarised here. Starting from the elicitation of salient beliefs, this work progressed to the 
wording, formatting, and development of a reliable and valid MRQ items. The TPB 
framework was used as a tool to construct the MRQ items. The results from the validity 
and reliability testing were used to standardise the MRQ and showed that the MRQ is both 
valid and reliable. The final version of the MRQ has been therefore shown to be a stable 
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and accurate tool to capture wider, representative views of people’s beliefs and attitudes 
toward the reuse of medicines in the future. The results from the validity and reliability 
testing, and the refinement of the MRQ items which required two piloting phases ensured 
that the final version of the MRQ is considered robust enough to predict the intention to 
reuse medicines in the future. The development of a robust MRQ was considered a vital 
step before disseminating the MRQ nationwide. 
A recent systematic review evaluating the quality assessment of TPB-based questionnaire 
by Oluka et al. (2014) highlighted the top problems associated with the development of 
TPB-based questionnaire. The areas of problems were related to sample size estimation, the 
inclusion of both direct and indirect measures of TPB, inclusion of background factors 
related to the behaviour, and finally whether the researcher provided more information 
about the questionnaire development process. In this research, the development of the 
MRQ followed step by step guidelines of constructing TPB-based questionnaire as 
recommended by Ajzen (2006) and Francis et al. (2004). To clarify more, the final version 
of the MRQ was carefully developed and included both indirect (from the elicitation study) 
and direct measure items, background factor items that are related to medicines reuse as a 
behaviour. In addition, all the development and construction procedures, validity and 
reliability tests were clearly described in this chapter. Finally, the MRQ was disseminated 
to large sample size of about 1000 which is above the required sample for TBP-based 
questionnaire (more than 80) as recommended by Francis et al. (2004) – this is the subject 
of the next chapter.  
Therefore, there were no limitations or problems associated with the design, validity and 
reliability of the MRQ in this research. Moreover, and comparing to the quality assessment 
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of TBP-based questionnaire (Oluka et al., 2014), and the standard procedures 
recommended by Ajzen (2006) and Francis et al. (2004), there was nothing that could be 
done differently regarding the construction, validity, and reliability testing of the MRQ. 
Therefore the next phase (i.e. phase 3) of this study focussed on the dissemination of the 
MRQ and the utility of the TPB in predicting people’s beliefs and intentions to reuse 
medicines in the future, described in the next chapter. 
5.9 Conclusion 
The final version of the MRQ underwent two piloting phases in which items were deleted, 
refined and reworded. The piloting process involved validity and reliability testing until the 
MRQ items became consistent, accurate, and valid and there were no limitations or 
problems associated with the design, validity and reliability of the MRQ in this research. 
Therefore, a stable and accurate MRQ questionnaire was developed and ready for 
dissemination to measure people’s (i.e. from respondents drawn from around the UK) 




Chapter 6 PUBLIC PERCEPTIONS ABOUT MEDICINES REUSE – 
RESPONDENTS DRAWN FROM AROUND THE UK 
6.1 Introduction 
Following the elicitation study (detailed in Chapter 4), MRQ items were created, reviewed 
and underwent validity and reliability testing (detailed in Chapter 5). The final version of 
the MRQ was made available online using the Qualtrics online platform. Qualtrics is a 
simple yet sophisticated online survey platform which allowed the creation and distribution 
of the final version of the MRQ. An online panel was used to recruit participants in 
collaboration with a market research panel company called Research Now®. Online panels 
are a group of selected and pre-screened research paid participants who have agreed to 
provide information at specified intervals over an extended period of time. Research Now® 
has more than 11 million panel members in more than 40 countries including the UK. It 
helped with panel recruitment and ensured the participants were relevant respondents, who 
could provide real, relevant insight. Moreover, Research Now® was able to provide a panel 
list that is in line with targeted sampling to ensure representation from different regions in 
the UK. This was confirmed by a adding a screen out question: ‘we are interested in the 
views of people with a long term health condition only, do you currently have a long term 
health condition? yes, no’ as well as adding a background item ‘in which region of the UK 
do you currently live’, respectively – the latter allowed the researcher to monitor 
completions and ensure representations spread across the regions of the UK. 
Before online recruitment started, the final version of the MRQ was reviewed. The review 
process included:  
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a) Inclusion of clarification statements which were added before each MRQ item. For 
example,  
a. complete the following sentence: reusing medicine in the future is good 1 2 
3 4 5 6 7 bad,  
b. How far do you agree the following statement: most people whose opinions 
I value, would approve if I decided to reuse medication in the future 
strongly disagree 1 2 3 4 5 6 7 strongly agree, 
c. Answer the following question: generally speaking, how much do you want 
to do what your family believes you should do? 
d. Do you agree with the following statement: I expect that any medication 
offered to me for reuse will be in the original, sealed, blister packaging. 
b) Three items were added to the MRQ. Those items were;  
a. We are interested in the views of people with a long term health condition 
only, do you currently have a long term health condition?  
b. Which of the following (or another) long term health condition(s) do you 
have,  
c. In which region of the UK do you currently live? 
c) It was decided to delete the question asking about the religion of the participants as 
this was considered a sensitive question and ultimately it was difficult to justify its 
inclusion. 
After the review, the MRQ that was distributed (v4) composed of 48 items (Appendix 13) 
and was ready to be disseminated nationwide to capture people’s beliefs and intentions to 
reuse medicine in the future.  
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6.2 Aims and objectives 
The aim of phase 3 of the study was to: 
a) Conduct a nationwide survey of people’s beliefs and intentions to take part in 
medicines reuse in the future.  
The objectives of phase 3 described in this chapter were to: 
a) Disseminate the MRQ via a market research company (Research Now®) to quantify 
views about medicines reuse of a cross section of 1,000 patients living in the UK.   
b) Evaluate the predictive utility of TPB in understanding people’s attitudes and 
intentions to reuse medicines in the future. 
6.3 Methodology  
An amendment to ethical application (reference number 30/15) was submitted to the 
University Reading’s Research Ethics Committee and was approved on 10/02/2017. The 
amendment contained information an online recruitment using Market Research Company, 
online panel and online platform. Participants from an online panel were recruited using 
targeted sampling technique targeting only participants with a long-term condition and 
screening out those not having chronic conditions. Sampling was aimed to be UK 
representative by recruiting participants from different regions in the UK, and across the 
different age groups and genders.  
The required sample size for TPB studies using multiple regression analysis is generally 
accepted to have at least 80 participants (Francis et al., 2004). However, the definitive 
sample size that is required for TPB studies using SEM analysis is not straightforward and 
174 
 
depend on the model complexity and the relationships among variables in the model 
(Stevens, 2012). Generally, the recommended sample is of at least 200 to be used for SEM 
analysis (Kline, 2011; Stevens, 2012). The sample size was not an issue in this study as 
1,003 usable responses were obtained.  
The intended sample size was divided into participants with long-term conditions who were 
using medicines (n=800), or not currently using medicines but used in the past (n=100), or 
had never taken any medicines for their long-term condition (n=100). The majority of the 
sample size was therefore targeting people with a long term condition who were using 
medicines as those people will be reasonable expected to reuse medicine in the future if 
medicines reuse became a reality. However, it was important not to miss the viewpoints of 
people who have long term condition and are not currently using medicines (10% of the 
sample size), or people who have long term condition and had never taken any medicines 
for their long-term condition (10% of the sample size), as those may require medicines for 
their long term condition in the future. 
A soft launch (10% of the total sample, n = 100) of the MRQ was undertaken to review and 
quality-check data before the full launch in September 2017. Data obtained during soft 
launch (i.e. internal piloting) were included in the main study analysis. During data 
collection, the representativeness of the sample was monitored for geographical spread, age 
groups and gender balance but no adjustment to the recruitment strategy was found to be 
necessary. Ethical approval for this element of the study was obtained via the in-school 




The main analysis of direct and indirect measures of TPB were by using multiple linear 
regression procedures and SPSS (V23), with preliminary analysis performed to ensure that 
there was no violation of the assumption on normality, linearity, and multicollinearity. 
Multiple linear regression procedure were performed on the data using SPSS (V23) to 
predict people’s intentions to reuse medicine in the future based upon their attitude, social 
pressure (subjective norm), and PBC to reuse medicines Simple linear regression procedure 
were also performed on the data using SPSS (V23) to predict people’s attitude to reusing 
medicines in the future based on their behavioural beliefs, subjective norms based on their 
normative beliefs, and PBC based on their control beliefs. 
Although the multiple linear regression procedures was useful in indicating a certain degree 
of relationship between the independent (predictor) variable and the dependent (outcome) 
variable when used to predict intention to reuse medicines in the future, it is never clear to 
what extent the observed relationship has been reduced by poor measurement of the 
variables in the analysis. In order to avoid this (i.e. the interpretation problems encountered 
in or associated with multiple regression), the Structural Equation Modelling (SEM) with 
the standardised path coefficient was applied using AMOS SPSS to test the various 
hypotheses in this study. The reason for applying SEM is that it allowed for variables to 
correlate (while multiple regression adjusts for variables in the model). In addition, SEM 
accounted for measurement error (while multiple regression assumes perfect 
measurement). Finally, SEM was used to assess the TPB model fit. 
Therefore, hypothesis testing was performed using SEM with standardized path 
coefficients, and several common model-fit measures were checked to assess the model’s 
overall goodness-of-fit using AMOS SPSS. These tests included chi-square, Root Mean 
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Square Error of Approximation (RMSEA) Normalized Fit Index (NFI), Tucker Lewis 
Index (TLI) and the Comparative Fit Index (CFI). 
6.4 Results 
6.4.1 Descriptive statistics 
A total of 1,181 people were invited to complete the questionnaire, with 178 excluded 
because they reported to not having a long-term condition, resulting in 1,003 relevant 
responses. Descriptive analysis was performed to illustrate the findings from the MRQ 
items. The background factors items and items of the direct and indirect measures of TPB 
are described below in sequence. 
6.4.1.1 Background factors 
Gender and ethnicity of the participants were in line with UK population census data, as 51 
% (n = 509) were female, 49% (n = 494) were male, and the majority of the participants 
reported their ethnicity as white British 92% (n = 927). Participant’s age range of 60 to 64 
was the highest 16 % (n = 163), and the lowest 1% (n=10) was for the age range 20 to 24. 
In addition, the participant’s age ranges 65 to 69 constituted 15% (n = 147) of the sample, 
55 to 59 was 13% (n = 133), and 70 to74 was 13% (n = 128) (Figure 6.1). Forty one percent 
(n=412) of the participant’s reported to have some form of higher education, while 59% 
(n=591) reported to have an A level or below (Table 6.1).  
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Figure 6.1 The frequency of participant’s responses according to their age ranges  
 
The participants responses were highest from South East (n = 151), and lowest from 
Northern Ireland (n = 26) areas in the UK. The participant responses according to the 
geographical areas from the UK are presented in Figure 6.2. 
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Figure 6.2 The frequency of participant’s responses according to the geographical 
areas of living 
 
The majority of the participants are taking medicines for their long term condition (86.4%) 
(n = 867), 10% (n = 100) are not currently taking medicines but did take medicines in the 
past, and only 3.6% (n = 36) are not currently taking medicines and have never taking any 
medicines for their long term conditions (Figure 6.3).  
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Figure 6.3 The number of participant’s responses according to whether are taking 
medicines for their long term conditions or have done in the past 
 
A summary of the background factors including gender, age, ethnicity, educational level, 
participant’s geographical areas of living in the UK, and if participants are taking 




Table 6.1 Summary of the background factors 
Variable Frequency Percentage 
Gender   
Male 494  49.3% 
Female 509  50.7% 
Age   
20-24 10  1% 
25-29 27  2.7% 
30-34 47  4.7 
35-39 45  4.5% 
40-44 57  5.7% 
45-49 73  7.3% 
50-54 92  9.2% 
55-59 133  13.3% 
60-64 163  16.3% 
65-69 147  14.7% 
70-74 128  12.8% 
75-79 60  6.0% 
80 or over 20  2.0% 
I prefer not to say 1  0.1% 
Ethnicity   
White (English / Welsh / Scottish / Northern Irish/British) 927  92.4% 
White (Irish) 14  1.4% 
White (Gypsy or Irish Traveller) 2  0.2% 
Any other White background 19  1.9% 
Mixed / Multiple ethnic groups (White and Black Caribbean) 3  0.3% 
Mixed / Multiple ethnic groups (White and Black African) 1  0.1% 
Mixed / Multiple ethnic groups (White and Asian) 5  0.5% 
Any other Mixed / Multiple ethnic background 2  0.2% 
Asian / Asian British (Indian) 10  1% 
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Variable Frequency Percentage 
Asian / Asian British (Pakistani) 3  0.3% 
Asian / Asian British (Bangladeshi) 3  0.3% 
Asian / Asian British (Chinese) 1  0.1% 
Any other Asian background 2  0.2% 
Black / Black British (African) 3  0.3% 
Black / Black British (Caribbean) 4  0.4% 
Arab 2  0.2% 
Other 1  0.1% 
I prefer not to say 1  0.1% 
Educational level   
University Higher Degree (e.g. MSc, PhD) 117  11.7% 
First degree level qualification including foundation degrees, 
graduate membership of a professional Institute, PGCE 
179  17.8% 
Diploma in higher education 74  7.4% 
Teaching qualification (excluding PGCE) 20  2.0% 
Nursing or other medical qualification not yet mentioned 22  2.2% 
A Level 129  12.9% 
Welsh Baccalaureate 1  0.1% 
International Baccalaureate 5  0.5% 
AS Level 17  1.7% 
Higher Grade/Advanced Higher (Scotland) 21  2.1% 
Certificate of sixth year studies 7  0.7% 
GCSE/O Level 235  23.4% 
CSE 40  4% 
Standard/Ordinary (O) Grade / Lower (Scotland) 37  3.7% 
Other school (including school leaving exam certificate or 
matriculation) 
32  3.2% 
I prefer not to say 27  2.7% 
Other 40  4% 
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Variable Frequency Percentage 
Geographical areas   
East of England 83  8.3% 
East Midlands 57  5.7% 
London 105  10.5% 
North East and Cumbria 68  6.8% 
Northern Ireland 26  2.6% 
North West 125  12.5% 
Scotland 86  8.6% 
South East 151  15.1% 
South West 95  9.5 % 
Cymru Wales 55  5.5% 
West Midlands 68  6.8% 
Yorkshire and the Humber 82  8.2% 
Other 1  0.1% 
Are you currently taking any type of medicines for your 
long term conditions? 
  
Yes 867  86.4% 
No, but I have done in the past 100  10% 
No, and I have never taken any medication for my long 
term condition(s) 
36  3.6% 
 
6.4.1.2 Theory of planned behaviour constructs 
Descriptive analysis was performed for the final version of the MRQ items. The analysis of 
the intention, direct, and indirect measures of TPB are detailed below.  
6.4.1.2.1 Intention 
Intention was measured using three items listed here with mean and standard deviation 
(SD) values, namely: 
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 I expect to reuse medication in the future (disagree or agree). Mean 4.67, SD 1.90.   
 I want to reuse medication in the future (disagree or agree). Mean 4.69, SD 1.98. 
 I intend to reuse medication in the future (disagree or agree). Mean 4.65, SD 1.90.  
Five hundred and seventy (56.8%) of the participants indicated that they were expecting 
themselves to reuse medicines in the future [i.e. chose 7 ‘strongly agree’, or 6 or 5, which 
also indicate some degree of agreement], while 245 (23.5%) of the participants indicated 
that they were not expecting themselves to reuse medicines in the future [i.e. chose 1 
‘strongly disagree’, or 2 or 3, which also indicate some degree of disagreement], and 198 
(19.7%) were neutral on this response. In addition, 567 (56.5%) agreed that they want to 
reuse medicines in the future, while 237 (23.7%) did not agree that they want to reuse 
medicines in the future, and 199 (19.8%) gave a neutral response. Finally, 547 (54.5%) 
respondents intended to reuse medicines in the future, 226 (22.6%) did not intend to reuse 
medicines in the future and 230 (22.9%) were neutral (see Table 6.2). 
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Table 6.2 Mean and frequency of distributions of intention items 
Items Mean 
(SD) 
Frequency Distribution of Responses (%) 
 Strongly 
disagree 
  Neither disagree 
nor agree 
  Strongly 
agree 
1 2 3 4 5 6 7 
I expect to reuse 












164(16.4%) 204(20.3%) 202 
(20.1%) 
I want to reuse 












147(14.7%) 177(17.6%) 243 
(24.2%) 
I intend to reuse 
















6.4.1.2.2 Attitude (direct and indirect) measures 
The direct measure of attitude was obtained using four items listed with mean and standard 
deviation (SD) values, namely:  
 Reusing medication in the future would be (harmful or beneficial). Mean 4.60, SD 
2.03. 
 Reusing medication in the future would be (good or bad). Mean 4.69, SD 2.03. 
 Reusing medication in the future would be (satisfying or dissatisfying). Mean 4.56, 
SD 1.95. 
 Reusing medication in the future would be (worthless or worthwhile). Mean 4.87, 
SD 1.97. 
Five hundred and forty two (54.1%) of the participants indicated that reusing medicines in 
the future would be beneficial, while 260 (26%) of the participants indicated that reusing 
medicines in the future would be harmful, and 201 (20%) were neutral on this response. In 
addition, 558 (55.7%) indicated that reusing medicines in the future would be good, while 
258 (25.8%) indicated that reusing medicines in the future would be bad, and 187 (18.6%) 
gave a neutral response. Five hundred (49.9%) respondents indicated that reusing 
medicines in the future would be satisfying process for them, 251 (25.1%) indicated that 
reusing medicines in the future would be dissatisfying process for them and 252 (25.1%) 
were neutral. Finally, 595 (59.4%) respondents indicated that reusing medicines in the 
future would be worthwhile for them, 215 (21.5%) indicated that reusing medicines in the 
future would be worthless for them for them and 193 (19.2%) were neutral (Table 6.3). 
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Table 6.3 Mean and frequency of distributions of direct attitude items 
Items Mean 
(SD) 
Frequency Distribution of Responses (%) 
 Harmful   Neither harmful nor 
beneficial 
  Beneficial 
1 2 3 4 5 6 7 
Reusing medication in the 

















 Good   Neither Good nor 
bad 
  Bad 
1 2 3 4 5 6 7 
Reusing medication in the 



















  Neither satisfying nor 
dissatisfying 
  Dissatisfying 
for me 
1 2 3 4 5 6 7 
Reusing medication in the 

















 Worthless   Neither worthless nor 
worthwhile 
  Worthwhile 
1 2 3 4 5 6 7 
Reusing medication in the 



















The indirect measure of attitude (i.e. the behavioural beliefs and the outcome evaluation) 
was measured using ten items. The behaviour belief was measured using five items listed 
here with mean and standard deviation (SD) values, namely: 
 I think for me to contribute toward reducing the harmful effects of medication on 
the environment is (good or bad). Mean 5.57, SD 1.48. 
 I think for me to contribute toward reducing the amount of money spent by the 
NHS on medication is (good or bad). Mean 5.84, SD 1.43. 
 I think for me to receive low quality medication is (good or bad). Mean 5.84, SD 
1.63. 
 I think for me to receive unsafe medication is (good or bad). Mean 6.40, SD 1.36. 
 I think for me to receive incorrect medication is (good or bad). Mean 6.40, SD 1.46. 
Seven hundred and forty one (73.9%) of the participants indicated that their contribution 
toward reducing the harmful effect of medicines in the environment would be good, while 
68 (6.8%) of the participants indicated that their contribution toward reducing the harmful 
effect of medicines in the environment would be bad, and 194 (19.3%) were neutral on this 
response. In addition, 794 (79.2%) indicated that their contribution toward reducing the 
amount of money spent by the NHS on medicines would be good, while 56 (5.6%) 
indicated that their contribution toward reducing the amount of money spent by the NHS 
on medicines would be bad, and 153 (15.3%) gave a neutral response. One hundred and 
four (10.4%) respondents indicated that receiving low quality medicines is good, while 795 
(79.2%) indicated that receiving low quality medicines is bad, and 104 (25.1%) were 
neutral. Moreover, sixty five (6.5%) respondents indicated that receiving unsafe medicines 
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is good, while 886 (88.4%) indicated that receiving unsafe medicines is bad, and 52 (5.2%) 
were neutral. Finally, 73 (7.3%) respondents indicated that receiving incorrect medicines is 
good, 883 (88.1%) indicated that receiving incorrect medicines is bad, and 47 (4.7%) were 
neutral (Table 6.4). 
The outcomes evaluation was measured using five items listed here with mean and 
standard deviation (SD) values, namely: 
 Reusing sealed, returned blister-pack medication will help me contribute toward 
reducing the harmful effects of medication on the environment (agree or disagree). 
Mean 5.47, SD 1.66. 
 Reusing sealed, returned blister-pack medication will help me contribute toward 
reducing the amount of money spent by the NHS on medication (agree or disagree). 
Mean 5.75, SD 1.59. 
 Reusing sealed, returned blister-pack medication is likely or unlikely to result in me 
receiving low quality medication. Mean 4.90, SD 1.84. 
 Reusing sealed, returned blister-pack medication is likely or unlikely to result in me 
receiving unsafe medication. Mean 4.87, SD 1.88. 
 Reusing sealed, returned blister-pack medication is likely or unlikely to result in me 
receiving incorrect medication. Mean 4.94, SD 1.88. 
Seven hundred and thirty two (73%) of the participants agreed that reusing sealed blister 
pack medicines will help them contribute toward reducing the harmful effect of medicines 
in the environment, while 108 (10.8%) of the participants did not agree that reusing sealed 
blister pack medicines will help them contribute toward reducing the harmful effect of 
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medicines in the environment, and 163 (16.3%) were natural. Moreover, Seven hundred 
and eighty four (78.2%) of the participants agreed that reusing sealed blister pack 
medicines will help them contribute toward reducing the amount of money spent by the 
NHS on medicines, while 85 (8.5%) of the participants did not agree that reusing sealed 
blister pack medicines will help them contribute toward reducing the amount of money 
spent by the NHS on medicines, and 134 (13.4%) were neutral. Five hundred and seventy 
nine (57.7%) indicated that reusing sealed blister pack medicines is extremely likely to 
result in them receiving low quality medicine, while 205 (20.5%) indicated that reusing 
sealed blister pack medicines is extremely unlikely to result in them receiving low quality 
medicine. and 219 (21.8%) were neutral. Moreover, 575 (57.3%) indicated that reusing 
sealed blister pack medicines is extremely likely to result in them receiving unsafe 
medicine, while 220 (22%) indicated that reusing sealed blister pack medicines is 
extremely unlikely to result in them receiving unsafe medicine, and 208 (20.7%) were 
neutral. Finally, 603 (60.1%) indicated that reusing sealed blister pack medicines is 
extremely likely to result in them receiving incorrect medicine, while 215 (21.5%) 
indicated that reusing sealed blister pack medicines is extremely unlikely to result in them 
receiving incorrect medicine, and 184 (18.3%) were neutral (Table 6.4). 
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Table 6.4 Mean and frequency of distributions of behavioural beliefs and outcome evaluation  
Items Mean 
(SD) 
Frequency Distribution of Responses (%) 
 Extremely 
bad 
  Neither bad 
nor good 
  Extremely 
good 
1 2 3 4 5 6 7 
I think for me to contribute toward reducing 
the harmful effects of medication on the 

















I think for me to contribute toward reducing 
the amount of money spent by the NHS on 

















I think for me to receive low quality 























































  Neither 
disagree nor 
agree 
  Definitely 
agree 
1 2 3 4 5 6 7 
Reusing sealed, returned blister-
pack medication will help me contribute 
toward reducing the harmful effects of 

















Reusing sealed, returned blister-
pack medication will help me contribute 
toward reducing the amount of money spent by 





















Frequency Distribution of Responses (%) 
 Extremely 
unlikely 
  Neither 
unlikely nor 
likely 
  Extremely 
likely 
1 2 3 4 5 6 7 
Reusing sealed, returned blister-pack 
medication is [..........] to result in me receiving 

















Reusing sealed, returned blister-pack 


















Reusing sealed, returned blister-pack 




















6.4.1.2.3 Subjective norm (direct and indirect) measures 
The direct measure of subjective norm was measured using four items namely with mean 
and standard deviation (SD) value: 
 Most people whose opinions I value, would approve if I decided to reuse 
medication in the future (disagree or agree). Mean 4.64, SD 1.83. 
  Most people who are important to me would want me to reuse medication in the 
future (disagree or agree). Mean 4.60, SD 1.85. 
  I would be expected by others to reuse medication in the future (disagree or agree). 
Mean 4.30, SD 1.85. 
 Most people who are important to me would think that I should or I should 
not reuse medication in the future. Mean 4.23, SD 1.98. 
Five hundred and fifty six (55.3%) of the participants agreed that most people whose 
opinion they value would approve them if they decided to reuse medicines in the future, 
while 216 (21.5%) of the participants did not agree that most people whose opinion they 
value would approve them if they decided to reuse medicines in the future, and 231 (23%) 
were neutral. In addition, 544 (54.1%), of the participants agreed that most people who are 
important to them would want them to reuse medicines in the future, while 226 (22.6%) of 
the participants did not agree that most people who are important to them would want them 
to reuse medicines in the future, and 233 (23.2%) were neutral. Four hundred and fifty 
three (45.3%) of the participants agreed that they would be expected by others to medicines 
in the future, while 280 (28%) of the participants did not agree that they would be expected 
by others to medicines in the future, and 270 (26.9%) were neutral. Finally, 430 (42.9%) of 
the participants thought that most people who are important to them would think that they 
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should reuse medicines in the future, while 336 (33.6%) of the participants thought that 
most people who are important to them would think that they should not reuse medicines in 
the future, and 237 (23.6%) were neutral (Table 6.5). 
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Table 6.5 Mean and frequency of distributions of direct measures of subjective norm 
Items Mean 
(SD) 
Frequency Distribution of Responses (%) 
 Strongly 
Disagree 
  Neither 
disagree nor 
agree 
  Strongly 
agree 
1 2 3 4 5 6 7 
Most people whose opinions I value, 
would approve if I decided to reuse 

















Most people who are important to me 


















I would be expected by others to 

















 I should   Neither I should 
or I should not 
  I should 
not 
1 2 3 4 5 6 7 
Most people who are important to me 
would think that [..........] reuse medication 



















The indirect measure of subjective norm (i.e. normative belief and motivation to comply) 
was measured using eight items. The normative beliefs were measured using four items 
listed here with mean and standard deviation (SD) values, namely: 
 My doctor would believe that I should reuse sealed, returned blister-pack 
medication (agree or disagree). Mean 4.58, SD 1.67. 
 My pharmacist would believe that I should reuse sealed, returned blister-pack 
medication (agree or disagree). Mean 4.58, SD 1.77. 
  My close friends would believe that I should reuse sealed, returned blister-pack 
medication (agree or disagree). Mean 4.45, SD 1.79.  
 My family would believe that I should reuse sealed, returned blister-pack 
medication (agree or disagree). Mean 4.48, SD 1.90. 
Four hundred and fifty five (45.4%) of the participants agreed that their doctor would 
believe that they should reuse sealed, returned blister-pack medicines in the future, while 
180 (18%) of the participants did not agree that their doctor would believe that they should 
reuse sealed, returned blister-pack medicines in the future, and 368 (37.7%) were neutral. 
In addition, 501 (49.9%) of the participants agreed that their pharmacist would believe that 
they should reuse sealed, returned blister-pack medicines in the future, while 208 (20.8%) 
of the participants did not agree that their pharmacist would believe that they should reuse 
sealed, returned blister-pack medicines in the future, and 293 (29.3%) were neutral.  Four 
hundred and fifty seven (45.7%) of the participants agreed that their close friends would 
believe that they should reuse sealed, returned blister-pack medicines in the future, while 
229 (22.9%) of the participants did not agree that their close friends would believe that they 
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should reuse sealed, returned blister-pack medicines in the future, and 317 (31.6%) were 
neutral. Finally, 497 (49.5%) of the participants agreed that their family would believe that 
they should reuse sealed, returned blister-pack medicines in the future, while 269 (26.9%) 
of the participants did not agree that their family would believe that they should reuse 
sealed, returned blister-pack medicines in the future, and 237 (23.6%) were neutral (table 
5.6). 
The motivation to comply was measured using four items listed here with mean and 
standard deviation (SD) values, namely: 
 Generally speaking, how much do you want to do what your doctor believes you 
should do? Mean 5.55, SD 1.29. 
  Generally speaking, how much do you want to do what your pharmacist believes 
you should do? Mean 5.22, SD 1.36. 
  Generally speaking, how much do you want to do what your close friends believes 
you should do? Mean 4.40, SD 1.54. 
 Generally speaking, how much do you want to do what your family believes you 
should do? Mean 4.94, SD 1.48. 
Seven hundred and seventy eight (77.5%) of the participants generally agreed that they 
wanted to do what their doctor believes they should do, while 54 (5.4%) of the participants 
generally disagreed that they wanted to do what their doctor believes they should do, and 
171 (17%) were neutral. In addition, 687 (68.4%) of the participants generally agreed that 
they wanted to do what their pharmacist believes they should do, while 87 (8.7%) of the 
participants generally disagreed that they wanted to do what their pharmacist believes they 
197 
 
should do, and 229 (22.8%) were neutral. Four hundred and forty four (44.3%) of the 
participants generally agreed that they wanted to do what their close friends believe they 
should do, while 216 (21.6%) of the participants generally disagreed that they wanted to do 
what their close friends believe they should do, and 343 (34.2%) were neutral. Finally, 613 
(61%) of the participants generally agreed that they wanted to do what their family believe 
they should do, while 135 (13.5%) of the participants generally disagreed that they wanted 
to do what their family believes they should do, and 255 (25.4%) were neutral (Table 6.6) 
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Table 6.6 Mean and frequency of distributions of normative belief and motivation to comply 
Items Mean 
(SD) 
Frequency Distribution of Responses (%) 
 Strongly 
Disagree 
  Neither disagree 
nor agree 
  Strongly 
agree 
1 2 3 4 5 6 7 
My doctor would believe that I should 

















My pharmacist would believe that I should 

















My close friends would believe that I 


















My family would believe that I should 

















  Not at all   Neither not at 
all nor very 
much 
  Very 
much 
 1 2 3 4 5 6 7 
Generally speaking, how much do you want 


















Generally speaking, how much do you want 


















Generally speaking, how much do you want 


















Generally speaking, how much do you want 




















6.4.1.2.4 Perceived Behavioural Control (direct and indirect) measures 
The direct measure of PBC was obtained using two items listed here with mean and 
standard deviation (SD) values, namely: 
 I am confident that I could reuse medication in the future if I wanted to (disagree or 
agree). Mean 4.89, SD 1.78. 
 For me it is (possible or impossible) to reuse medication in the future. Mean 4.86, 
SD 1.86. 
Six hundred and twenty eight (62.5%), of the participants agreed that they are confident 
that they could reuse medicines in the future if they wanted to, while 195 (19.5%), 
disagreed that they are confident that they could reuse medicines in the future if they 
wanted to, and 180 (17.9%) were neutral. Moreover, 594 (59.2%) of the participants 
indicated that for them it is possible to reuse medicine in the future, while 221 (22.1%) 
indicated that for them it is impossible to reuse medicine in the future, and 188 (18.7%) 
were neutral (Table 6.7). 
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Table 6.7 Mean and frequency of distributions of PBC 
Items Mean 
(SD) 
Frequency Distribution of Responses (%) 
 Strongly 
Disagree 
  Neither disagree 
nor agree 
  Strongly 
agree 
1 2 3 4 5 6 7 
I am confident that I could reuse 

















 Possible   Neither possible 
nor Impossible 
  Impossible 
1 2 3 4 5 6 7 
For me it is [..........] to reuse 



















The indirect measure of PBC (i.e. control factor and power of the control factor) was 
measured using eight items. The control factors items are listed here with mean and SD 
value, namely: 
 I expect that any medicines offered to me for reuse will be in the original, sealed, 
blister packaging (definitely no or definitely yes). Mean 6.19, SD 1.29. 
 I expect to see evidence that any medicines offered to me for reuse would have 
been quality-checked (definitely no or definitely yes). Mean 6.48, SD 1.03. 
 I expect to see evidence that any medicines offered to me for reuse would have 
been safety-checked (definitely no or definitely yes). Mean 6.55, SD 0.97. 
 I expect that any medicines offered to me for reuse will have more than six months 
of shelf-life remaining (definitely no or definitely yes). Mean 6.10, SD 1.29. 
Eight hundred and seventy two (87%) agreed that they expect any medicines that will be 
offered to them for reuse will be in the original, sealed, blister packaging, while 35 (3.5%) 
disagreed that they expect any medicines that will be offered to them for reuse will be in 
the original, sealed, blister packaging, and 96 (9.6%) were neutral. In addition, 920 (91.8%) 
of the participants agreed that they expect any medicines that will be offered to them for 
reuse would have been quality checked, while 18 (1.8%) disagreed that they expect any 
medicines that will be offered to them for reuse would have been quality checked, and 65 
(6.5%) were neutral. Nine hundred and twenty eight (92.6%) of the participants agreed that 
they expect any medicines that will be offered to them for reuse would have been safety 
checked, while 14 (1.4%), disagreed that they expect any medicines that will be offered to 
them for reuse would have been safety checked, and 61 (6.1%) were neutral. Finally, 854 
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(85.2%) of the participants agreed that they expect any medicines that will be offered to 
them for reuse will have more than six months of shelf-life remaining, while 34 (3.4%) 
disagreed that they expect any medicines that will be offered to them for reuse will have 
more than six months of shelf-life remaining, and 115 (11.5%) were neutral (table 5.8). 
The power of control factors items are listed here with mean and SD value, namely: 
 It would make it easier for me to reuse medication if I could see that it was in the 
original, sealed, blister packaging (disagree or agree). Mean 6.13, SD 1.32. 
 It would make it easier for me to reuse medication if I could see that it had been 
quality-checked (disagree or agree). Mean 6.37, SD 1.10. 
 It would make it easier for me to reuse medication if I could see that it had been 
safety-checked (disagree or agree). Mean 6.40, SD 1.11. 
 It would make it easier for me to reuse medication if I could see that it had more 
than six months of shelf-life remaining (disagree or agree). Mean 6.01, SD 1.35. 
Eight hundred and forty seven (84.5%) of the participants agreed that it would make it 
easier for them to reuse medicines in the future if they could see that it was in the original, 
sealed, blister packaging, while 40 (4%) disagreed that it would make it easier for them to 
reuse medicines in the future if they could see that it was in the original, sealed, blister 
packaging, and 116 (11.6%) were neutral. In addition, 909 (90.7%) of the participants 
agreed that it would make it easier for them to reuse medicines in the future if they could 
see that it had been quality-checked, while 24 (2.4%) disagreed that it would make it easier 
for them to reuse medicines in the future if they could see that it had been quality-checked, 
and 70 (7%) were neutral. Nine hundred and fifteen (91.3%) of the participants agreed that 
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it would make it easier for them to reuse medicines in the future if they could see that it had 
been safety-checked, while 22 (2.2%) disagreed that it would make it easier for them to 
reuse medicines in the future if they could see that it had been safety-checked, and 66 
(6.6%) were neutral. Finally, 839 (83.6%) of the participants that it would make it easier 
for them to reuse medicines in the future if they could see that it had more than six months 
of shelf-life remaining, while 46 (4.6%) disagreed that it would make it easier for them to 
reuse medicines in the future if they could see that it had more than six months of shelf-life 
remaining, and 118 (11.8%) were neutral (Table 6.8). 
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Table 6.8 Mean and frequency of distributions of control belief and power of control factor 
Items Mean (SD) Frequency Distribution of Responses (%) 
 Definitely 
no 




  Definitely 
yes 
1 2 3 4 5 6 7 
I expect that any medication offered to me for 


















 I expect to see evidence that any medication 


















I expect to see evidence that any medication 


















I expect that any medication offered to me for 





















  Neither 
disagree nor 
agree 
  Strongly 
agree 
1 2 3 4 5 6 7 
It would make it easier for me to reuse medication 


















It would make it easier for me to reuse medication 

















It would make it easier for me to reuse medication 

















It would make it easier for me to reuse medication 




















In order to determine the relative importance of beliefs or to select beliefs to be targeted in 
behavioural interventions (i.e. in a relation to medicines reuse), multiple regression 
procedures and SEM were used to identify beliefs that are most important to medicines 
reuse as a behaviour. 
Multiple regressions procedures were used to analyse the direct and indirect measures of 
TPB as follows. Regarding the analysis of direct measures, intention to reuse medicines in 
the future was the dependent (outcome) variable, with attitude, subjective norm, and PBC 
as the independent (predictor) variables.  
Moreover, the analysis of the indirect measures was by entering the directly measured 
attitude scores as the dependent variable with the sum of the weighted behavioural beliefs 
(i.e. the sum of multiplying behavioural beliefs with outcome evaluation) as the predictor 
variable, the directly measured subjective norms scores as a dependent variable with the 
sum of the weighted normative beliefs (i.e. the sum of multiplying normative beliefs with 
motivation to comply) as the predictor variable, and finally by entering directly measured 
PBC scores as a dependent variable with the sum of the weighted control beliefs (i.e. the 
sum of multiplying control beliefs with the power of control factor) as the predictor 
variable. The preliminary regression analysis and multiple regression procedures are 
described in the next two sections. 
6.4.2 Preliminary regression analysis  
Several assumptions were checked before performing multiple regression analysis. While 
the assumptions of a linear model are never perfectly met, it was important to check if 
these assumptions were reasonable to work with before performing linear multiple 
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regression (Berry, 1993). Results from the preliminary analysis were important in allowing 
the researcher to generalise the findings from the sample to the entire population in the UK. 
The summary of the assumption results is that: 
a) The relationship between the independent variables and dependent variables was 
linear. 
b) There was no multicollinearity in the data. 
c) The values of residuals were independent and uncorrelated. 
d)  The values of the residuals were normally distributed. 
e) There were no influential cases biasing the model. 
These results showed that linear multiple regression can be performed without an inclusion 
of outliers or influential cases and non-normal distributed nonlinear data, which could 
potentially bias the regression models and hence affect the findings. A full description of 
the assumption tests is below 
6.4.2.1 Multicollinearity 
First, all predictor (independent) variables except the control belief (indirect measures) 
showed a good relationship with the dependent (outcome) variable (i.e. with intention) as 
the correlation coefficients all were above 0.3, the preferable required value. The control 
belief variable showed a poor (<0.3) correlation value of 0.192 with the outcome variable 
(intention). Second, the correlation between each of the predictor variables (of both direct 
and indirect measures) were not too high (preferably less than 0.7) except between 
subjective norm and attitude where the value was 0.74 (Appendix 14).   
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In order to confirm that multicollinearity (that could be resulted from the poor correlation 
value of control belief with intention, and the high correlation between subjective norm and 
attitude) is not a problem, the multicollinearity diagnostic test was performed (Appendix 
15). The result from the multicollinearity diagnostic test confirmed that multicollinearity is 
not a problem. This was because the tolerance values were all >0.10 indicating that the 
multiple correlation with other variables was not high and suggesting that the 
multicollinearity was not possible. In addition the Variance Inflation Factor (VIF) values 
were all <10 indicating that there is no multicollinearity. The tolerance and VIF values 
confirmed that multicollinearity was not violated. 
6.4.2.2 Normality, linearity, and outliers 
The normal probability plot (P-P) of the regression standardised residual and the scatterplot 
were used to check the normality and linearity (Appendix 16 and 17, respectively). In the 
normal probability plot (P-P) of the regression standardised residual, the points (line) lay in 
a reasonably diagonal line from bottom left to top right suggesting no major deviation from 
normality (Berry, 1993). In the scatter plot of the regression standardised residual, the 
residuals were roughly rectangular distributed, with most of the scores concentrated in the 
centres (i.e. along the 0 point line), and there was no clear systematic pattern to the 
residuals suggesting that there was no major deviation of the assumption (Berry, 1993). 
Results from the normal probability plot (P-P) of the regression standardised residual and 
the scatterplot confirmed normality and linearity. 
With a large sample (such as that of this study), it is not uncommon to have a number of 
outlying residuals (Tabachnick and Fidell, 2007; Field, 2009). Outliers were checked by 
both Mahalanobis distances and Cook’s distance output, but were difficult to detect from 
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the scatter plot. The Mahalanobis distances values were checked and 29 cases of outliers 
were found as potential problems with their values being above the critical value of 22.46, 
for 6 predictors (Tabachnick and Fidell, 2007).  
However, the Cook’s distance value was also checked with the maximum value being 
0.071, suggesting no major problem (all cases in the sample had values <1) and indicated 
that no single case had significant influence on the model (Tabachnick and Fidell, 2007). 
Stevens (2012) advised that there is no point in deleting outliers if the criteria of Cook’s 
distance are met, as these would not have a large effect on the regression analysis. As a 
result, the 29 cases with Mahalanobis distances value >22.46, were included in the 
analysis. 
6.4.2.3 Model evaluation 
The model explained 73.8% of the total variance (R square = 0.738) in medicines reuse. 
Moreover, the model summary table (Appendix 18) reported other values such as adjusted 
R square and the Durbin–Watson value. The R-squared value in the small sample tends to 
be a rather optimistic overestimation of the true value in the population (Tabachnick and 
Fidell, 2007). The adjusted R-Squared corrects the R square value to provide a better 
estimate of the true population value and generally reported with small sample size. In this 
study, the sample size was large and the adjusted R-Squared value was 0.736 compared to 
R square value (0.738), which showed no significant adjustment as the sample size was 
large. Finally, the Durbin–Watson value tests if there is a correlation among the residuals. 
The Durbin–Watson value ranged from 0 to 4, with residuals being uncorrelated if the 
Durbin–Watson value is approximate to 2, strong positive correlation if the value is close 
to zero, and strong negative correlation if the value is close to 4. In this study, the Durbin–
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Watson value was 1.951, indicating that the residual were uncorrelated. The model 
summary results are shown in the ANOVA (Analysis of Variance) table (Appendix 18). 
The results were significant as the (P < 0.001). 
6.4.3 Main regression analysis 
6.4.3.1 Analysis of direct measures 
Multiple linear regression procedures were performed by entering intention as the 
dependent (outcome) variable, and the direct measures of attitude, subjective norm and 
perceived behavioural control (PBC) as the predictor (independent) variables.  The multiple 
linear regression was calculated to predict people’s intentions to reuse medicine in the 
future based on their attitude, social pressure (subjective norm), and PBC to reuse 
medicines. A significant regression equation was found F (3, 999) = 920.645, P < 0.001, 
with an R square of 0.734 (i.e. three independent variables accounted for 73.4% of the 
variance in intention to reuse medicines in the future). Attitude, subjective norm (social 
pressure), and PBC toward reusing medicines were positive and (statistically) significant 
predictors of intention to reuse medicines (B = 0.212, p < 0.001), (B = 0.497, p < 0.001), 
and (B = 0.326, p < 0.001), respectively as shown in table 5.1. 
6.4.3.2 Analysis of indirect measures 
To confirm the validity of indirect measures of TPB, simple bivariate correlation between 
the direct and indirect measures of the same construct of TPB was performed (Francis et 
al., 2004). Validating the belief-based measures (indirect constructs) was an important step 
in the analysis, as it illustrated to what degree the designed indirect constructs were able to 
explain the direct constructs.  
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Bivariate correlation between behavioural beliefs and attitude construct, normative belief 
and subjective norm construct, and control belief and PBC construct was performed using 
Pearson correlation (Appendix 19). The correlation between behavioural belief and attitude 
(0.591), and normative belief and subjective norm (0.582) were good and significant (P < 
0.01), while the correlation between control belief and PBC was poor (0.219) and 
significant (P < 0.01). The possible explanation for the poor correlation between control 
belief and PBC is that during piloting process (chapter 4), the factor loading of the items 
that measures the controllability of the medicines reuse behaviour was very low in two 
consecutives CFA analysis and hence some of the items were deleted. Therefore, the 
remaining items that measured self-efficacy of the medicines reuse behaviour may not have 
covered the breadth of the control belief construct. However, reusing medicine will be in 
the future as it is not allowed now to redistribute the returned unused medicine to people. 
This may affect people’s decisions and controllability over medicines reuse behaviour 
which was shown in the low factor loading in the piloting phase. 
Simple linear regression procedures were performed by entering directly-measured attitude 
scores as the dependent variable, and the sum of the weighted behavioural beliefs (the 
composite score of behavioural belief and outcome evaluation) as the predictor variables. A 
similar approach was used to predict directly measured subjective norms and perceived 
behavioural control (Francis et al., 2004). The simple linear regression was calculated to 
predict people’s attitude to reuse medicines in the future based on their behavioural beliefs, 
subjective norms based on their normative beliefs, and PBC based on their control beliefs 
(Table 6.9). A significant regression equation was found between behavioural belief and 
attitude F (1, 1001) = 537.756, P < 0.001, with an R square of 0.349 (i.e. behaviour beliefs 
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accounted for 34.9% of the variance in attitude toward reusing medicines in the future), 
normative belief and subjective norm F (1, 1001) = 512.301, P < 0.001, with an R square of 
0.339 (i.e. normative beliefs accounted for 33.9% of the variance in subjective norm 
toward reusing medicines in the future), and control belief and PBC F (1, 1001) = 50.507, P 
< 0.001, with an R square of 0.048 (i.e. control beliefs accounted for only 4.8% of the 
variance in PBC toward reusing medicines in the future). 
Behavioural beliefs, normative beliefs, and control beliefs were positive and statistically 
significant predictors of attitude, subjective norm, and PBC (B = 0.024, p < 0.001), (B = 




Table 6.9 Results of multiple regression analysis of TPB constructs using both direct 
and indirect measures 
PREDICTOR VARIABLE B SE 
Beta 
(β) t p 
Direct Measures     < 0.001 
Attitude 0.212 0.025 0.217 8.545 <0.001 
Subjective norm 0.497 0.029 0.445 16.900 <0.001 
PBC 0.326 0.025  0.296 12.941 <0.001 
N = 1003 participants, F = 920.645, df = 3 p < 0.001, R = 0.857, R2 = 0.734, Adjusted R2 = 
0.734 
Indirect Measures      
Behaviour………Attitude  
F = 512.301, df = 1 p < 0.001, R = 0.582, R2 = 
0.339, Adjusted R2 = = 0.339 0.024 0.001 0.591 2.18 <0.001 
Normative belief………Subjective norm  
F = 512.301, df = 1 p < 0.001, R = 0.591, R2 = 
0.349, Adjusted R2 = = 0.349 0.027 0.001 0.582 22.634 <0.001 
Control belief………PBC  
F = 50.507, df = 1 p < 0.001, R = 0.219, R2 = 
0.048, Adjusted R2 = = 0.047 0.013 0.002 0.219 7.107 <0.001 
 
Next in this chapter was the hypothesis testing and model fit assessment. The SEM with the 
standardised path coefficient was used to test the hypotheses and to assess the model fit. 
The SEM allowed for variables to correlate (while multiple regression adjusts for variables 
in the model) and accounted for measurement error (while multiple regression assumes 




6.4.4 Hypothesis testing  
Structural Equation Modelling (SEM) with the standardised path coefficient was applied 
using AMOS SPSS to test several hypotheses in this study (Figure 6.4). 
a) Hypothesis 1: There will be a positive relationship between attitude toward 
reusing medicines and intention to reuse medicine in the future? 
Hypothesis 1 was supported by the data. The attitude toward reusing medicines had the 
lowest standardized path coefficient of 0.27 (p < 0.001, n = 1,003). This showed a low to 
moderate and statistically significant relationship suggesting that the attitude toward 
reusing medicines had a positive effect on the intention to reuse medicines in the future. 
Therefore, people’s attitude (i.e. if reusing medicines in the future would be beneficial, 
worthwhile, satisfying, and good) had some, but in fact the lowest, influence in on their 
intentions to reuse medicines in the future. 
b) Hypothesis 2: There will be a positive relationship between subjective norm 
toward reusing medicines and intention to reuse medicine in the future? 
Hypothesis 2 was strongly supported by the data. The subjective norm toward reusing 
medicines had the highest standardized path coefficient of 0.55 (p < 0.001, n = 1,003). This 
showed a moderate to high and statistically significant relationship suggesting that the 
subjective norm toward reusing medicines had the strongest positive effect on the intention 
to reuse medicines in the future, among the three direct-measure constructs of TPB. 
Therefore, the social pressure (for example, most people who are important to me would 
want me to reuse medicines in the future, or approve if I decided to reuse medicine in the 
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future, or think that I should reuse medicine in the future) had significant influence on 
people’s intentions to reuse medicines in the future. 
c) Hypothesis 3: There will be a positive relationship between PBC toward 
reusing medicines and intention to reuse medicine in the future? 
Hypothesis 3 was supported by the data. The PBC toward reusing medicines had the 
standardized path coefficients of 0.37 (p < 0.001, n = 1003), this showed a moderate and 
statistically significant relationship suggesting that the PBC toward reusing medicines had 
moderate positive effect on the intention to reuse medicines in the future among the three 
direct-measure constructs of TPB. Therefore, people’s self-efficacy (for example, if people 
are confident to reuse medicine in the future or reusing medicine in the future is possible 
for them) has moderate influence on their intentions to reuse medicines in the future. 
d) Hypothesis 4: There will be a positive relationship between behavioural beliefs 
and attitude toward reusing medicines in the future? 
Although a person may hold many behavioural beliefs in relation to any behaviour, only a 
relatively small number are readily accessible at a given moment (Ajzen, 2002). This 
hypothesis assumed that people’s beliefs, in combination with the subjective values of the 
expected outcomes, had an effect to determine attitude. The hypothesis was supported by 
the data. In fact, it was the highest standardized path coefficient in the analysis with a path 
coefficient of 0.59 (p < 0.001, n = 1,003). This suggests that there is moderate to strong 
relationship in which behavioural beliefs (for example, if people think that by reusing 
medicine they will contribute in reducing the harmful effect of medicines on the 
environment and the amount of money spent by the NHS on medicines) predict attitude 
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toward (for example, medicines reuse is beneficial, worthwhile, good, and satisfying for 
them) reusing medicines in the future. The more positive people’s beliefs, the more they 
are likely to indicate a positive attitude toward reusing medicines in the future.  
e) Hypothesis 5: There will be a positive relationship between normative beliefs 
and subjective norms toward reusing medicines in the future? 
The hypothesis was supported by the data. The standardized path coefficient was the 
second highest in the analysis with a path coefficient of 0.58 (p< 0.001, n = 1,003). This 
suggests that there is a moderate to strong relationship in which normative beliefs predict 
subjective norms toward reusing medicines in the future. The more positive people’s 
normative beliefs (for example, people think that their doctor, pharmacist, family, and close 
friends would want them to reuse medicines in the future), the more they are likely to 
indicate a positive subjective norm toward reusing medicines in the future (for example, 
most people who ae important to me would want me to reuse medicines in the future, or 
approve if I decided to reuse medicine in the future, or think that I should reuse medicine in 
the future).   
f) Hypothesis 6: There will be a positive relationship between control beliefs and 
PBC toward reusing medicines in the future? 
Although the hypothesis was supported by the data, the standardized path coefficient was 
the lowest in the analysis with a path coefficient of 0.22 (p< 0.001, n = 1,003). This 
suggested that there is a low to moderate relationship in which control beliefs predict PBC 
toward reusing medicines in the future. The more positive people’s control beliefs (for 
example, people expect that medicines offered for reuse are in original sealed blister 
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packaging and would have been quality and safety checked), the more they are likely to 
indicate a positive PBC (for example, are more likely to be confident in reusing medicines 
in the future and medicines reuse will be possible for them) toward reusing medicines in 
the future.  
Figure 6.4  SEM of the TPB model with standardised path analysis results (before 
model fit procedures) 
 
BBIN (Behavioural Belief Indirect measure), NBIN (Normative Belief Indirect measure), CBIN (Control 
Belief Indirect measure), AD (Attitude Direct measure), SND (Subjective Norm Direct measure), PBCD 
(Perceived Behavioural Control Direct measure), ID (Intention Direct measure), SEA (Standard Error 
Attitude), SESN (Standard Error Subjective Norm), SEPBC (Standard Error Perceived Behavioural Control), 




g) Hypothesis 7: There is no significant difference in intention to reuse medicines 
in the future by gender 
An independent t-test was performed and showed no statistically significant difference in 
the mean intention scores between male (mean = 4.58, SD = 1.852, n = 494) and female 
participants (mean = 4.75, SD = 1.740, n = 509) with t value = -1.506, d.f = 1001, and (P = 
0.132). 
h) Hypothesis 8: There is no significant difference in intention to reuse medicines 
in the future by age 
A one-way ANOVA was performed and showed no statistically significant difference in 
mean intention score between the different age groups (F = 0.971, d.f = 13, 1002, p = 
0.478). 
i) Hypothesis 9: There is no significant difference in intention to reuse medicines 
in the future by ethnicity 
A one-way ANOVA was performed and showed no statistically significant differences in 
mean intention score between different ethnicity groups (F = 0.954, d.f = 17, 1002, p = 
0.509). 
j) Hypothesis 10: There is no significant difference in intention to reuse medicines 
in the future by level of education.  
A one-way ANOVA was performed and showed no statistically significant differences in 
mean intention score between educational levels (F = 1.665, d.f = 16, 1002, p = 0.480). 
218 
 
k) Hypothesis 11: There is no significant difference in intention to reuse medicines 
in the future by geographical distribution 
A one-way ANOVA was performed and showed no statistically significant difference in 
mean intention score between different geographical areas (F = 0.989, d.f = 12, 1002, p = 
0.457). 
6.4.5 Model fit analysis  
Having analysed the standard inter-relationship between the different constructs of the 
TPB, an additional set of tests was completed in order to check the model fit. This is 
completed to check whether the standard relationship between the different constructs of 
the TPB proposed by the original model apply in relation to the data obtained in this study. 
This means, for example, that although the TPB predicts a relationship between the indirect 
and direct measures of attitude toward medicines reuse, it might be that in fact indirect 
measures of attitude also strongly predict another direct measure. Checking the model fit 
will highlight whether there is a need to explore other new relationships between the 
constructs of this particular questionnaire that would better predict people’s intention to 
reuse medication.  
Several common model-fit measures were checked to assess the model’s overall goodness-
of-fit using AMOS (SPSS). These tests included Chi-square, Root Mean Square Error of 
Approximation (RMSEA), Normalized Fit Index (NFI), Tucker Lewis Index (TLI) and the 
Comparative Fit Index (CFI). These are standard modification indices offered by AMOS 
SPSS. Overall, the path analysis of SEM reported non-satisfactory results in terms of 
model-fit and significance of relationships. This means that the diagnostic analysis of 
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model-fit, as listed above, showed poor fit of the TPB model to the data. The details of this 
model fit is described in the next sections and summarized in Table 6.10. 
6.4.5.1 RMSEA 
The Root Mean Square Error of Approximation (RMSEA) is a common way to measure 
model-fit. The RMSEA was applied and failed to show a satisfactory score. The RMSEA 
for the default model was 0.327 (all relationships in this model reported significant p-
values (p = 0.000)). According to Kenny (2011), the recommend RMSEA for good models 
is 0.05 or less, and models in which RMSEA is 0.10 or more have a poor fit. The RMSEA 
value of 0.327 reported in this study indicated poor model fit.  
6.4.5.2 Chi-Square 
Chi square (χ2) is the original fit index and is considered the basis for most other fit 
indices. However, there are many factors that affect the χ2 such as sample size, the number 
of the variables in the model, and the distribution of the variables (Bentler, 1990). The χ2 
value was 1298.857, (degrees of freedom (D.F) = 12; p < 0.001). The χ2 value was very 
large and statistically significant which indicated a poor model fit. 
In this study, the distribution of the variables was checked to be normally distributed and 
had no effect to increase the value of χ2. However, the reason of having large and 
statistically significant χ2 value is possibly the number of variables in this model (as the 
number of variables increase the χ2 value will increase), and more importantly the large 
sample size. Although the χ2 value did not meet its recommended value which indicated 
poor fit, the significant p-value might be explained by the large sample size in this study. 
As a result, χ2 value was considered not to be a useful fit index parameters to report as it is 
very sensitive to sample size.  
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6.4.5.3 Other fit indices 
The default model-fit reported scores with 0.676 for NFI, 0.435 for TLI, and 0.677 for CFI. 
These value indicated poor model fit. A score of 0.90 or above on these indices indicates a 
good fit as recommended by Kenny (2011). While the CFI and NFI values was close to 0.9, 
TLI was away from the recommended value. These fit indices also indicated poor model 
fit. 
Table 6.10 Measures of model fit value which indicate poor model fit 
Test Recommended value Model value Degree of model fit 
Chi-square 
Chi-square/d.f 





RMSEA ≤ 0.08 0.327  Poor fit 
NFI ≥ 0.9 0.676 Poor fit 
TLI ≥ 0.9 0.435 Poor fit 
CFI ≥ 0.9 0.677 Poor fit 
d.f = degree of freedom; * P ≤ 0.001 
6.4.6 Modification indices 
Having found that the standard TPB model fit was poor, further analyses were completed 
in order to examine and explore the additional relationships between the different 
constructs of the MRQ and to report the statistically significant relationships which 
potentially override the standard relationships proposed by the original TPB. This was 
important to complete because if the model does not have a good fit, its predictive power 
(i.e. to predict intention to reuse medicines) will be low despite the path analysis reported 
in Figure 6.4. Thus for example, although there is a strong correlation between the indirect 
and direct measures of subjective norm (which in Figure 6.4 was reported to be the strongest 
predictor of intention to reuse medicine), i.e. correlation of 0.58, if the model fit is poor, in 
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fact there might be other stronger relationships between the different constructs that would 
override this apparent relationship. Therefore in order to explore a better model for 
predicting intention to reuse medication (i.e. a model whose fit would be good), the 
Modification Indices (MI) were calculated. This is a standard mechanism within AMOS 
SPSS.   
Using AMOS to assess the model, the Modification Indices (MI) - a lower bound estimate 
of the expected chi square decrease that would result when a particular parameter is left 
unconstrained or there is the addition of an extra path was used improve TPB model fit. 
The modification indices were checked to be at least 5 before the model was considered to 
be modified as recommended by Jöreskog and Sörbom (2005). 
Using AMOS SPSS, MI suggested 11 new relationships between the construct of TPB 
model as presented in (Table 6.11). These relationships were checked carefully and only 
logical relationships between constructs (i.e. the new relationships between the constructs 
should make sense in a relation to medicine reuse as the behaviour) were used to improve 
the model fit.  
Table 6.11 All the new relationships between the model constructs suggested by MI to 
improve the model fit 
All the new relationships between the constructs MI 
Normative belief                                                Perceived Behavioural Control  191.137 
Behavioural belief                                              Perceived Behavioural Control 241.787 
Subjective norm                                                 Perceived Behavioural Control 430.755 
Attitude                                                              Perceived Behavioural Control 372.591 
Behavioural belief                                             Subjective norm  53.964 
Perceived Behavioural Control                         Subjective norm  238.809 
AD (Attitude Direct measure)                           Subjective norm  312.129 
Normative belief                                               Attitude 37.007 
Perceived Behavioural Control                         Attitude 156.050 
Subjective norm                                                Attitude 288.170 
Normative belief                                               Intention  7.701 
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In this study, the MI was not allowed to drive the process of improving fit without 
checking if the new relationships proposed in the model make sense and logic in a relation 
to medicine reuse as behaviour, this was in line with the SEM guidelines for determining 
model fit which was recommended by Hooper et al. (2008). The logical new relationships 
used for improving model fit were described below and are presented in (Table 6.12). 
First, the AMOS model analysis indicated that the chi-square would drop dramatically 
(M.I. = 288.170) if a path is drawn from subjective norms to attitude (Figure 6.5). After the 
path was drawn from subjective norms to attitude, a significant improvement in 
modification indices occurred as (χ2) value improved (from 1298.857 into 791.621), 
RMSEA (from 0.327 into 0.266), NFI (from 0.676 into 0.803), TLI (from 0.435 into 
0.626), and CFI (from 0.677 into 0.804). This would make sense theoretically as people’s 
own attitudes generally could be affected by what they believe to be the perceptions of key 
referents in their lives. For example, individuals would believe that people who are 
important to them would approve of them reusing medicines in the future and this could 
positively impact on the individual’s attitude toward reusing medicines in the future. While 
this cross effect between subjective norms and attitude was not part of Ajzen’s TPB, it was 
reported by Powpaka (2002), who noted a direct relationship between attitude and 
subjective norms when using TPB to study management decision-making. Moreover, 
Bansal and Taylor (2002), also identified an interaction between subjective norms and 
attitude toward the behaviour when using TPB to study service providers switching 
context. Finally, Koo and Kwong (2006) reported the same crossover effect in which 
subjective norms influenced attitude formation in a study using TPB to examine the 
adoption of podcasting in enhancing learning.  
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Second, the AMOS Model also indicated the chi-square would drop significantly (M.I. = 
430.755) if a path is drawn from subjective norms to PBC (Figure 6.5). After the path was 
drawn from subjective norms to attitude, a further significant improvement in modification 
indices occurred as (χ2) value improved (from 791.621 into 214.535), RMSEA (from 0.266 
into 0.143), NFI (from 0.803 into 0.946), TLI (from 0.626 into 0.892), and CFI (from 0.804 
into 0.949). This could be explained as the people’s own confidence or decision to reuse 
medicines in the future could be affected by what they believe to be the perceptions of key 
referents in their lives. 
Third, the AMOS Model also indicated the chi-square would drop (M.I. = 48.405) if a path 
is drawn from behavioural beliefs to PBC (Figure 6.5). After the path was drawn from 
subjective norms to attitude, a further improvement in modification indices occurred as 
(χ2) value improved from (214.535 into 141.030), RMSEA (from 0.143 into 0.121), NFI 
(from 0.946 into 0.965), TLI (from 0.892 into 0.923), and CFI (from 0.949 into 0.967). 
This make sense as person individual beliefs for a behaviour, for example (I think for me to 
reuse medicine in the future would reduce the harmful effect of medicines in the 
environment) may affect their confidence or decision to perform the behaviour (i.e. I am 
confident to reuse medicines in the future). 
Fourth, the AMOS Model also indicated the chi-square would drop (M.I. = 20.627) if a 
path is drawn from PBC into attitude (Figure 6.5). After the path was drawn from PBC into 
attitude, a further improvement in modification indices occurred as (χ2) value improved 
(from 141.030 into 101.341), RMSEA (from 0.121 into 0.108), NFI (from 0.965 into 
0.975), TLI (from 0.923 into 0.939), and CFI (from 0.967 into 0.977). The possible 
explanation is that a person’s confidence or decision to reuse medicine could have an 
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influence in the person’s attitude to reuse medicine in the future (i.e. if participants were 
confident in their decision to reuse medicine, they will value if medicine reuse is 
worthwhile or not). 
Finally, the AMOS Model also indicated the chi-square would drop (M.I. = 53.964) if a 
path is drawn from behavioural belief into subjective norm (Figure 6.5). After the path was 
drawn from behavioural belief into subjective norm, a further improvement in modification 
indices occurred as (χ2) value improved (from 101.341 into 16.755), RMSEA (from 0.108 
into 0.037), NFI (from 0.975 into 0.996), TLI (from 0.939 into 0.993), and CFI (from 0.977 
into 0.998). This makes intuitive sense as a person’s positive belief for a behaviour, for 
example (I think for me to reuse medicine in the future would reduce the harmful effect of 
medicines in the environment) would influence what they believe other people they 
consider important to them such as family or close friends, would think about the reuse of 
medicine. This was shown in the qualitative interview (i.e. elicitation study), where some 
participants said that they were discussing the value of medicine reuse (i.e. their 
behavioural beliefs about medicine reuse) with their partners (i.e. their subjective norm) 
therefore it is possible that projecting their own beliefs onto those of others close to them. 
Table 6.12 The only relationships used to improve the model fit 
Only the relationships between the constructs that were used to improve the model fit  
Subjective norm                                                  Attitude 
Subjective norm                                                  Perceived Behavioural Control 
Behavioural belief                                              Perceived Behavioural Control 
Perceived Behavioural Control                          Attitude 




After modification indices were corrected, model had a very good fit. The new path 
analysis are shown in (Figure 6.5). Although the subjective norm standardized path 
coefficient value reduced from 0.55 to 0.45 (p < 0.001, n = 1003) as a results of new 
relationships between the construct, the subjective norm is still the strongest predictor of 
intention to reuse medicines compared to attitude and PBC. The measured value of model 
fit achieved after MI were applied to improve the model fit are shown in ( 
Table 6.13 ). 
Figure 6.5 TPB model after modification indices was corrected showing the new 





Table 6.13 Measures of model fit achieved after MIs were applied to improve the 
model fit 
Test Recommended value Model value Degree of model fit 
Chi-square 
Chi-square/d.f 




Good fit (taking into 
consideration the 
effect of large 
sample) 
RMSEA ≤ 0.08 0.037 Good fit 
NFI ≥ 0.9 0.996  Good fit 
TLI ≥ 0.9 0.993  Good fit 
CFI ≥ 0.9 0.998  Good fit 
d.f = degree of freedom; * P ≤ 0.001 
6.5 Discussion 
This chapter described phase 3 of the larger study the results of which are briefly 
summarised here. In the literature, there are no previous reports about people’s attitudes 
and intention to reuse medicines in the future. The purposes of this study was first to 
disseminate the MRQ to predict nationwide views about people’s attitudes and intentions to 
reuse medicines in the future and then to evaluate the predictive utility of TPB in 
understanding people’s attitudes and intentions to reuse medicines in the future. 
This study demonstrated the key findings about medicines reuse and how TPB can be used 
to identify and measure factors that influence reusing medicines in the future, which can 
facilitate the design of medicines reuse intervention strategies. Supporting previous studies, 
all of the main prediction variables from (Ajzen, 2006) TPB model (subjective norm, 
attitude toward reusing medicines and PBC) were statistically significant at varying 
strengths. In contrast to previous studies, the subjective norms construct had the strongest 
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standardized beta of the three independent variables of direct measures. The subjective 
norms had the strongest positive effect on intentions with standardized path coefficient of 
0.55 (p < 0.001, n = 1003). As there are no studies using TPB in relation to reusing 
medicines in the literature, it was difficult to assess if the strong subjective norm influence 
is unique to medicines reuse. The subjective norms having the strongest positive effect on 
intention can be considered as the strongest candidate for a medicines reuse behavioural 
intervention and this could help inform any future policy on reducing medicines waste 
through reuse in the future. The strong subjective norm influence was a surprising results 
as it was reported that subjective norm has the weakest effect on intention by Armitage and 
Conner (2001), who reviewed 185 studies involving TPB.  
In addition, in this chapter, the attitude toward reusing medicines has the weakest positive 
effect on intentions compared to subjective norm and PBC with standardized path 
coefficient of 0.27 (p < 0.001, n = 1003). This is also possibly contradicting with previous 
research involving TPB specifically for attitude. For example, in the meta-analysis of 56 
studies involved  TPB (Godin and Kok, 1996), it was reported that attitude toward the 
behaviour and PBC were found to be the most significant predictors. In the current study, 
the PBC has the positive effect on intention with standardized path coefficient of 0.37 (p < 
0.001, n = 1003). The PBC positive effect on intention was consistent with previous 
research involved TPB as reported by Godin and Kok (1996). 
There were no significant relationships found between the background factors variables 
such as age, gender and ethnicity, level of education and demographic distribution and 
intention to reuse medicines in the future, possibly also contradicting several previous 
studies that used TPB.  
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The model fit for this study was poor as indicated by five different scores and tests (i.e. χ2, 
RMSEA, NFI, TLI and CFI). Given the complexity of SEM, it is not uncommon have a 
poor model fit. The normality of the data was checked and confirmed in the preliminary 
analysis, therefore this was excluded as a possible cause of having poor model fit. Other 
possible reasons related to having poor model fit in this study were (Iacobucci, 2010; 
Kenny, 2011);  
a) In this study, the sample size was large. The Chi square (χ2) test is sensitive to 
sample size, the larger the sample size the larger the χ2 value, the poorer the model 
fit. In addition, NFI, TLI and CFI are possible affected by large sample 
sizes.  However, these are not considered to be as sensitive to large sample sizes as 
Chi square is. 
b) This study has constructs that have four or more items and this is probably 
considered excessive when using SEM and adds complexity to the model possibly 
affecting the model fit. 
c) The constructs of past behaviour and the actual behavioural control were not 
included in this study as medicines reuse is not allowed in the UK, therefore it is 
not possible to measure the actual behaviour or past behaviour. As a result, the 
variables in these constructs (i.e. past behaviours and actual behavioural control) 
were not included in the TPB model, this possibly affecting model fit. 
It is important to mention that MIs was used carefully. Only modification indices that the 
researcher felt is logical with medicines reuse as a behaviour were used to improve the 
model fit. Therefore the researcher did not allow the MIs to drive the process of improving 
fit without checking if the new relationships proposed in the model make sense and are 
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logic, this was according to the recommendation by Hooper et al. (2008). In this chapter, 
the MIs indicated a significant relationship between subjective norms to attitude, between 
subjective norms and PBC, behavioural beliefs to PBC, PBC into attitude, and behavioural 
belief into subjective norm. These relationships are not part of Ajzen (2006) TPB and may 
require further research. 
The strength of this largescale study is that it captured representative views about 
medicines reuse, something that has never been addressed in the literature. This study 
provided the first detailed and robust investigation about people’s beliefs, attitudes and 
intentions to reuse medicines in the future. Another strength is the application of TPB (i.e. 
applying the theory driven approaches) which helped the selection of variables used for 
statistical analysis and directed the interpretation of findings, at the same time enhancing 
the reliability and validity of the findings and conclusions made. Moreover, the design of 
TPB provided structured and robust information about medicines reuse behaviour that will 
inform any future policy on reducing medicines waste through reuse in the future. Finally, 
the analysis of the results involved checking the assumptions of the statistical tests during 
preliminary analysis, and also a test of model fit and modifying the indices. These 
processes have not been well explored or sometimes neglected in past studies raising 
questions about the validity and reliability of the TPB construct in some of these studies 
but clearly these areas were addressed in this thesis. 
Research using panels can be limited by issues relating, for example, to whether members 
are representative of the target population. This was addressed by using quotas and 
screening questions resulting in a representative sample. However, the use of an online 
panel would have excluded people with no internet access. Therefore, this could be a 
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limitation in this study as the use of an online questionnaire which would have excluded 
views from people with no internet access.  
In addition, another limitation is that the PBC construct (i.e. direct measure) was measured 
using only two items (items measuring self-efficacy of medicine reuse), as the items 
measuring controllability of medicines reuse were deleted as result of two consecutive 
CFA. Having only two items may not cover the depth of the PBC construct and result in 
lower internal consistency compared to attitude and subjective norm construct.    
This chapter presents a novel approach of investigating nationwide opinions on medicines 
reuse that has not been fully addressed in the literature. It provides the first detailed 
research about people’s beliefs, attitudes and intentions to reuse medicines in the future. 
The viewpoints were captured from a large and representative sample of the UK patient 
population, providing robust evidence about patients’ beliefs and intentions to take part in 
medicines reuse. The results from this chapter can inform any future policy on reducing 
medicines waste through reuse in the future. 
6.6 Conclusion  
The results from this research suggest that people in UK have a positive intention to reuse 
medicines and could reuse medicine in the future. This was supported by their strong and 
positive beliefs and attitudes. However, assuring the safety and quality of the medicines 
that will be offered for reuse is a vital criteria for them to agree to reuse medicines in the 
future. In addition, People’s behavioural (advantages and disadvantages), normative (social 
pressure) and control beliefs (safety and quality of unused medicines) were all statistically 
significant concepts to predict people’s intention to reuse medicines in the future. From 
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these three concepts, social pressure (i.e. subjective norm) from pharmacist, GPs, family 
and friends were found to have the strongest effect in predicting intentions to reuse 
medicines in the future. These concepts especially social pressure concepts can be targeted 
and used to develop behavioural intervention and can help inform any future policy on 
reducing medicines waste through reuse in the future. This study demonstrated how TPB 
can be used to identify and measure factors that influence reusing medicines in the future, 
and this could facilitate the design of medicines reuse intervention strategies, in addition, 
showed the importance of PBC to predict medicine reuse as behaviour. Moreover, this 
study also showed new relationships between the direct and indirect measures of TPB that 
have not been reported by Ajzen TPB and may require further research. The new 
relationships between the direct and indirect measures of TPB demonstrated the flexibility 
of TPB and its effectiveness as a tool to predict people’s beliefs and intentions to reuse 




CHAPTER 7 THESIS SUMMARY, SIGNIFICANCE AND 
LIMITATION, IMPACT AND FUTURE, AND MEDICINAL WASTE IN JORDAN 
7.1 Summary and key findings 
This thesis examines the idea that unused prescribed medicines returned by one patient to a 
pharmacy can be dispensed and reused by another patient (“medicines reuse”) as a strategy 
for reducing medicinal waste in the UK. Medicinal waste can be generated when the 
prescribed medicines are left unused and stored at home, returned back to the pharmacies, 
or disposed of into household waste, or flushed down sinks and toilets, ending up in landfill 
sites and the water system. Medicinal waste has a financial cost which is estimated in the 
UK to be £300 million per year for prescribed medicines (Trueman et al., 2010). However, 
monetary cost is only part of the burden of medicinal waste. Environmental costs are also a 
concern as the presence of pharmaceuticals in the environment increases with inappropriate 
disposal of medicinal waste potentially contributing. Research has found that people are 
more likely to dispose of their unused medicines in the common refuse or flush down the 
sink/toilet than return them to the pharmacies for correct disposal (Vellinga et al., 2014).  
The causes of medicinal waste are thought of as avoidable (e.g. patient non-adherence, 
adverse drug reactions, medicine accumulation) or non-avoidable (e.g. patient death, 
prescription changes). To reduce medicinal waste, one approach is to prevent waste in the 
first place. Interventions that have tried to prevent waste have not always been effective 
and paradoxically, the most common causes of medicinal waste are non-preventable (West 
et al., 2014). Another approach is to reuse medicines.  Medicines reuse is a sustainable 
concept yet to be tested in the UK. Medicines reuse remains largely unexplored because 
unused medicines are not currently allowed to be reused in the UK. Instead the returned 
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unused medicines are automatically considered as waste that requires appropriate disposal. 
Medicine reuse could potentially have a wider impact on medicinal waste by enabling 
medicines returned by patients (irrespective of reasons) to be considered for re-distribution 
to others following quality control. Medicines reuse has the potential to reduce the 
environmental and economic impact of medicinal waste, providing a sustainable solution 
for all causes of medicinal waste in the future. 
Anecdotally, patients returning their medicines to the pharmacies often voice a wish for 
these to be reused by others. In fact, an NHS sustainability survey which was carried out by 
Ipsos MORI in 2011 reported that half of the respondents were likely to accept the reissued 
medicines returned to the pharmacies.  Moreover, there is precedence of medicines reuse in 
other countries. For example in the United States, unused medicines are collected and 
redistributed to patients who are less able to afford the cost of medicine.  
The implementation of medicines reuse in the UK would rely heavily on people’s uptake of 
this idea. Therefore, this thesis set out to develop an understanding of what the public 
thinks about this concept. To date no other formal research study had examined the general 
public’s views about and openness to the idea of medicines reuse, with one study only 
focussing on pharmacists’ views (McRae et al., 2016a).  
This thesis aimed to capture nationwide views about people’s beliefs, attitudes, and 
intentions to reuse medicines in the future using a mixed method design and applying TPB. 
It provides the first detailed research reports about people’s beliefs, attitudes and intentions 
to reuse medicines in the future. The viewpoints were captured from a large and 
representative sample of the UK patient population, providing robust evidence about 
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patients’ beliefs and intentions to take part in medicines reuse. The results can inform any 
future policy on reducing medicines waste through reuse in the future. 
In the elicitation study (i.e. phase one), qualitative interviews were used to define 
medicines reuse as a behaviour and identify behavioural, normative, and control beliefs 
about medicines reuse. Medicine reuse as a behaviour was defined as the idea that you 
would accept for your own personal use a prescription medicine that has been previously 
given out to another patient but then returned to a pharmacy, where the pharmacist has 
verified that the medicine: has been kept by the other patient for less than three months, has 
more than 6 months of shelf-life remaining, has not been tampered with, has been kept 
under normal storage conditions, and has been kept in the original sealed blister pack (i.e. 
medication strip). This is in relation to adult patients prescribed medicines for a long-term 
condition with the capacity to consent. In addition, the mapped themes obtained from 
inductive thematic analysis in the elicitation study were then categorised against TPB 
within a deductive approach in which three major categories were identified and labelled 
(in Chapter 4). This is summarised in the (Figure 7.1). 
After an elicitation study was completed (phase 1), the MRQ was developed, piloted and 
evaluated using validity and reliability tests. A valid and reliable final version of the MRQ 
(phase 2) was ready to be disseminated nationwide to capture people’s beliefs, attitudes, 
and intentions to reuse medicines in the future (phase 3 of the study).  
The key findings from the quantitative analysis of the MRQ (i.e. phase 3) suggested that 
people living in the UK have positive intentions to reuse medicines and could reuse 
medicines in the future. The positive intentions to reuse medicines were based on people’s 
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strong beliefs about the economic and environmental advantages that medicines reuse 
could provide. However, safety and quality of the medicines that will be offered for reuse 
are vital for people to agree to reusing medicines in the future.  Most of the respondents 
thought reusing medicines in the future would be beneficial, worthwhile, would contribute 
to reducing the harmful effect of medicinal waste into the environment and reducing the 
NHS medicines spend. This was juxtaposed with a belief that medicines reuse was more 
likely to result in receipt of low quality unsafe, or incorrect medication. Nonetheless, more 
than half of the respondents intended or wanted to reuse medicines in the future with the 
expectation that medicines offered for reuse would have been subjected to safety and 
quality checks, would remain in original sealed blister packaging, with  more than  six 
months remaining shelf-life.  
Another key finding from the quantitative analysis of the MRQ suggested that subjective 
norm has the strongest positive effect on people’s intentions to reuse medicines in the 
future. This suggests that the social pressure of people who might approve someone’s 
decision to reuse medicines in the future, such as pressure from doctors, pharmacists, 
family, and close friends was found to be the highest influence on the decisions of the 
participant’s to reuse medicines in the future compared to the (low to moderate) 
participant’s own attitude (i.e. whether reusing medicines is good, worthwhile, beneficial, 
and satisfying for them) and moderate influence of the participant’s PBC (i.e. participant 
confidence to reuse medicines and if medicines reuse is possible to them) to reuse 
medicines in the future. 
The final key finding from quantitative analysis was related to the utility of applying Ajzen 
(2006) TPB model, explained by the SEM procedure in which the modification indices 
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suggested new relationship that are not part of TPB model proposed by Ajzen (2006) TPB 
model. These relationships were between subjective norms to attitude, subjective norms to 
PBC, behavioural beliefs to PBC, PBC to attitude, and behavioural belief to subjective 
norm (Figure 7.2).  
The key findings in this thesis suggested that although people have concerns about 
medicines reuse, the idea is not unpalatable provided certain caveats are put in place. In 
addition, these key findings can inform any future policy on reducing medicines waste 
through reuse in the future. Moreover, the subjective norms having the strongest positive 
effect on intention can be considered as the strongest construct for a medicines reuse 
behavioural intervention and can help inform any future policy on reducing medicines 
waste through reuse in the future.   
The strength of this research is that it captured viewpoints from a large and representative 
sample of the UK patient population, providing robust evidence about patients’ beliefs and 
intentions to take part in medicines reuse in the future. The limitations of this research are 
related to the use of an online questionnaire which would have excluded people with no 
internet access. The strengths and limitations of this thesis are further described below. 
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Figure 7.2 TPB model fit with new relationships showed in red (squared dot) arrows 















7.2 Strength of the thesis 
This thesis presents a novel approach of investigating nationwide opinions on medicines 
reuse that has not been fully addressed in the literature. It provides the first detailed 
research about people’s beliefs, attitudes and intentions to reuse medicines in the future. 
The viewpoints were captured from a large and representative sample of the UK patient 
population, providing robust evidence about patients’ beliefs and intentions to take part in 
medicines reuse. The results from this thesis can inform any future policy on reducing 
medicines waste through reuse in the future. 
The design, development, and validation of the MRQ, which required an elicitation study, 
















validation involved a series of reliability and validity testing to pilot the MRQ. In addition, 
the results were quantified via disseminating the MRQ to a cross section of 1,003 people in 
the UK. The analysis of the results involved checking the assumptions of the statistical 
tests during preliminary analysis, and also a test of model fit and modifying the indices. 
These processes have not been well explored or sometimes neglected in past studies raising 
questions about the validity and reliability of the TPB construct in some of these studies 
but clearly these areas were addressed in this thesis. 
Another strength to this thesis is applying the theory driven approaches especially when 
using mixed methods design (Evans et al., 2011). The TPB worked as a navigational device 
throughout this thesis, helped in simplifying the study of a complex human behaviour (i.e. 
in terms of methods of investigation that take into account the importance of causal 
mechanisms). In particular, the TPB helped scaffolding and refining the design in this 
study during development of the MRQ constructs. Moreover, TPB helped advise the 
selection of variables used for statistical analysis and directed the interpretation of findings, 
at the same time enhancing the reliability and validity of the findings and the 
conclusions made. Finally, the design of the TPB provided structured and robust 
information about medicines reuse behaviour that will influence policy makers in the future 
if medicines reuse is to become a reality. Some of the findings from this thesis have already 
been disseminated through a journal publication as well as presentations at conferences. 
7.3 Limitation of this thesis 
Although the application of TPB was considered a strength in this study at the same time 
there were a few limitations in applying the TPB. First, not all constructs of TPB were 
used. The past behaviour and actual behavioural constructs were both not used. This is 
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mainly because it was not possible to measure the past or actual behaviour of reusing 
medicines as medicines are not yet allowed to be redistributed to other patients. In addition, 
the TPB as any other social cognitive model has received a lot of criticism regarding the 
conceptual, methodological and predictive ability of these models over the recent years 
(Armitage and Conner, 2001; Carpenter, 2010; and Donyai, 2012). However, it is 
important to mention here that TPB received less criticism compared to other social 
cognitive models (Armitage and Conner, 2001; Taylor et al., 2006; and Donyai, 2012). 
This could be considered an advantage of TPB over other social cognitive models rather 
than a limitation. 
The second limitation, in this thesis is that the TPB model fit was poor and required a five 
modification indices. These modification indices suggested new relationships between the 
TPB constructs that was not reported or part of the TPB model proposed by Ajzen (Ajzen, 
2006). Although, some of these relationships were reported by previous studies which used 
TPB model, it is difficult to determine how much significance these relationships hold and 
how unique they are to medicines reuse behaviour. This is simply because there have been 
no previous studies which applied TPB to understand medicines reuse behaviour to 
compare with. Finally, the use of an online questionnaire which would have excluded 
views from people with no internet access is considered another limitation in this thesis.  
7.4 The potential impact of this thesis 
The immediate pathway to impact is by disseminating the results of this thesis to other 
researchers and to the patient population. Some of this work has already been carried out 
but there is further scope to publish papers, attend conferences and write articles on social 
blogs about the findings. 
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The other pathway to impact will be by communicating the results of this thesis to policy 
decision makers in order to change the law regarding reusing medicines. Medicines are 
reused already in countries such as the USA therefore there is precedence for the reuse of 
medicines in a western economy. This thesis explored medicines reuse processes and 
identified the stakeholders perceived to be relevant to the discussion meaning that relevant 
parties can be approached in order to highlight the findings and explore willingness to 
bring about a change in the use of returned unused medicines. In addition to this, the results 
from this thesis can be used in order to develop targeted behavioural interventions should 
medicines reuse become a reality in the future. This means that should there be a need to 
encourage people to take part in reusing medicines in the future, the findings from this 
study can help inform the type of intervention that might best influence people’s 
behaviours. 
As it stands, normative beliefs were identified to be the strongest predictor of people’s 
intention to reuse medicines. Therefore, in the future it may well be worth running a 
marketing campaign in relation to normative beliefs about medication reuse. But in 
addition to that, because all of the constructs of the TPB were in fact found to be 
statistically relevant to intentions to reuse medicines, a marketing campaign could also 
target these other construct. For example a campaign might target people’s behavioural 
beliefs in terms advantages of reusing medicines, such as its beneficial direct impact on the 
environment and its economic impact, and indirectly through reducing accidental poisoning 
or self-medication when medicinal wastes are stockpiled at home. Or advertising by 
showing other people who advocate the reuse of medicines in the future might be 
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completed with pharmacists GPs, friend’s family or partners because these groups were 
evidenced to be important in relation to people’s decisions to reuse medicines. 
In addition, findings relating to control beliefs would also help the process of bringing 
medicines reuse into reality. For example, it would be necessary to confirm that the 
returned unused medicines are safe and have maintained their quality to be reused. Also 
pharmacists would need to confirm that they are willing and have time and space to engage 
in medicine reuse processes. Finally,  pharmaceutical companies would need to be involved 
so that they can develop the technology necessary for illustrating the safety and stability of 
returned unused medicines. This might be achieved, for example by placing a label, which 
is sensitive to light, temperature, and humidity on the packaging of medicinal products. 
7.5 Future work 
In principle, although people have concerns about medicines reuse, results from this thesis 
have confirmed that more than half intend, wanted, and were confident to reuse medicines 
in the future provided that certain caveats are put in place. These caveats include 
addressing concerns about safety and quality of the medicines that will be offered for reuse.  
The participants interviewed recognised the problem of medicines waste and the potential 
for medicines reuse to minimise waste in the future. However, in identifying particular 
groups that might disapprove of medicines reuse, this study highlights the need to take 
account of vulnerable patient groups, and to address political challenges if medicines reuse 
were to become a reality. For example, the stance of the Association of the British 
Pharmaceutical Industry who represent the pharmaceutical industry in the UK remains 
unexplored. In addition, the participants expressed positive views about the involvement of 
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pharmacists in the medicines reuse process, which needs to be explored by pharmacy 
funding, professional and regulatory bodies. Interestingly, the people in this study 
commented only on financial incentives for patients and not for pharmacists. An alternative 
model not requiring CPs to quality check medicines for reuse was also suggested in this 
study, which partly mimics the American medication collection system (Cauchi, 2012).  
However, US legislation dictates for “A state-licensed pharmacist or pharmacy to be part of 
the verification and distribution process” (Cauchi, 2012). The logistic of medicines reuse in 
the UK therefore needs to be further explored. Concerns about tampering and counterfeit 
medicines entering the medicines reuse supply chain might be addressed when the 
European Union directive on falsified medicinal products (EU2016/161) comes into force 
in the UK in 2019, since a supplementary Delegated Regulation requires marketing 
authorisation holders to add tamper evidence and a unique identifier to the outer packaging 
of medicinal products (Medicine and Health-care products Regulatory Agency, 2016). The 
role of heat, light and moisture sensitive monitoring labels as a means of addressing 
concerns about the degradation of returned medicines during storage remains to be 
investigated. Resolving the logistics of medicines reuse in the UK could support the 
international work of charities such as InterCare (InterCare, 2017) that rely on donated 
medicines. 
Reusing medicine is a process which involves mainly patients, pharmacists, and to a lesser 
extent pharmaceutical companies. Therefore, the implementation of medicines reuse in the 
UK would rely heavily on guaranteeing the safety and stability of the returned medicines, 
people’s uptake of this idea, and pharmacist’s views and pharmaceutical company 
involvement. This thesis has provided a good insight from a patient point of view regarding 
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medicines reuse but views from other stakeholders are needed. A Delphi study by (McRae 
et al., 2016a) showed that pharmacists would be happy too to reuse medicines if certain 
factors are met.  
The (McRae et al., 2016a) study provide an initial pharmacist views, and showed that 
pharmacists would be willing to redistribute medicines if certain criteria were met such as 
being solid dosage forms with a tamper evident seal. Other criteria expressed by 
pharmacists included liability protection, guidance from the professional regulator, that 
reused medicines must be supplied in new packaging, that technologies would need to be 
developed to indicate inappropriate storage, and that there must be public engagement on 
medicine redistribution. However, pharmacist views about reusing medicines may require 
further research and on a larger scale.  
After achieving patient and pharmacist views and agreement to reusing medicines, 
exploring the involvement of pharmaceutical companies in medicines reuse would be the 
next step. Here it would be worth exploring whether companies would like to be involved 
in facilitating the medicines reuse process, for example, by placing a temperature sensitive 
label on the packaging, or repackaging the returned unused medicines, and taking the 
responsibility to ensure that the repackaged unused medicine is safe to be reused. This can 
be linked to the fact that in the UK, manufacturers will be required to place safety features 
on the packaging to check the safety of the returned unused medicines with respect to 
counterfeit issues using a unique identifier (a 2-dimension barcode) and an anti-tampering 
device no later than 9 February 2019. Although the purpose of adding the two safety 
measures is to prevent the entry of falsified medicines, potentially the two safety measures 
can be used to evaluate if the returned unused medicines can be suitable to be reused. 
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Further to this, the stability of the unused returned medicines and how the medication has 
been stored also needs to be confirmed before offering these medicines for reuse. This 
needs further research to investigate, for example if the pharmaceutical company will be 
able or willing to provide a technology (such as the temperature monitor alluded to above) 
that can check for medicines stability under different storage conditions. 
Finally the modification indices indicated new relationships between the direct and indirect 
constructs of TPB that was not reported or part of the TPB model proposed by Ajzen 
(2006). These relationships provide an opportunity for further research and should be taken 
into consideration if TPB model will be used to capture pharmacist beliefs or other 
stakeholder beliefs about medicine reuse. 
7.6 Medicinal waste in Jordan 
In Jordan, medicines are obtained from community and hospital pharmacies. In the hospital 
settings, very limited interaction occurs between the pharmacist and the patient. Most 
hospital pharmacies still have antiquated dispensing windows where medicines are placed 
for patients to pick up (Al-Wazaify and Albsoul-Younes, 2005). 
Although the Jordanian Food and Drug Administration (JFDA) drug classification and law 
in relation to drug dispensing is quite similar to those in the West, these laws are not 
strictly enforced or followed in the community pharmacies in Jordan (Al-Wazaify and 
Albsoul-Younes, 2005; and Yousef et al., 2008). A patient can buy any medicine without 
prescription, with the exception of controlled narcotics and major tranquillizers (e.g. 
benzodiazepines), which can only be dispensed upon the issue of a special prescription 
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signed by a registered physician (Al-Wazaify and Albsoul-Younes, 2005; and Albsoul-
Younes et al., 2010).  
There is no evidence or research study performed to explore people’s disposal practices of 
unused medicinal waste in Jordan. Moreover, and unlike the UK, people in Jordan are not 
required or even told by health-care professionals to return their unused medicines to 
community or hospital pharmacies. The lack of awareness regarding the potential 
environmental effect of medicinal waste in Jordan may be a factor in facilitating 
unfavourable disposal practices such as throwing medical in general household waste, and 
flushing these down the sink or the toilet. Although there are anecdotal observations 
confirming these practices, still there is no evidence confirming or research investigating 
these unfavourable disposal practices of unused medicinal waste. The only evidence 
available is that unused medicinal wastes are stored in relatively large quantities in 
people’s households (Al-Azzam et al., 2012; and Abushanab et al., 2013).  
Medicinal waste in Jordan poses a risk to human health and also has economic impact. The 
risk to human health was referred to inappropriate storage condition with around 50 % of 
unused medicinal waste stored outside pharmacy cabinets in places accessible to children. 
These storage conditions could be considered unsafe and with potential risk of accidental 
poisoning especially with children (Abushanab et al., 2013). In addition, there is a high risk 
of self-medication of these unused medicinal waste as self-medication is reported to be a 
common practice among Jordanian people (42.5%) (Yousef et al., 2008).  Self-medication 
was reported to be common with antibiotics as 39.5% of antibiotic users had used 
antibiotics without a prescription (Al-Azzam et al., 2007) and medicines used for headache  
(Al-Azzam et al., 2012).  
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In addition, the economic impact of medicinal waste is possibly more destructive to the 
brittle Jordanian economy. In the study by (Al-Azzam et al., 2012) the total extrapolated 
cost of unused medicinal waste that were stored in patients’ homes in Jordan was around 
$30 million . Moreover, another study by Abushanab et al. (2013), showed that the total 
cost of unused medicinal waste that were stored at patient home from one city (Amman, the 
capital city of Jordan) was $12 million. Those figures are the only evidenced and reported 
in the literature. There is no research investigating the environmental impact or people’s 
disposal practices of medicinal waste in Jordan.  
Only two studies reported in the literature have investigated medicinal waste in Jordan. 
However, the causes as well as the interventions to reduce medicinal waste in Jordan have 
not been studied. The researcher HA will apply the research skills and knowledge 
developed during the PhD and from this research to further explore the causes of medicinal 
waste, and possible interventions to reduce medicinal waste in Jordan (the researcher HA’s 
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Unused/expired drugs were returned 
from households and collected from 
85 community pharmacy centre over 
12 months from March 2012 to 
February 2013. 
Random sample of 22,140 items, 
30 % of total drugs collected over 
12 month) as 70% were unable to 
be classified. 
Not studied.  
2008 Braund 
et al. 
New Zealand Over a five-week period medications 
returned to two collection point 
pharmacies and questionnaire was 
completed by returners. 
163 returns, comprising of 1399 
items, with only 126 returned 
questionnaire. 
 
The majority of those returning 
medications fall within the age 







Medications returned unsolicited to 
Otago pharmacies over a 9 months 
period, from 1st April to 31st 
December 2005. 
A random sample (159kg, 12%) of 
the 1294kg of medications 
returned for destruction over a 
nine-month period from the Otago 










A Disposal of Unwanted Medication 
Properly (DUMP) campaign was 
conducted for 4 weeks in November 
2007 in 31 community pharmacies. 
Questionnaire was completed by the 
returners. 
Of the total 1,605 bags returned 
over 4 weeks for disposal, only 
329 bags (20%), containing a total 
of 1,253 items were fully analysed. 
Only 653 questionnaire were 
completed (41%)  
 
The age distribution of the 
patients with unused medications 
was <20 (8%), 21–40 (13%), 41–
60 (28%), 61–80 (40%) and > 81 
years (11%). 






A Disposal of Unwanted Medication 
Properly (DUMP) campaign was 
conducted for 5 weeks in November 
and December 2009) and for 3 weeks 
Of the 6500 DUMP bags 
distributed across the Nelson Bays 
region, 1244 bags were returned 
(response rate 19%), with an 










Research instrument Sample Demographics 
afterwards. Surveys were completed 
in 379 bags. 
average of 7 items per bag 
(number of items returned 8609). 









Unused medications returned for 
disposal to the 24 community 
Pharmacies over 6 weeks. 
716 individuals returned 3777 
items of unused medications. . Of 
the 3777 information for the 
amount issued and returned was 
complete for 2704.The majority 
(51%) of returns contained 75–
100% of the original dispensed 
amount of medication. 
Not studied.  
2005 Langle





Unused medications returned to 8 
community pharmacies and 5 general 
practices (GP) surgeries over 4 weeks 
each (4 weeks during August 2001, 4 
weeks during March 2002, 
respectively). 
A total of 114 returns; 24 (21.1%) 
to GP surgeries and 90 (78.9%) to 
community pharmacies. The total 
returns comprised 340 items, of 
which 42 (12.4%) were returned to 
GPs and 298 (87.6%) to 
community pharmacies. 
Older patients (60 years and 
over) returned 61.4% of items 
with 24.6% of returns coming 
from patients aged 30–59 years 
and 5.3% of returns originating 
from patients under 30. Ages 











Unused medications returned to 
pharmacies and GP surgeries were 
collected over 8 weeks in May and 
June 2003 in Eastern Birmingham 
Primary Care Trust (PCT). Three-
quarters of the PCT sites participated, 
51/60 (85%) pharmacies and 42/61 
(70.5%) GP surgeries. 
934 return events were made from 
910 patients (190 GP surgeries, 
744 pharmacies), comprising 3765 
items (431 GP surgeries, 3334 
pharmacies) and totalling 4934 
individual packs. 
The mean age of 63.5+0.78 years 
(10 months to 99 years) and there 
was no detectable correlation 
between the mean number of 

















A medicine waste audit in 
community pharmacies of Cumbria 
where each pharmacy asked to 
analyse 20 returns of unused 
medicines. Further qualitative data 
was collected by interviewing the 
patients and their representatives. 
A total 4,563 items was received 




n et al. 
United 
Kingdom 
Unused medications returned to 114 
pharmacies (51 from London/urban, 
32 from North-West/rural & urban, 
24 from Yorkshire & Humber/rural 
& urban, 7 from West-
Midlands/rural) from 5 primary care 
trusts. 
In total, 8626 items were reported 
as returned with 7,500 of the 
returned items identified and coded 
for analysis. 
Not studied 




Unused medications returned to 
random sample of 118 community 
pharmacies in Barcelona invited to 
participate, 38 (32%) agreed to 
participate. Data were collected from 
February to April 2005. 
Questionnaire was completed by the 
returners. 
 
In total, 1,176 packages were 
returned by 227 patients. The 
majority were medicines (96.6%), 
and the rest were medical supplies 
or devices (0.5%) or other products 
sold in the community pharmacy 
(2.9%; e.g., personal care, 
nutrition). Most medicines 
returned were drugs for human use 
(99.8%) and only 0.2% were for 
veterinary use. 
(54.6% women, 64 ± 20 years-
old) 





Cross sectional, observational two 
phases study was conducted using a 
convenience sample in Southern 
Phase I: A total of 539 prescription 
medications were reported, with an 
average of 4 per household. 
Phase I: Average household age 










Research instrument Sample Demographics 
California. In Phase I, a web-based 
survey was conducted at one health 
sciences institution; and in Phase II, a 
paper-based survey at drug take-back 
events. 
Approximately 7% of the unused 
medications were expired, and 
30% were brand name. 
Phase II: of the 776 unused 
medications returned for disposal, 
311 (40%) medications were brand 
name. Nearly two-thirds (66.2%) 
were expired, discontinued by the 
physician (25%), or became 
unused after the patient indicated 
feeling better (17.6%). 
in Phase II which the drug take 
back program.  





Unused medications returned to 
community pharmacy during 
“Medicine Cabinet Clean up 
Campaign” over 6 months between 
April and September 2002 (pilot 
study). 
In total, 1315 medication 
containers were returned to the 
community pharmacy. 63% of 
returned medications were 
dispensed between 2000 and 2002, 












 Telephone survey conducted by a 
survey research centre. 
Not studied Not studied 




Unused medications collected from 
household garbage in all districts of 
Vienna between (12/10-24/11) 2009. 
In total, 152 packs were identified 
from manually investigated sample 











Research instrument Sample Demographics 







Discarded drugs were collected from 
the Drug Discarding Bin at the 
Shuang-Ho Hospital over 4 weeks. 
A total of 98kg (51,972) discarded 
medications collected from the 







Cross sectional survey using pre-
piloted questionnaire was used in the 
interview of 219 households in 9 
areas of Amman to about the types of 
drugs stored at home conducted 
between November 2009 and April 
2010. 
From the 2393 drug product were 
presented in surveyed household, 
24.99% was considered as drug 
waste (Drug wastage, calculated as 
the sum of drug products that had 
expired 10.91%, had no clear 
expiration date 1.84%,  or which 
had never been used since 
dispensing 15.04%(EWFD)). 
Age of the interviewee (years) 
42.15 ± 14.67 








Validated questionnaire was 
administered to 435 households 
selected randomly from different 
areas in the north of Jordan 
(particularly in Irbid governorate) in 
the period from April 2007 and until 
August 2007. 
Of the total of 2835 medication 
items found in the 435 selected 
houses, 65.3% were in use, and 
34.7% were not in use. 











A questionnaire was administered to 
a total of 1641 households 
participated in the study (1554 in 
Saudi Arabia; 87 in other countries). 
 
A total of 12,463 drug products 
were found in 1554 households in 
Saudi Arabia. Among the 87 
households surveyed in the 4 other 
























Observational study of returned 
unused medicines to the pharmacy at 
SQUH between February and June 
2003. 
A total of 1,171 items 
(medications) were returned to the 
pharmacy at SQUH, among these, 
99 drugs were excluded. Medicines 
were included only if they had 
SQUH patients’ labels. And any 
items without SQUH patient’ 




k et al. 
Thailand; 
Songkhla 
A cross-sectional survey of unused 
medicines of a random sample of 931 
households in the Songkhla. Of the 
931 households surveyed and 
interviewed by using structured 
questionnaire there were 453 (48.7%) 
where at least one person reported 
having unused medications.  
A total of 1,004 unused medication 
(items) were identified from 523 
respondents who had unused 
medications in 453 households. 
Nine items could not be identified 
because their physical appearance 
did not match that of any known 
medication. Thus 995 items were 
included. 
Gender: 
Male 224 (42.8%). 
Female 299 (57.2%). 
Age: 
0–9 years 167 (31.9%). 
10–19 years 52 (10.0%). 
20–29 years 66 (12.6%). 
30–39 years 76 (14.5%). 
40–49 years 64 (12.2%). 
50–59 years 40 (7.7%). 











Structured questionnaire developed 
to survey 357 households which were 
interviewed and during January and 
March 2011. 46% in Bangkok and 
54% in upcountry 
 
2,208 drug items were found in 
357 households. 952 items (43%) 
of these drug items were dispensed 
by public hospitals, 750 items 
(34%) from drug stores, 163 items 
(8%) from private hospitals and 

















Egypt; Cairo  Pilot study where all drugs returned 
unused to 20 community pharmacies 
in Cairo over period of one month 
(April 2009). 
A total of 541 drugs were returned 
and collected over one month.  
Not studied.  
2012 Ibrahim 
et al.  
Egypt; 
Alexandria  
A cross-sectional descriptive study 
where all drugs returned unused into 
randomly selected 60 pharmacies in 
Alexandria over a period of one 
month during march 2011. 
A total of 657 drugs were returned 
from 600 patients to the 60 
pharmacies over one month. 
Males constituted the higher 
percentage of the participants 
56.7%. 
Elderly having 60 years or above 
constituted the highest proportion 
of the sample 28.3%, while the 
lowest percentage 4.0% was 
within the age group (10 to less 
than 20). 
2010 Guirgui





Retrospective audit looked at all 
expired medications or those no 
longer needed were collected at St 
Vincent’s Hospital, Melbourne over 
2 months (July and August of 2008) 
A total of 293 items were collected 
from 40 patients recruited over 2 
months. 
 
Older than 65 years of age. 
2014 Kagash






Cross sectional study carried out at a 
tertiary hospital in Dar es Salaam city 
Tanzania where patient files were 
analysed for last admission treatment 
information for the year 2012. 
About 56.3% of medicines 
prescribed were dispensed to 
patients. Out of the total 1418 
dispensed drugs, 730 medicines 
were wasted. 
The mean age of the study 
population was 44 years, with 
minimum age of 11 years and 
maximum of 88 years. 
Medicines wastage was reported 
from female more than in male 











Research instrument Sample Demographics 
2007 Abahus
sain  
et al.  
Kuwait; 
Kuwait city 
Municipal collection program of 
unwanted medicines from 
households in Kuwait City. 
Sample of 200 households in 
Kuwait received an educational 
letter and special plastic bags in 
which to place unwanted 
medicines to be collected by the 
municipality. A second 
convenience sample of an 
additional 14 households in 
Kuwait received the same 
educational letter together with a 
face-to-face interview and 
assistance in collecting unwanted 
medicines. 





North India.  
Descriptive cross sectional survey of 
dental students based on a structured 
questionnaire format) was carried out 
in a teaching dental hospital in North 
India 
244 students, with 8 students were 
excluded due to incomplete forms 
only 236 were included. 
Age of participants from 20-40 
years. 
2011 Gupta  





A simple randomised prospective 
survey study which was carried out 
for a period of six months in selected 
areas of Greater Noida City.  
Randomly selected 102 houses were 
visited to educate and assess the 
people about Home Medicine 
Cabinet. 
 
A total of 392 people were 
surveyed in 92 houses with 
exception of 10 houses. 
Of the total 392 people surveyed: 
The male vs. female for those 
with age >12 years is 144 
(36.73%) vs.133 (33.93%), 
respectively. 
The male vs. female for those 
with age <12 years is 69 (17.6%) 











Research instrument Sample Demographics 





A prospective descriptive, cross-
sectional survey was conducted from 
February to June 2005 in the 
Universiti Sains, Malaysia. 
A total of 481 single female 
respondents were targeted for a 
questionnaire-based survey on 
randomly sampled students. A 
total 1724 different types of 
medicines were found with 
average number of 4 medicines 
found per student. 
 
Respondent were only females 
ages varied from 19 to 54 years 
old. 89.2% (n=429) of the 
students were categorised in the 
19-24 years age category while 
8.7% (n=42) were aged between 
25-30 years old. The remaining 
2.1% (n=10) were aged between 
31-54 years. 
2014 Aboagy
e et al. 
Ghana The study was conducted over 
selected areas in Ghana with a 
questionnaires were randomly issued 
out from the 13th to the 20th of 
December, 2009. 
Out of the 200 questionnaires sent 
out, 180 were retrieved and 
analysed. 
The majority of the respondents 
62.8% (113/180) were between 
the ages of 21 – 40 years, and the 
minority 5.6% (10/180) were 
above 61years. A total of 99 
(55%) of the respondents were 













Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 
2015  Gracia-
Va´squ






The most commonly returned 
medications were of Non-steroidal anti-
inflammatory followed by 
Cardiovascular drugs. Non-steroidal 
anti-inflammatory drugs 16.11%. 
Cardiovascular drugs 14.21% (Anti-
hypertensive 55%). 
Gastrointestinal drugs 11.43%. 
Antibacterial drugs 10.05%. 
Respiratory system drugs 8.75%. 
Neurological drugs 6.13% (anti-
depressant 34%). 
Dietary supplement 5.23%. 
Anti-diabetic drugs 4.34 %. 
Miscellaneous drugs3.79 %. 
Hypolipemic drugs 3.67%.  
Anti-parasitic drugs 2.48%. 
Hormonal drugs 1.89%. 
Anti-micotic drugs 1.84%. 
Steroidal anti-inflammatory drugs 
1.72%. 
Dermatological drugs 1.71%. 
Ophthalmic drugs 1.64%. 
Anti-viral drugs 1.53%. 
The majority of 
unused/expired medications 
collected (73 %) was in solid 
dosage form (tablets, 
capsules, granules, powders, 
and lozenges). 
20 % were liquid 
pharmaceutical forms 
(syrups, injections, eye 
drops, suspensions, 
emulsions, and lotions). 6 % 
were semisolid (ointments, 
creams, gel, paste and 
suppositories). 
 1 % were other forms, such 
as metered dose inhalers, 
sprays, patches, strips, and 
chewing gums 






The most commonly returned 
medications were of the nervous system 
Only oral dosage form 
reported. 











Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 
Nervous system drugs, followed by 
Alimentary tract and metabolism. 
Nervous system drugs 17%. 
Alimentary tract and metabolism system 
drugs14%. 
Cardiovascular system drugs 12%. 
Respiratory system and allergies 11%. 
Musculoskeletal system drugs 11%. 
Infections – agents for systemic use 9%. 
Blood and blood-forming organs 8%. 
Oncology agents and 
immunosuppressants 6%. 
Genitourinary system 5%. 
Dermatologicals 3%. 
Sensory organs 2%, and Hormone 
preparations – systemic 2%. 
2007 Braund 





The returned medications were not 
classified by therapeutic group, but by 
generic name. 
The most commonly returned tablet was 
paracetamol (9% of all tablets returned).  
The most commonly returned capsule 
was omeprazole 20mg (8% of capsules), 
additionally omeprazole 40mg 
accounted for a further 5% of all 
capsules. 
There were 65 907 tablets 
returned and 7599 capsules 
returned. 
Others include injections, 
inhalers, eye drops, creams, 
gels, ointment, test strips, 
liquids, and suppositories. 
Unable to describe respondent 
demographic information.  







The predominant therapeutic group was 
drugs affecting the Nervous system. But 
Oral solid forms (tablets and 
capsules) were counted.  
The chosen sample of the total 










Therapeutic category of the unused 
wasted medicine 





individually diclofenac sodium and 
ibuprofen was the most returned 
medications respectively.  
Nervous system drugs 19%. 
Alimentary tract & metabolism 13%. 
Cardiovascular system 12%. 
Musculo-skeletal system 11%. 
Respiratory system & allergies, and 
Miscellaneous 8%. 
Blood & Blood forming organs7%, 
Dermatological, and Anti-infective 7%. 
Genitourinary3%, Hormones 3%. 
Liquid medications were 
quantified by the amount left 
in the original container, 
semisolid preparations were 
estimated as a proportion of 
original container. Inhalers 
were recorded as either full, 
half-full or empty.  
Anything almost empty was 
excluded from the analysis. 
around 20%, which maybe not 









region.   
The most common returned (top 20) by 
quantities (individual unit) were (n:435, 
397): 
Salazopyrin 94,271 tablets.     
Paracetamol 23,251 tablets. 
Lactulose 11,324 mL.             
Aspirin 10,047 tablets. 
Simvastatin 7,380 tablets.  
Diclofenac 7,014 (mixed preparation) 
Prednisolone 7,004 tablets 
Metoprolol 6,627 tablets. 
Warfarin 6,590 tablets. 
Furosemide 6,117 tablets. 
Lemnis fatty cream 6,095g. 
Cilazapril 5,687 tablets. 
Oral solid forms (tablets and 
capsules) with tablet as most 
common returned dosage 
form. 
Oral liquid forms. 
Cream, and ointment. 
 
 
Unable to describe respondent 











Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 
(Paracetamol & Codeine) preparation 
5,003 tablets. Ibuprofen 4,873 tablets. 
Codeine 4,794 tablets.  Laxsol 4,267 
tablets. Morphine 4, 107 (mixed 
preparations). Emulsifying ointment 
4,030 g, Quinapril 3,890 tablets. 
2009 James  








The predominant therapeutic group was 
drugs affecting Nervous system. But 
individually, paracetamol 
(acetaminophen) was the most returned 
medication respectively. 
Nervous system drugs (n = 658, 24.3%). 
Cardiovascular system (n = 559, 20.7%). 
Alimentary tract & metabolism (n = 529, 
19.6%). 
Blood & Blood forming organs (n = 283, 
10.5%). 
Respiratory system & allergies (n = 190, 
7.1%). 
Not studied. Unable to describe respondent 
demographic information.  
 
Also due the different policies for 
collection and disposal of medicines, 
the majority of unused medicines 
were disposed into landfills and 
water system, which may means that 
the returned amount may be 
underestimate of the extent of unused 
medicines. 
2005 Langle






The predominant therapeutic group was 
drugs affecting cardiovascular system. 
Cardiovascular system drugs 28.5%. 
Central Nervous system drugs 18.8%. 
Respiratory system drugs 14.7%. 
Gastrointestinal drugs 10.6%. 
Endocrine system drugs 5.6% 
Musculo-skeletal and joint disease drugs 
5% 
Tablet or capsule, oral liquid, 
cream or ointment and 
inhalers. 
Sample size and the number of return 
is small which make it difficult to 











Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 
Anti-infective Drugs 4.7%. 
Eye Drugs 3.5%. 
Nutrition & blood drugs 2.1% 
Skin drugs 1.8%. 
Obstetrics, gynaecology, and urinary-
tract disorders 1.5% 
Nutrition and blood & unknown 1.2%. 













The predominant therapeutic groups 
were drugs affecting cardiovascular 
system and drugs acting on the central 
nervous system, respectively. The most 
commonly returned drugs were aspirin 
(102 items), co-codamol (98 items), 
salbutamol (96 items), furosemide (90 
items) and glyceryl trinitrate (78 items). 
Drugs affecting cardiovascular system 
(1003 items, 26.6%). Drugs acting on 
the central nervous system (884 items, 
23.5%). 
Drugs affecting respiratory system (358 
items, 9.5%) and gastrointestinal system 
(358 items, 9.5%). 
Drugs affecting endocrine System (257 
items, 6.8%). 
Drugs treating Musculoskeletal and joint 
diseases (235 items, 6.2%). 
Tablet or capsule, oral liquid, 
cream or ointment and 
inhalers. 
The author reported that this study 
did not attempt to estimate the 
quantities of unused medicines at 
patient’s home, as a result, it is more 
likely that the unused medicines 











Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 
Anti-infective drugs (165 items, 4.4%). 
Drugs for skin (124 items, 3.3%). 
Drugs for Nutrition and blood (116 
items, 3.1%). 
Drugs for eye (65 items, 1.7%). 
Obstetrics, gynaecology, and urinary-
tract disorders (59 items, 1.6%). 
Drugs for Ear, nose, and oropharynx (58 
items, 1.5%) & others (58 items, 1.5%). 
Drugs for Malignant disease and 
immunosuppression 20 items, 0.5%). 







The greatest value of returned of 
medicines were from Cardiovascular and 
Central nervous system categories 
(BNF), total number of returns 
(n=4562):  
Cardiovascular (n=1232).  
Central nervous system (n=1149).  
Gastrointestinal system (n=468) 
Endocrine (n=334). 
Respiratory (n=307).  
Anti-infective (n=250). 
Musculoskeletal and joint (n=228). 
Nutrition and blood (n=141). 
Skin (n=134). 
Others (n=319) 
Not studied  It is an audit report with a result from 
Cumbria/north west of England 
which may not representative of 
whole United Kingdom and may 
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wasted medicine 
Dosage form Study limitation 
2010 Truema
n et al. 
United 
Kingdom 
Coding was based on guidance provided 
by the Royal Pharmaceutical Society of 
Great Britain/BNF. The most common 
retuned medication was for 
cardiovascular and central nervous 
system. 
Cardiovascular system drugs (1950 
items, 22.6%). 
Central nervous system drugs (1907 
items, 22.11%). 
Gastro-intestinal system drugs (828 
items, 9.6%). 
Respiratory system drugs (528 items, 
6.12%). 
Endocrine system drugs (518 items, 
6.01%). 
Endocrine system drugs (518 items, 
6.01%). 
Anti-infective drugs (444 items, 5.15%). 
Musculoskeletal, joint disease drugs 
(364 items, 4.22%). 
Nutrition and Blood drugs (249 items, 
2.89%). 
Skin drugs (192 items, 2.23%). 
Eye drugs (129 items, 1.5%). 
Ear, nose, oropharynx drugs (68 items, 
0.79%). 
Not studied Unable to describe respondent 











Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 
Malignant disease & immuno-
suppression drugs (53 items, 0.61%). 
Wound management drugs (34 items, 
0.39%). 
Borderline substances (25 items, 0.29%). 
Drugs for Anaesthesia (9 items, 0.10%). 




The predominant therapeutic groups 
were drugs affecting Alimentary tract 
and metabolism, Nervous system, 
Cardiovascular system, respectively. All 
drugs were categorised according to 
Anatomical Therapeutic Chemical 
(ATC) system/code of the World Health 
Organisation (WHO). 
Alimentary tract and metabolism drugs 
(215 items, 18.3 %) 
Nervous system drugs (214 items, 
18.2%). 
Cardiovascular drugs (137 items, 
11.6%). 
Respiratory system drugs (103 items, 
8.8%) 
Musculo-skeletal system drugs (88 
items, 7.5%). 
Dermatological drugs (85 items, 7.2%). 
Anti-infective drugs (77 items, 6.5%). 
Not studied Unable to describe the respondent 










Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 
Missing drugs (could not be coded 
according to the ATC system), (66 
items, 5.6%). 
Sensory organs drugs (63items, 5.4%). 
Drugs affecting Genitourinary system & 
sex hormones (50 Items, 4.3%). 
Drugs affecting Blood & blood forming 
organs (32 items, 2.7%). 
Antineoplastic and immune-modulating 
drugs (22 items 1.9%). 
Systemic hormonal preparations 
excluding sex hormones and insulins, 
(17 items, 1.4%). 
Various Drugs (5 items, 0.4%). 
Anti-parasitic products, insecticides and 
repellents (2items, 0.2%). 
2015 Law  




Approximately 2 of 3 prescription 
medications were reported unused. 
In phase I, pain medications (23.3%) and 
antibiotics (18%) were most commonly 
reported as unused.  
In Phase II, 17% of medications for 
chronic conditions (hypertension, 
diabetes, cholesterol, heart disease) and 
8.3% for mental health problems 
(antidepressants/antipsychotic/Anti-
convulsant) were commonly reported as 
Tablets, pills, capsules and 
liquid preparations. 
 
Use of a web-based survey may 
limited the accessibility of this study 
to people without computer and 
Internet access at home, which may 
to some extent underestimated the 
extent of unused medicines.  
 











Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 
unused. 7% painkillers, and 4% 
electrolytes and dietary supplements. 










Drugs for cough/cold/allergy 15%. 
Anti-infective drugs 11%. 
Cardiovascular drugs 10%. 
Respiratory drugs 9%. 
Neurological drugs 8%. 
Dermatological 7% and Gastrointestinal 
7%. 
Oral medications (capsules 
or tablets) were most 
commonly returned (64%), 
followed by liquid (12%), 
creams (11%), inhalers (7%), 
or miscellaneous (6%; e.g., 
eye glasses, hearing aid 
batteries, medical 
equipment). Approximately 
17 000 oral pills were 
collected during the study 
period. 











The predominant therapeutic group was 
Pain medication (15%), hypertension 
(14%), antibiotics (11%), and 
psychiatric disorders (9%) 
Not studied Unable to describe respondent 
demographic information. 




The predominant therapeutic group was 
cardiovascular drugs. 
Cardiovascular drugs (36 packs, 23.7%). 
Musculoskeletal system drugs (17 packs, 
11.2%). 
Nervous system drugs (16 packs, 10.5%) 
Alimentary tract & metabolism 15 
packs, 9.9%). 
Oral medications were the 
most commonly founded 
86.8% (usually solid oral), 
followed by dermal 6.7%, 
parental 4%, nasal 0.7% 
pulmonary0.7%, eye 0.7%  
Dental 0.7%. 











Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 
Anti-infective drugs for systemic use (5 
packs, 3.3%). 
Drugs for Blood & blood forming 
organs (4 packs, 2.6%). 
Genitourinary system drugs & sex 
hormone (2 packs 1.3%) and 
Dermatological drugs (2 packs 1.3%). 
Other ATC code or not attributable (45 
packs, 29.6%). 







Among the discarded medications, 
gastrointestinal drugs were at the top of 
the list of all discarded medications. The 
analysis of discarded and unused drugs 
revealed that 
Strocain (oxethazaine, polymigel) was 
on top of the list, followed by Glucobay 
(acarbose), Mopride (mosapride) and 
Loditon (metformin). 
Gastrointestinal drugs 25.93%. 
Cardiovascular drugs 22.49%. 
Anti-inflammatory drugs 12.15%. 
Anti-diabetic drugs 9.49%. 
Cold medicines 6.83%. 
Psychiatric drugs 5.44%. 
Respiratory drugs 2.16%. 
Rheumatological drugs 1.52%. 
Antimicrobial drugs 1.42%. 
Others 9.19%. 











Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 






Alimentary tract & metabolism drugs 
were the most commonly found in 
household (both used and unused). 
Stored drug products were classified by 
ATC code of WHO. 
Alimentary tract and metabolism 519 
(20.7%). 
Nervous system 370 (17.3%). 
Musculoskeletal system 313 (12.9%). 
Respiratory system 291 (12%). 
Cardiovascular system 256 (10.9%). 
Anti-infective for systemic use 252 
(10.6%). 
Dermatological 149 (5.4%). 
Blood and blood forming organs 109 
(4.6%). 
Genitourinary system and sex hormones 
31 (1.1%). 
Systemic hormonal preparations, excl. 
sex hormones and insulin 18 (1.1%). 
Anti-parasitic products, insecticides and 
repellents 13 (0.7%). 
Anti-neoplastic and immune-modulating 
Sensory organs 63 (2.5%) agents 8 
(0.3%). 
Not studied Studied the medication stored at 
home the estimated the unused 
wasted medicine as the sum of drug 
products that had expired, had no 
clear expiration date,  or which had 
never been used since dispensing. So 
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wasted medicine 
Dosage form Study limitation 








Central nervous system drugs were 
found to be the most common, followed 
by anti-infective agents 
The most common individual 
medications found were amoxicillin, 
paracetamol, metronidazole, 
antihistamines, hypoglycaemic 
medications, and adult cold medications. 
Central nervous system drugs (713 
items, 25.2%).  
Anti-infective agents (493 items, 
17.4%). 
Musculoskeletal agents (381 items, 
13.4%) 
Respiratory system agents (348 items, 
12.3) 
Gastro-intestinal agents (301 items, 
10.6%) 
Cardio-vascular agents (216 items, 
7.6%) 
Endocrine system agents (200 items, 
7.0%) 
Nutrition agents (127 items, 4.5%) 
Eye, Ear, Nose and Skin agents (56 
items, 2.0%). 
Tablets (1794 items 63.3%) 
Capsules (332 items, 11.7%) 
Syrups (250 items, 8.8%) 
Suspensions (201, 7.1%) 
Suppositories (117 items 
4.1%) 
Creams / ointments / gels (43 
items, 1.5%) 
All forms of injections (53 
items, 1.9%) 
Drops /nasal or oral puff (45 
items, 1.6%) 
Sample was selected from northern 
Jordan which may not representative 




5 regions in 
Saudi 
Arabia and 
Medications were also categorized 
according to their pharmacologic or 
therapeutic class using the classification 
Not studied Unable to describe respondent 
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of drugs adopted in the Saudi National 
Formulary (SNF). 
 
Respiratory system drugs Saudi Arabia 
2095 (16.8%), other gulf countries 94 
(15.3%). 
Central nervous system drugs Saudi 
Arabia 2050 (16.4%), other gulf 
countries 84 (13.6%). 
Antibiotics Saudi Arabia 1779 (14.3%), 
other gulf countries 111 (18.0%). 
Gastrointestinal drugs Saudi Arabia 
1382 (11.1%), other gulf countries 60 
(9.7%). 
Miscellaneous Saudi Arabia 847 (6.8%), 
other gulf countries 57 (9.3%).  
Nutrition and blood drugs Saudi Arabia 
823 (6.6%), other gulf countries 24 
(3.9%). 
Musculoskeletal/joints drugs Saudi 
Arabia 790 (6.3%), other gulf countries 
52 (8.4%). 
Skin drugs Saudi Arabia 735 (5.9%), 
other gulf countries 33 (5.4%). 
Ear, nose, throat drugs Saudi Arabia 553 
(4.4%), other gulf countries 26 (4.2%). 
Cardiovascular drugs Saudi Arabia 465 










Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 
Eye drugs Saudi Arabia 398 (3.2%), 
other gulf countries 25 (4.1%). 
Endocrine drugs Saudi Arabia 375 
(3.0%), other gulf countries 16 (2.6%). 
Obstetric/gynaecologic and/or urinary 
drugs Saudi Arabia 140 (1.1%), other 
gulf countries 12 (1.9%).  
Cytotoxic drugs Saudi Arabia 31 (0.2%), 
other gulf countries 0 (0.0%).  
Total drugs Saudi Arabia 12,463 
(100%), other gulf countries 616 
(100%).  
The mean medication wastage was 
estimated to be 25.8% Saudi Arabia and 
41.3% other gulf countries. 
2007 Al-
Siyabi  







Cardiovascular drugs were the most 
common pharmacological group of 
returned drugs. The drugs were 
classified according to the classification 
index of the British National Formulary. 
Cardiovascular drugs 24%. 
Central nervous system drugs 14%. 
Anti-infective drugs 13%. 
Endocrine drugs 10%. 
Nutrition 9%. 
Gastro-intestinal drugs 8%, and 
Musculoskeletal system drugs 8%. 
Respiratory system drugs 5%. 
Not studied Unable to describe respondent 
demographic information. 
  
As it included only medicines with 
SQUH labels, others missed, as this 











Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 
Immunosuppressant drugs 3%. 
Eye/Ear drugs 2%. 
2004 Wongp
oowara
k et al. 
Thailand; 
Songkhla 
Musculoskeletal system drugs were the 
most common pharmacological group of 
returned drugs. The medications were 
pharmacologically classified using 
MIMS Thailand, a standard reference 
source. 
Musculoskeletal system drugs (229 
items, 23.3%). 
Anti-infective drugs (189 items, 19.2%). 
Respiratory system drugs (166 items, 
16.9%). 
Gastrointestinal system drugs (129 
items, 13.1%). 
Allergy and immune system drugs (91 
items, 9.2%). 
Vitamins and minerals (68 items, 6.9%). 
Others (EWFD, 2008) (54 items, 5.5%). 
Central nervous system (37 items, 
3.8%). 
Cardiovascular (21 items, 2.1%). 
Oral dosage forms 
compromised 95.6% (951 
items). 
Oral tablets or capsules (636 
items, 63.9%). 
Oral liquids (311 items, 
31.3%). 
Eye drops (23 items, 2.3%). 
Topical liquids (14 items, 
1.4%). 
Creams (5 items, 0.5%). 
Oral powders (4 items, 
0.4%). 
Inhalers (2 items, 0.2%). 
This study was a snapshot study, as 
studied population was one of 14 









 Of the total of 2,208 drug items found 
in household surveys into 5 groups of 
the mostly found drugs. These were 343 
non-opioid analgesics and antipyretic 
drugs, 188 antacids, anti-reflux agents 
and anti-ulcer, 180 non-steroidal anti-












Therapeutic category of the unused 
wasted medicine 





inflammatory drugs (NSAIDs), 127 
antihistamine and anti-allergic and 119 
anti-diabetic drugs. 
Top 5 of the most found rarely or unused 
drugs, classified as leftover medicines, 
were NSAIDs (49 items), penicillins (38 
items), GIT regulators, Antiflatulents 
(36 items). 
 
Of the total of 2,208 drug items found in 
household, 82 items (3.7%) and 45 items 
(2.0%) of drugs were already expired 
and deteriorated respectively. 
2011 El-
Hamam
sy A  
Egypt; 
Cairo 
The returned medications were classified 
according to the British National 
Formulary (BNF). Antibiotics were the 
most common pharmacological group of 
returned medications. 
Antibiotics (109 items, 20.15%). 
Gastro-intestinal system drugs (88 items, 
16.27%). 
Cardiovascular system drugs (58 items, 
10.72%). 
Respiratory system drugs (44 items, 
8.13%). 
Nervous system drugs (39 items, 
7.20%). 












Therapeutic category of the unused 
wasted medicine 
Dosage form Study limitation 
Analgesics and anti-inflammatory (38 
items, 7.02%). 
Dermatological drugs (35 items, 6.47%). 
Blood and blood forming organs (29 
items, 5.36%). 
Systemic hormonal preparations, sex 
hormones and insulin's (27 items, 
4.99%). 
Anti-parasitic products, insecticides and 
repellents (25 items, 4.62%). 
Genitourinary system (20 items, 3.69%). 
Antineoplastic and immune-modulating 
agents (3 items, 0.55%). 





Cardiovascular system drugs were the 
most common pharmacological group of 
returned medications. The returned 
medications were classified according to 
the British National Formulary (BNF). 
Cardiovascular system (127 items, 
19.4%). 
Anti-infective (126 items, 19.2%). 
Gastrointestinal system (66 items, 
10.9%). 
Nutrition and Blood (69 items, 10.6%). 
Non-steroidal anti-inflammatory (64 
items, 9.8%). 
Nervous system (61 items, 9.3%). 
Not studied. This study did not estimated the 
quantities of unused medicines in 
patient’s home. As result, it is likely 
that it may underestimated the extent 
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wasted medicine 
Dosage form Study limitation 
Respiratory system (58 items, 8.9%). 
Endocrine system (49 items, 7.5%). 
Skin care (19 items, 2.9%). 
Ear-Nose-Throat (7 items, 1.1%) and 
Genitourinary system (7 items, 1.1%). 
Musculo-skeletal system (2 items, 
0.3%). 
2010 Guirgui





Cardiovascular system drugs were the 
most common pharmacological group of 
returned medications. The smallest 
group was that of topicals, e.g. creams 
and ointments. 




Neuropsychiatry drugs (8.5%).   
Respiratory system drugs (8%). 
Eye/Ear/Nose drugs (7.5%). 
Gastrointestinal drugs (7%), and 
Antimicrobials (7%). 
Herbals and vitamins (12 items, 4.1%). 
Diabetes drugs (3%). 
Topicals, e.g. creams and ointments (8 
items, 2.7%) 
Miscellaneous (4.5%). 
They report that they collect 
topicals cream, ointment 
along with other dosage 
forms (that was not defined).  
Sample size and the number of return 
is small which make it difficult to 
extrapolate the result to whole 
Australia. 
2014 Kagash
e et al. 
Tanzania; 
tertiary 
Medicines wasted in this study were 
categorized into three major groups, 
Oral solids drugs were the 
most common wasted dosage 
Because only hospital prescribed 
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medications and others. 
Anti-infective drugs 18.9%. 
Cardiovascular drugs 8.9%. 
Other drugs 23.7%. 
form 40.6% followed by 
injections 9.2%, with very 
few topicals preparations.  
maybe missed which may 







No medicines were collected from the 
200 households participating in the 
municipal collection program The 
second intervention yielded 123 
medicines from 14 homes, the most 
common class of unwanted medicines 
were drugs for respiratory system. 
Unwanted medications were classified 
according to the ATC WHO 
classification. 
A third of all unwanted medicines were 
for the respiratory system (38% of these 
were cough and cold preparations, 25% 
nasal preparations). 12% of the 
medicines were for the musculoskeletal 
system (53% oral NSAIDs) or were 
dermatologicals (33% topical 
antibiotics)  
There were 141 items 
(including duplicates). 508 
tablets/capsules, 25 oral 
liquids, 20 tubes, 21 dropper 
bottles and various other 
dosage forms. 
Sample size and the number of return 
is small which make it difficult to 
extrapolate the result to whole 
Kuwait. 
 









Qualitative analysis of expired 
medications at home revealed 
antipyretics (54%), analgesics (64%), 
followed by antihistamines (35%) to be 
hoarded in home pharmacies/medicine 
Not studied  Small sample size from specific 
region in India, which make it 
difficult to generalise and extrapolate 
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Dosage form Study limitation 
chests. Other drugs were antibiotics 
(26%), antacids (23%), topical drugs 
(39%) and supplements (vitamins) 
(41%) 
Excessive buying of over-the counter 
(OTC) drugs 
(53%); self-discontinuation (17%), and 
expiration of drugs (24%) resulted in 
possession of unused/leftover 







Most of the expired drugs are in the 
category of analgesics and NSAID’s 
(23.93%) followed by nutritional 
supplements (22.56%), antibiotics 
(14.94%), expectorants and mucolytics 
(6.77%), bronchodilators (5.31%) and 
antacids (6.53%). 
Oral tablets were the most 
common, other dosage forms 
include syrups, capsules, 
suspensions, powders, eye 
drops, gels, churna, cream, 
and ear wax softener.  
Defined medicine wastes as only 
expired medicines which may 
underestimated the extent of unused 
wasted medicines. 
2009 Ali  




The total number of medicines found 
unused was 1724 drug products with 
vitamins and minerals as the most 
common class of unused drugs. 
Vitamins & minerals 427 (24.8%) 
Gastrointestinal drugs 298 (17.3%) 
Analgesic & antipyretics 293 (17.0%) 
Antibiotics 174 (10.0%) 
Ear, nose & throat drugs 159 (9.2%) 
Respiratory drugs 106 (6.3%) 
Dermatological products 97 (5.6%) 
68.5% (n=1181) of the 
medications were in the form 
of tablets and pills while 
capsules constituted 14.6% 
(n=252) of the overall 
amount. 5% (n=87) syrups 
and suspensions while 4.9% 
(n=84) were creams and 
ointments. 
Less than 1.0% (n=5) 
consisted of inhalers, with 
Sampling of only female students 
made it impossible to generalize the 
results to the whole student 
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Anti-rheumatic & anti-inflammatory 
69 (4.0%) 
Others (CNS drugs, endocrine & 
metabolic drugs, cardiovascular drugs, 
genitourinary drugs, and others 101 
(5.8%) 
0.2% (n=4) suppositories of 
the overall total. 
2014 Aboagy
e et al. 
Ghana Leftover medicines: 
Paracetamol tablets 27 
Amoxicillin capsules 12 
Aspirin tablets 4 
Metronidazole tablets 5 
F-PAC (Paracetamol/Aspirin/Caffeine) 3 
Vitamin B Complex tablets 7 
Multi-vitamins tablets 7 
Diclofenac tablets 3 
Magnesium Trisillicate tablets 3 
Ibuprofen tablets 5 
Others/Unidentified 45 
Do not remember 1 
Not studied Sample size and the number of return 
is small which make it difficult to 
extrapolate the result to whole 
Ghana. 
 
Leftover medicines were described 





Appendix 3 University of Reading Research Ethics Committee approving ethical 
application through the school exemption process (copy of the email approval) 
Dear Parastou, 
  
I am pleased to say that Prof Osborn has approved your application for ethical approval via 
the in-School exceptions route. This email constitutes your permission to proceed with the 
studies as described in your application. 
  
The following study number has been assigned to your study and you should quote this 
number in any correspondence you undertake about your studies. 
  
30/15 Public perceptions about medication reuse: to explore public perceptions and 
attitudes towards medication reuse 
  
If you feel that you need to make changes to the way your studies are run, please let us 
know at the earliest opportunity and we can advise you of whether a formal amendment to 
your proposal is required or not. 
  
I wish you the best of luck with the projects and finish by reminding you of the need for 



















Letter of information for consent to participate in the interviews 
Title of Study: Public perceptions about medication reuse: to explore public 
perceptions and attitudes towards medication reuse 
Invitation 
I would like to invite you to take part in a research study. Before you decide I would like you 
to understand why the research is being carried out and what it would involve. If you need 
any clarification after reading this information sheet, I can arrange to meet and go through 
the information sheet with you in order to answer any questions you have – please see the 
top of this information sheet for my contact details. I believe that reading this information 
sheet should take about 5 to 10 minutes of your time. 
Part 1 tells you the purpose of this study and what will happen to you if you take part.  
Part 2 gives you more detailed information about the conduct of the study.  
PhD Pharmacy Student 




Director, Pharmacy Practice 
Dr Parastou Donyai 
PHD, BPHARM, PGDPRM(OPEN), 
PGCERT LTHE 




Reading School of Pharmacy 
Food and bioscience building, 
whitenights, P.O.Box 226,  
Office Room 1.02 








Please contact me if there is anything that is not clear.  
Part 1  
What is the purpose of the study? 
The purpose of this study is to find out patients’ and the public’s view on medication 
waste, and their thoughts on potentially reusing any returned, unwanted and unused 
medication.   
The aim is to examine reasons that might lead to medication waste and thoughts on reusing 
someone else’s returned medicines. This research will form the basis of my PhD (Mr. Hamza 
Alhamad).  I am studying under the supervision of Dr Parastou Donyai at the School of 
Pharmacy, University of Reading. 
Why have you been invited?  
You are being invited because we would like patients’ and the public’s perspective on 
medication waste and the idea of reusing returned unwanted and unused medication. You 
are invited as you match the study selection criteria: a member of the public who is more 
than 18 years old, who has any chronic condition (disease), is currently taking one or more 
prescribed medication, and has been taking medication for their chronic condition for at 
least 12 months. 
Do you have to take part? 
It is up to you to decide to join the study. The participation is voluntary. I can arrange to meet 
with you in order to describe the study further and go through this information sheet if 
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necessary.  If you agree to take part, I will then ask you to sign a consent form before I 
interview you.  You are free to withdraw at any time, without giving a reason.  A copy of 
this information sheet and a signed consent form will be given to you to keep. 
What will happen to you if you take part? 
The consent form and information sheet will be given to you before the interview to re-read 
and then sign two copies for each of us to keep a copy.  If you agree to take part in the 
study, we will arrange a suitable time for you to come to the University of Reading to 
speak with me in a 30-45-minute interview.  The interview could potentially last an hour, 
depending on the question and answer responses but the average interview time we expect 
would be 30-45 minutes. With your permission, the interview will be audio-recorded to 
make sure I obtain all the information accurately. The information provided and recorded 
will be kept securely.  
Expenses and payments  
A £10 Amazon voucher will be emailed to you after the interview to thank you for taking 
part.     
What will you have to do? 
If you are interested in participating in this study, please contact me by e-mail 
(h.q.m.alhamad@pgr.reading.ac.uk).  I will then contact you in order to invite you to the 
University of Reading, so we can meet and arrange a time and date convenient to you. I 
will bring with me a list of pre-arranged questions to discuss, but we will also have the 
flexibility to talk about other issues which you find important in this area. As I mentioned 
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above, although expected to last 30-45 minutes, the interview may take up to a maximum 
of an hour, depending on our discussions. The questions will be about your opinions and 
experiences relating to medicines waste and the thought of reusing returned medication. 
What are the possible disadvantages and risks of taking part? 
This study should not pose any risks. During the interview, you have a right to not answer 
any questions that you feel uncomfortable with and can stop the interview at any time.  If 
you feel you need a break within the interview, let me know and we can take a break. The 
contact details of my supervisor are provided at the top of this sheet and they will be able to 
talk to you if you require additional support. 
What are the possible benefits of taking part?  
I cannot promise the study will help you in any specific way but you may find participating 
and reflecting on the topic helpful personally and of course the information we get from this 
study may help gain an understanding of views on this current topic, and could help reduce 
medication waste in the future. 
What if there is a problem? 
Further information on this is given in Part2. 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled 
in confidence. The details are included in Part 2. 
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If the information in Part 1 has interested you and you are considering participating, 
please read the additional information in Part 2 before making any decision. 
Part 2  
What will happen if you don’t carry on with the study? 
If you do not wish to carry on with this study, for example you wish to pull out of the 
interview having arranged it in advance, you can withdraw at any time without giving a 
reason. 
What if there is a problem? 
If you have any complaints about the way you have been dealt with during the study, this 
can be addressed by contacting my research supervisor. For contact details, please see the 
header of this Information Sheet. 
Will my taking part in the study be kept confidential? 
Confidentiality will be ensured for all participants, and all data collected from the 
interviews will be used only for scientific research purposes. Interviews will be recorded 
with your permission using a digital audio-recorder. All recordings made will be removed 
from the audio-recorder and transferred to a secure memory stick as soon as possible.  This 
memory stick will then be stored in a locked in a cupboard in a secure office and accessible 
only to the PhD student (Hamza Alhamad), and PhD supervisor Dr. Parastou Donyai. The 
recordings will then be transcribed into a word document by ‘’ “The Transcription 
Agency” which is an approved University of Reading supplier for transcribing services and 
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names or any other details that might identify the participant will be removed from the 
transcripts. All information will be anonymised using a number to prevent association of 
participants to defined quotations – non-identifiable codes will be used and other 
identifiable information will be altered. This is critical to ensure your anonymity and 
confidentiality throughout the write up of the results. During the study the memory stick 
and the transcript as word documents will be stored safely and will be accessible only by 
the researcher and the supervisor. The information will not be saved on public or personal 
computers.  If requested, you will be given the access to the transcript of your own 
interview, and you will have the opportunity to review this before it is finalised and used in 
the research. At the conclusion of the study the digital recordings will be deleted. None of 
the information that you provide will be disclosed to a third party. 
What will happen to the result of the study? 
The results of the study will be used in my PhD thesis. The outcomes may be presented at 
academic and professional conferences and in academic journals. The detail of all 
participants will be kept confidential and you will not be identifiable from any research paper 
or other publications. The data collected from your interview will be destroyed when the 
research is completed. 
Who is organising and funding the research? 
This study is being conducted with the University of Reading acting as the academic 
institution for my PhD.  In addition, my research is supported by a full-time scholarship 
provided by ALZARQA University in Jordan. 
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Who has reviewed the study? 
This study has been reviewed and approved by the University of Reading Research Ethics 
Committee procedures. 
Thank you for taking the time to read about my research. 









Title of Study: Public perceptions about medication reuse: to explore public 
perceptions and attitudes towards medication reuse 
Name of Researcher: Hamza Alhamad 
I have read and had explained to me by the researcher the accompanying 
Information Sheet relating to the project entitled above I have had explained to me 
the purposes of the project and what will be required of me, and any questions I 
had, have been answered to my satisfaction. I agree to the arrangements described 
in the Information Sheet in so far as they relate to my participation.  
1. I confirm that I have read and understand the information sheet for the above study. I 
have had the opportunity to consider the information, ask questions and have had these 
answered satisfactorily (                ). 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason (                ). 
3.  I understand that while most interviewees will find the discussion interesting and 
thought-provoking, if nonetheless I feel uncomfortable in any way during the interview 
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Dr Parastou Donyai 
PHD, BPHARM, PGDPRM(OPEN), 
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session, I have the right to decline to answer any question or to end the interview (                
). 
4. I understand that my participation in this study involves being interviewed by researcher 
from University of Reading and the interview will last approximately 30-45 minutes and 
will be audio-recorded. I give my permission to the researcher to audio-record the 
interview by using a digital voice recorder (                ). 
5. This project has been subject to ethical review, according to the procedures specified by 
the University Research Ethics Committee, and has been given a favourable ethical 
opinion for conduct (                ). 
6. I understand that my confidentiality as a participant in this study will remain secure and 
that the transcript of my interview will not contain my name (                ). 
7. I have been given a copy of this consent form and the accompanying information letter  
(                ). 
8. I wish to receive a summary of the results once the study is complete and 
analysed scientifically. For that to take place (receiving a summary of the 






































Appendix 7 Interview schedule used in the elicitation study 
From the email you sent, you indicated your interest in the concept of medicines reuse. 
Please outline any experience of unused medicine (for example, which you might have 
returned back to the pharmacy. Would you please tell me more about unused medicines 
returned back to a pharmacy? What do you imagine the pharmacist does with these 
returned medicine?) 
Please take a few minutes to tell us what you think about the possibility of people reusing 
returned medicines in the UK. 
There are no right or wrong responses; we are merely interested in your personal opinions. 
In response to the questions below, please tell us the thoughts that come to mind. 
What do you see as the advantages of medicines reuse? 
What do you see as the disadvantages of medicines reuse? 
What else comes to mind when you think about medicines reuse? 
Would you agree to accept medicines for yourself that have been returned to a pharmacy 
by others? 
When it comes to you reusing medicines, there might be individuals or groups who would 
think you should or should not perform this behaviour. 
Which individuals or groups would approve or think you should reuse medicines? 




Sometimes, when we are not sure what to do, we look to see what others are doing. Please 
list the individuals or groups who are likely to reuse medicines? 
Please list the individuals or groups who are least likely to reuse medicines? 
Please list any factors or circumstances that would make it easy or enable you to reuse 
medicines 
Please list any factors or circumstances that would make it difficult or prevent you from 
reusing medicines 
  





Appendix 8 Summary of thematic coding and analysis  
Participant responses (the final quoted ones) Final coding Major theme/minor 
theme 
sub- theme 
Medicine reuse should be regulated and monitored by NHS to 
avoid the risk of having black market, this include pharmacist 
selling the collected medicines online, and also counterfeit 
medicines that patient bought online should not put back the shelf 
(if returned) and this will be assured during a quality check by the 
pharmacist. (P17, female, >70 age group) 
 
- Medicine reuse process 
- Medicine reuse process 
risks  
- Medicine bought online 
- black market 
1. and counterfeit 
medicines  
 
Medicine reuse process: 
Regulation of medicine 
reuse process 
Risks associated with 
medicine reuse process e.g. 
Black market and 
counterfeit medicines 
Medicine reuse to 
be regulated by 
NHS. 
I think the majority of people because of the trust they have in the 
health service, if it was standard practice for the health service then 
they may well accept it.  The difficulty would be if you made it 
look as though it was a practice carried out by pharmacists, they 
might object.  It would have to be seen to be something that’s done 
by the health service, OK, rather than by the pharmacy, the 
pharmacy only acting as an agent for the health service. (P15, male, 
50-59 age group) 
- Trust in in the services 
provided by NHS 
- If it is run as pharmacy 
service it should be 
under control by NHS 
NHS should the regularity 
body for medicine reuse 
process.  
Medicine reuse should not 
be just regulated by 
pharmacy service alone 
without NHS control 
 
Trust in the NHS 
services 
Mainly I would say economy, because it does seem wasteful that 
these things cost a lot of money to research and develop and 
produce, then package and transport, then being wasted, so it is a 
question of economy. (P2, male, >70 age group) 
- Medicine reuse is 










Saving money for 
NHS 
I would say the main advantage of reusing medicines is saving on 
cost, in this country masses of drugs are wasted. When you have 
been prescribed something and did not need much of it, and then 
you think what an awful waste?  Surely it would be better to return 
it and somebody else able to use it. (P5, Male, 60-69 age group) 
 
- A lot of medicine is 
wasted reusing 




Potential advantages of 









Participant responses (the final quoted ones) Final coding Major theme/minor 
theme 
sub- theme 
I think medicine reuse would be an efficient thing to do financially 
and environmentally, because if you are reusing you are not having 
to produce as much, and also you are reducing waste.  (P7, female, 
60-69 age group) 
 






Potential advantages of 







Generic medicines, maybe they are so cheap that a packet of aspirin 
cost maybe 16p or something, but maybe some of the more 
expensive medicines that is definitely worth reusing. (P3, male, 40-
49 age group) 
 
- Medicine costs (cheap 
vs. expensive 
medicines) 
Medicine reuse is mainly 
applicable for expensive 
medicines 
Medicine reuse is financial 
solution of medicine waste 






Most people just dispose of their medicines in the bin, and probably 
only a minority of people actually take the medicines back to the 
pharmacy. A lot of these medicines contain chemicals which 
probably make their way into the water and could pollute water 
supply. Oestrogen for example could make its way into the water 
supply. I don’t know whether these chemicals break down within a 
period of time and become inert, or whether they continue to be 
active and modify the environment. (P3, male, 40-49 age group) 
 
- Medicines reuse reduce 
the proportion of 
medicines thrown into 
household bins. 
-  Medicines reuse 
encourage people to 
return their unused 
medicines to the 
pharmacy  
- Medicines reuse 
decrease environmental 




Potential advantages of 





I do believe there’s an enormous amount of medicine wasted, and 
sometimes I wonder what happens to these wasted medicines as it 
would be awful to wash it down the water works, all these drugs 
and chemicals would harm health in another sort of way. And I 




Potential advantages of 






Participant responses (the final quoted ones) Final coding Major theme/minor 
theme 
sub- theme 
have always wondered why if they’re intact they’re not reused 
(P11, female, 40-49 age group) 
- Negative environmental 
effect of medicinal 
waste 
 
People Flush medicines down the loo or just put it in the rubbish 
bin.  Dreadful.  When Hormones such as oral contraceptives 
flushed down the loo, it was linked to low sperm count in men 
(P16, female, 40-49 age group).  
 
- Flushing hormones into 
the water system has a 










I think one of the reasons people put medicines down the loo is 
because they know if they take the medicine back to the pharmacist 
he is going to destroy them anyway so they think, why I should 
make the effort with this, pointless. They don't understand the 
damage they might be doing so I think there would be an 
environmental benefit. (P15, male, 50-59 age group)  
 
- Perception of people 
about the reason on 
slushing medicines 
down the low 
- Pharmacy will destroy 
the returned medicines , 










So what I'm describing I think are people who are more aware, 
shall I say, of a bigger picture, they’re not thinking just personally, 
they’re thinking what can I do, does it save the environment, if one 
less packet of pills has to be made that's one less energy, that’s less 
transport, it’s all the good reasons, not just money. (P2, male, >70) 
 
- Unused medicinal waste 










I think my concerns about medicine reuse would be the hygiene 
aspects of the returned medicine as I want to know if it was stored in 
a clean place, and that I wasn’t going to get any kind of infection or 
problem with it. (P1, female, 60-69 age group) 
 
- concerns about reusing 
medicines 
- Medicines storage? 
- Risk of infection? 
Consequences of 
medicines reuse 
Potential disadvantages of 
medicines reuse 
Medicine reuse 
risks e.g. infection 
transmission 
I think the main issue of reusing medicines would be the risk.  I 
suppose some medications have to be stored at certain temperatures, 








Participant responses (the final quoted ones) Final coding Major theme/minor 
theme 
sub- theme 
like insulin. Also you would have to be assured that the medicine had 
not been tampered with. (P4, female, 60-69 age group) 
 
- Medicines require 
certain storage 
temperature. 




The thing that would concern me about reusing medicines is if the 
drugs had become contaminated somehow, so there would have to 
be a very thorough check to make sure something has not been 
contaminated in some way. (P5, male, 60-69 age group) 
 Consequences of 
medicines reuse 
Potential disadvantages of 
medicines reuse 
Medicine reuse 
risks e.g. medicines 
being contaminated 
There could be a risk of medication error being made, for example 
if somebody put a medication back in the wrong box and returned 
it.  There have to be very strict rules on checking the returned 
medicines. (P6, male, >70 age group) 
Medicine reuse can be 









I suppose there is a slight risk of a wrong drug getting into a wrong 
packet or being placed in the wrong place somewhere, so being 
mis-prescribed but I think it is quite small because pharmacists are 




Medicine reuse can be 









I'm a dyed in the wool Conservative, but I think the Green Party for 
example would be positive about medicine reuse and may 
campaign for it.” (P2, male, >70 age group) 
 




exemplar individuals and 
groups 
Individuals or group of 
people who might approve 
of medicine reuse 
The green 
movement 
I think people part of the Green movement will approve medicine 
reuse. (P3, male, 40-49 age group) 
 
- People who thinks green 
will support medicine 
reuse 
- Green party will support 
medicine reuse 
Exemplar and anti-






Participant responses (the final quoted ones) Final coding Major theme/minor 
theme 
sub- theme 
 Individuals or group of 
people who might approve 
of medicine reuse 
I think my husband and some friends, I think people who thinks 
green would support it.  I would have thought most 
environmentalists would support it because the other things is, a lot 
of this stuff does end up in the water somehow or other, and affects 
wildlife. (P17, female, >70 age group) 
 
- Friends, spouses and 
partners, families and 
people who thinks green 
will support medicine 
reuse 
Exemplar and anti-
exemplar individuals and 
groups 
Individuals or group of 
people who might approve 
of medicine reuse 
Friends, families 
and people who 
thinks green 
I think older people, the make do and mend generation who 
experienced shortages after Second World War, who are fast 
becoming rare and rarer (P14, male, 60-69 age group) 
 
- Elderly people may like 
the idea of reusing 
medicines 
Exemplar and anti-
exemplar individuals and 
groups 
Individuals or group of 
people who might approve 
of medicine reuse 
Elderly people may 
like the idea of 
reusing medicines 
I think particularly amongst the older generation would probably be 
more susceptible to saying, yeah medicine reuse is good idea, 
because we were brought up not to waste things.  I do not know if 
youngsters think about that kind of thing as much because there is a 
surplus of everything these days but there was not when we grew 
up so we don’t, we still don’t waste things, we still mend things. 
(P17, female, >70 age group) 
- Elderly people may like 
the idea of reusing 
medicines 
Exemplar and anti-
exemplar individuals and 
groups 
Individuals or group of 
people who might approve 
of medicine reuse 
Elderly people may 
like the idea of 
reusing medicines 
I think drug manufacturers may think that medicine reuse is a bad 
idea, because they are making an absolute fortune out of the NHS. 
(P6, male, >70 age group) 
 
- Pharmaceutical 
companies may not like 
the idea of reusing 
medicines. 




exemplar individuals and 
groups 
Individuals or group of 
people who might not  
approve of medicine reuse 
Pharmaceutical 
companies profit 
vs. medicine reuse 
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Participant responses (the final quoted ones) Final coding Major theme/minor 
theme 
sub- theme 
I wonder if people working in pharmaceuticals would not frown 
upon it in some way if their profits are being affected. (P11, female, 
40-49 age group) 
 




exemplar individuals and 
groups 
Individuals or group of 
people who might not  
approve of medicine reuse 
Pharmaceutical 
companies profit 
vs. medicine reuse 
I’m very suspicious of the pharmaceutical companies as they like to 
produce more drugs and they make more money, so really I’m very 
suspicious because they are enormous conglomerates. It’s to their 
benefit because they make a lot of money, absolutely. (P18, male, 
>70 age group) 
- Pharmaceutical 
company like to produce 
more drugs and more 
money 




exemplar individuals and 
groups 
Individuals or group of 
people who might not  
approve of medicine reuse 
Pharmaceutical 
companies profit 
vs. medicine reuse 
Getting access to the NHS services is at the cost of the UK 
taxpayer. I think because it’s so ingrained in this country, the NHS 
and the prescription process, that people almost feel that it is now 
like an entitlement to have the genuine medicine at a fixed cost, and 
that kind of thing. (P1, female, 60-69 age group) 
 
- Taxpayer may think 
they are entitled to have 
brand new medicine as 
they pay taxes and may 
not like the idea of 
medicine reuse 
Exemplar and anti-
exemplar individuals and 
groups 
Individuals or group of 
people who might not  
approve of medicine reuse 
Taxpayer may not 
like medicine reuse 
I think mothers are probably very cautious for their offspring, and 
wants the best for her child, there's a kind of feeling because it’s 
brand new, off the shelf, it’s purer, it’s safer, there’s no element of 
risk. (P2, male, >70 age group) 
 
- Mother may not approve 
reusing medicines for 
their children 
- Safety issues 
Exemplar and anti-
exemplar individuals and 
groups 
Individuals or group of 
people who might not  
approve of medicine reuse  
Mother may not 
approve medicine 
reuse 
I think people might be resistant for example with drugs that are for 
babies.  I think that might be seen as a very special group. 
(Participant 7, female, 60-69 age group) 
- Medicine should not be 
reused for babies 
Exemplar and anti-
exemplar individuals and 
groups 
babies is a special 




Participant responses (the final quoted ones) Final coding Major theme/minor 
theme 
sub- theme 
Individuals or group of 
people who might not  
approve of medicine reuse 
should not be 
reused for babies 
Elderly people, I think might think that you shouldn’t do that when 
it comes to elderly people, people with maybe cancer, and these 





- Medicine should not be 
reused for Elderly 
Exemplar and anti-
exemplar individuals and 
groups 
Individuals or group of 
people who might not  
approve of medicine reuse 
Elderly may have 
serious disease such 
as cancer and may 
require brand new 
medicines 
I don’t think medicine in a liquid form can be reused, someone 
might introduce something such as foreign body. This apply to gel 
and cream which is maybe easier to inject or get something in it, 
whereas in a blister pack you can tell whether it is been tampered 
with or not. (P7, female, 60-69 age group) 
- Liquid medicines 
dosage forms should not 
be reused 
- Blister pack medicines 
can be reused 
Expectations about 
returned medicines 




forms vs. medicine 
reuse 
 
If the returned medicine has only six months life left then it may 
not be put back on the shelf to give it to some people. (P9, female, 
>70 age group) 
- Medicines should have 
more than six months of 
shelf life to be reused 
Expectations about 
returned medicines 
Physical characteristics of 
returned medicines 
 
Medicine shelf life 
vs. medicine reuse 
 
I can understand why opened packets have to be destroyed, as there 
is too high a risk of being tampered with. But there should be a way 
of reusing those unopened medicines, and those still within date, I 
do not know what would need to be put in place, but it just seems 
wrong to bin them. (P10, male, 60-69 age group) 
- Opened medicines 
should not be reused 
- Blister pack medicines 
can be reused 
Expectations about 
returned medicines 
Physical characteristics of 
returned medicines 
 
Medicine shelf life 
can’t be reused as 
there is a risk to be 
tampered with 
 
I would be quite happy to reuse medicines as long as I know that 
the safeguards have been put in place that the returned medicines 
has not been tampered with. (P4, female, 60-69 age group) 
 
- Medicines that can be 
reused should be quality 
checked and should not 
be tampered with. 
Expectations about 
returned medicines 
The quality assurance of 
returned medicines 
Medicine quality 









I think another key thing is temperature control, I think most people 
would have a medicine cabinet in the bathroom, and that always 
amuses me because you have got the humidity and the heat of 
showers and baths.  So I think whenever people buy medicine 
cabinets there should be an instruction saying don’t use them in a 
bathroom.” (P5, Male, 60-69 age group) 





The quality assurance of 
returned medicines 
Quality of the 
returned medicines 
vs. medicine reuse 
So all returned medicine have to be checked, I suppose there is a 
slight risk of having counterfeit medicines from untrusted sources 
include those bought online getting into pharmacy shelf. (P17, 
female, >70 age group) 
- Returned medicines 
should be quality 
cheeked before being 
redistributed 
- Counterfeit medicines 




The quality assurance of 
returned medicines 
Returned medicines 
should be quality 
cheeked before 
being redistributed 
and medicines from 
untrusted sources 
should not be 
reused 
As all returned medicine have to be checked.  So this could be a 
disadvantage in terms of pharmacists’ time because they are very 
busy in chemists, aren’t they?  Very busy pharmacists. (P17, 
female, >70 age group) 
 
- Does the pharmacist 





The logistics of medicine 
reuse 
pharmacist time a 
vs. medicine reuse 
Pharmacist may not have the room to put back medicines into the 
shelf , I am thinking of our pharmacy, it is small, and maybe there 
is no enough space in the pharmacy for the returned medicines. (P6, 
male, >70 age group) 
 
- Is there any space in the 
pharmacy to put back 
the returned medicines 
into the shelf 
Expectations about 
returned medicines 
The logistics of medicine 
reuse 
space in the 
pharmacy vs. 
medicine reuse 
I think the pharmaceutical companies will have to collaborate to 
help in medicine reuse process, I know this is terrible thing, 










Participant responses (the final quoted ones) Final coding Major theme/minor 
theme 
sub- theme 
could have some way of collaborating whereby the pooled, they all 
put money into these centres to fund it as almost like a, not exactly 
a charity, but like a community investment type idea. (P7, female, 
60-69 age group) 
 
in medicine reuse 
process 




Medicines have labels on them, so one assumes that if you gave 
them back to the pharmacy, for example, he would then have to 
send them back to the supplier, the supplier would have to send 
them back to the manufacturer, the manufacturer would then have 
to repackage them, and then they have to come all the way back 
down the chain. (P12, female, 60-69 age group) 
- Medicines may need 
repackaging and or 




The logistics of medicine 
reuse 
Can the unused 
medicines send 




I would have a knowledge of my pharmacist because I go to the 
same place and they know what medication I’m on and if 
somebody has changed their medication or whatever and so returns 
some tablets and the pharmacist know that I take those.  So 
pharmacist can probably say here we are Mr. X, here is those 
returned tablet and they are 50 pence instead of £1 or whatever it 
is.  So that sort of thing. (P14, male, 60-69 age group) 
- Incentives were thought 
to encourage patients to 
return unused medicines 
instead of unsafe 
disposal practices 














Appendix 9 First draft (v1) of Medicine Reuse Questionnaire (MRQ)  
1. Reusing medication in the future is Harmful 1   2   3   4   5   6   7 beneficial 
2. Reusing medication in the future is good 1   2   3   4   5   6   7 bad 
3. Reusing medication in the future is satisfying (for me) 1   2   3   4   5   6   7 dissatisfying (for me) 
4. Reusing medication in the future is worthless 1   2   3   4   5   6   7 worthwhile 
5. I would feel under social pressure to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
6. Most people who are important to me would want me to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 
strongly agree 
7. It would be expected of me to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
8. Most people who are important to me would think that ------------- reuse medication in the future  I should 1   2   3   4   5   6   7  I 
should not 
9. I expect to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
10. I want to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
11. I intend to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
12. I am confident that I could reuse medication in the future if I wanted to strongly disagree 1   2   3   4   5   6   7 strongly agree 
13. For me to reuse medication in the future is possible 1   2   3   4   5   6   7 impossible 
14. The decision to reuse medication in the future is beyond my control strongly disagree 1   2   3   4   5   6   7 strongly agree 
15. Whether I reuse medication or not in the future is entirely up to me strongly disagree 1   2   3   4   5   6   7 strongly agree 
16. I think for me to contribute toward reducing the harmful effects of medication on the environment is extremely bad 1   2   3   4   
5   6   7 extremely good 
17. I think for me to contribute toward reducing the NHS drug expenditure is extremely bad 1   2   3   4   5   6   7 extremely good 
18. . I think for me to receive low quality medication is extremely bad 1   2   3   4   5   6   7 extremely good 
19. I think for me to receive unsafe medication is extremely bad 1   2   3   4   5   6   7 extremely good 
20. I think for me to receive incorrect medication is extremely bad 1   2   3   4   5   6   7 extremely good 
21. Reusing sealed, returned blister-pack medication will help me contribute toward reducing the harmful effects of medication on 
the environment definitely disagree -3   -2   -1   0   1   2   3 definitely agree 
22. Reusing sealed, returned blister-pack medication will help me contribute toward reducing NHS drug expenditure definitely 
disagree -3   -2   -1   0   1   2   3 definitely agree 
23. . Reusing sealed, returned blister-pack medication will result in me receiving low quality medication definitely disagree -3   -2     
-1   0   1   2   3 definitely agree 
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24. Reusing sealed, returned blister-pack medication will result in me receiving unsafe medication definitely disagree -3   -2   -1   0   
1   2   3 definitely agree 
25. Reusing sealed, returned blister-pack medication will result in me receiving incorrect medication definitely disagree -3   -2   -1   
0   1   2   3 definitely agree 
26. Environmentalists would believe that I should reuse sealed, returned blister-pack medication definitely disagree -3   -2   -1   0   1   
2   3 definitely agree 
27. The pharmaceutical industry would believe that I should reuse sealed, returned blister-pack medication definitely disagree  -3    -
2   -1   0   1   2   3 definitely agree 
28. My close friends would believe that I should reuse sealed, returned blister-pack medication definitely disagree  -3    -2   -1   0   1   
2   3 definitely agree 
29. My family would believe that I should reuse sealed, returned blister-pack medication definitely disagree  -3    -2   -1   0   1   2   3 
definitely agree 
30. Generally speaking, how much do you want to do what environmentalists believe you should do? Not at all 1   2   3   4   5   6   7 
very much 
31. Generally speaking, how much do you want to do what pharmaceutical industry believes you should do? Not at all 1   2   3   4   
5   6   7 very much 
32. Generally speaking, how much do you want to do what close friends believe you should do? Not at all 1   2   3   4   5   6   7 very 
much 
33. Generally speaking, how much do you want to do what your family believes you should do? Not at all 1   2   3   4   5   6   7 very 
much 
34. I expect that any medication offered to me for reuse will be in the original, sealed, blister-packaging definitely no 1   2   3   4   5   
6   7 definitely yes 
35. I expect to see evidence that any medication offered to me for reuse would have been quality-checked definitely no 1   2   3   4   
5   6   7 definitely yes 
36. I expect to see evidence that any medication offered to me for reuse would have been safety-checked definitely no 1   2   3   4   5   
6   7 definitely yes 
37. I expect that any medication offered to me for reuse will have more than six months of shelf-life remaining definitely no 1   2   3   
4   5   6   7 definitely yes 
38. I expect to be offered some form of reward for reusing medication definitely no 1   2   3   4   5   6   7 definitely yes 
39. It would make it easier for me to reuse medication if I could see that it was in the original, sealed, blister-packaging strongly 
disagree -3   -2   -1   0   1   2   3 strongly agree 
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40. It would make it easier for me to reuse medication if I could see that it had been quality-checked strongly disagree -3   -2   -1   0   
1   2   3 strongly agree 
41. It would make it easier for me to reuse medication if I could see that it had been safety-checked strongly disagree -3   -2   -1   0   
1   2   3 strongly agree 
42. It would make it easier for me to reuse medication if I could see that it had more than six months of shelf-life remaining strongly 
disagree -3   -2   -1   0   1   2   3 strongly agree 
43. It would make it easier for me to reuse medication if I were offered some form of reward strongly disagree -3   -2   -1   0   1   2   
3 strongly agree 
44. Are you currently taking medication for a long term condition? 
a) Yes 
b) No 
45. Choose one option that best describes your age range? 
a) 25 or under 
b) 26-40 
c) 41-55 
d) 56 or older 
e) I prefer not to say 
46. What is your gender? 
a) Male 
b) Female 
c) Other (please specify here) 
d) I prefer not to say 
47. What is your religion? 
a) No religion 









i) I prefer not to say 
48. Choose one option that best describes your ethnicity? 
a) White (English / Welsh / Scottish / Northern Irish/British) 
b) White (Irish) 
c) White (Gypsy or Irish traveller) 
d) Any other White background, please describe below 
e) Mixed / Multiple ethnic groups (White and Black Caribbean) 
f) Mixed / Multiple ethnic groups (White and Black African) 
g) Mixed / Multiple ethnic groups (White and Asian) 
h) Any other Mixed / Multiple ethnic background, please describe here 
i) Asian / Asian British (Indian) 
j) Asian / Asian British (Pakistani) 
k) Asian / Asian British (Bangladeshi) 
l) Asian / Asian British (Chinese) 
m) Any other Asian background, please describe here 
n) Black / Black British (African) 
o) Black / Black British (Caribbean) 
p) Any other Black / African / Caribbean background, please describe below 
q) Arab 
r) Any other ethnic group, please describe here 
a) I prefer not to say 
49. Choose one option that best describes your highest level of educational achievement? 
a) University Higher Degree (e.g. MSc, PhD) 
b) First degree level qualification including foundation degrees, graduate membership of a 
c) professional Institute, PGCE 
d) Diploma in higher education 
e) Teaching qualification (excluding PGCE) 
f) Nursing or other medical qualification not yet mentioned 
g) A Level 
h) Welsh Baccalaureate 
i) International Baccalaureate 
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j) AS Level 
k) Higher Grade/Advanced Higher (Scotland) 
l) Certificate of sixth year studies 
m) GCSE/O Level 
n) CSE 
o) Standard/Ordinary (O) Grade / Lower (Scotland) 
p) Other school (including school leaving exam certificate or matriculation) 
q) I prefer not to say 
a) Other 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 11 Second draft (v2) of Medicine Reuse Questionnaire (MRQ) after first piloting  
1. Reusing medication in the future is Harmful 1   2   3   4   5   6   7 beneficial 
2. Reusing medication in the future is good 1   2   3   4   5   6   7 bad 
3. Reusing medication in the future is satisfying (for me) 1   2   3   4   5   6   7 dissatisfying (for me) 
4. Reusing medication in the future is worthless 1   2   3   4   5   6   7 worthwhile 
5. Most people whose opinions I value, would approve of my decision to reuse medication in the future strongly disagree 1   2   3   
4   5   6   7 strongly agree 
6. Most people who are important to me would want me to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 
strongly agree 
7. It would be expected of me to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
8. Most people who are important to me would think that ------------- reuse medication in the future  I should 1   2   3   4   5   6   7  
I should not 
9. I expect to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
10. I want to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
11. I intend to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
12. I am confident that I could reuse medication in the future if I wanted to strongly disagree 1   2   3   4   5   6   7 strongly agree 
13. For me to reuse medication in the future is possible 1   2   3   4   5   6   7 impossible 
14. The decision to reuse medication in the future is within my control strongly disagree 1   2   3   4   5   6   7 strongly agree 
15. Whether or not I reuse medication in the future is completely up to me strongly disagree 1   2   3   4   5   6   7 strongly agree 
16. I think for me to contribute toward reducing the harmful effects of medication on the environment is extremely bad 1   2   3   4   
5   6   7 extremely good 
17. I think for me to contribute toward reducing the NHS drug expenditure is extremely bad 1   2   3   4   5   6   7 extremely good 
18. I think for me to receive low quality medication is extremely bad 1   2   3   4   5   6   7 extremely good 
19. I think for me to receive unsafe medication is extremely bad 1   2   3   4   5   6   7 extremely good 
20. I think for me to receive incorrect medication is extremely bad 1   2   3   4   5   6   7 extremely good 
21. Reusing sealed, returned blister-pack medication will help me contribute toward reducing the harmful effects of medication on 
the environment definitely disagree -3   -2   -1   0   1   2   3 definitely agree 
22. Reusing sealed, returned blister-pack medication will help me contribute toward reducing NHS drug expenditure definitely 
disagree -3   -2   -1   0   1   2   3 definitely agree 
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23. Reusing sealed, returned blister-pack medication will result in me receiving low quality medication definitely disagree -3   -2     
-1   0   1   2   3 definitely agree 
24. Reusing sealed, returned blister-pack medication will result in me receiving unsafe medication definitely disagree -3   -2   -1   0   
1   2   3 definitely agree 
25. Reusing sealed, returned blister-pack medication will result in me receiving incorrect medication definitely disagree -3   -2   -1   
0   1   2   3 definitely agree 
26. My doctor would believe that I should reuse sealed, returned blister-pack medication definitely disagree -3   -2   -1   0   1   2   3 
definitely agree 
27. My pharmacist would believe that I should reuse sealed, returned blister-pack medication definitely disagree  -3    -2   -1   0   1   
2   3 definitely agree 
28. My close friends would believe that I should reuse sealed, returned blister-pack medication definitely disagree  -3    -2   -1   0   
1   2   3 definitely agree 
29. My family would believe that I should reuse sealed, returned blister-pack medication definitely disagree  -3    -2   -1   0   1   2   
3 definitely agree 
30. Generally speaking, how much do you want to do what your doctor believes you should do? Not at all 1   2   3   4   5   6   7 very 
much 
31. Generally speaking, how much do you want to do what your pharmacist believes you should do? Not at all 1   2   3   4   5   6   7 
very much 
32. Generally speaking, how much do you want to do what close friends believe you should do? Not at all 1   2   3   4   5   6   7 very 
much 
33. Generally speaking, how much do you want to do what your family believes you should do? Not at all 1   2   3   4   5   6   7 very 
much 
34. I expect that any medication offered to me for reuse will be in the original, sealed, blister-packaging definitely no 1   2   3   4   5   
6   7 definitely yes 
35. I expect to see evidence that any medication offered to me for reuse would have been quality-checked definitely no 1   2   3   4   
5   6   7 definitely yes 
36. I expect to see evidence that any medication offered to me for reuse would have been safety-checked definitely no 1   2   3   4   
5   6   7 definitely yes 
37. I expect that any medication offered to me for reuse will have more than six months of shelf-life remaining definitely no 1   2   
3   4   5   6   7 definitely yes 
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38. It would make it easier for me to reuse medication if I could see that it was in the original, sealed, blister-packaging strongly 
disagree -3   -2   -1   0   1   2   3 strongly agree 
39. It would make it easier for me to reuse medication if I could see that it had been quality-checked strongly disagree -3   -2   -1   
0   1   2   3 strongly agree 
40. It would make it easier for me to reuse medication if I could see that it had been safety-checked strongly disagree -3   -2   -1   0   
1   2   3 strongly agree 
41. It would make it easier for me to reuse medication if I could see that it had more than six months of shelf-life remaining 
strongly disagree -3   -2   -1   0   1   2   3 strongly agree 
42. Are you currently taking medication for a long term condition? 
a) Yes 
b) No 
43. Choose one option that best describes your age range? 
a) 25 or under 
b) 26-40 
c) 41-55 
d) 56 or older 
e) I prefer not to say 
44. What is your gender? 
a) Male 
b) Female 
c) Other (please specify here) 
d) I prefer not to say 
45. What is your religion? 
a) No religion 









i) I prefer not to say 
46. Choose one option that best describes your ethnicity? 
a) White (English / Welsh / Scottish / Northern Irish/British) 
b) White (Irish) 
c) White (Gypsy or Irish traveller) 
d) Any other White background, please describe below 
e) Mixed / Multiple ethnic groups (White and Black Caribbean) 
f) Mixed / Multiple ethnic groups (White and Black African) 
g) Mixed / Multiple ethnic groups (White and Asian) 
h) Any other Mixed / Multiple ethnic background, please describe here 
i) Asian / Asian British (Indian) 
j) Asian / Asian British (Pakistani) 
k) Asian / Asian British (Bangladeshi) 
l) Asian / Asian British (Chinese) 
m) Any other Asian background, please describe here 
n) Black / Black British (African) 
o) Black / Black British (Caribbean) 
p) Any other Black / African / Caribbean background, please describe below 
q) Arab 
r) Any other ethnic group, please describe here 
b) I prefer not to say 
47. Choose one option that best describes your highest level of educational achievement? 
a) University Higher Degree (e.g. MSc, PhD) 
b) First degree level qualification including foundation degrees, graduate membership of a 
c) professional Institute, PGCE 
d) Diploma in higher education 
e) Teaching qualification (excluding PGCE) 
f) Nursing or other medical qualification not yet mentioned 
g) A Level 
h) Welsh Baccalaureate 
i) International Baccalaureate 
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j) AS Level 
k) Higher Grade/Advanced Higher (Scotland) 
l) Certificate of sixth year studies 
m) GCSE/O Level 
n) CSE 
o) Standard/Ordinary (O) Grade / Lower (Scotland) 
p) Other school (including school leaving exam certificate or matriculation) 
q) I prefer not to say 
b) Other 





Appendix 12 Third draft (v3) of Medicine Reuse Questionnaire (MRQ) after second piloting that required only CFA analysis 
and alpha (α) coefficient (direct measures and intention construct) 
1. Reusing medication in the future is Harmful 1   2   3   4   5   6   7 beneficial 
2. Reusing medication in the future is good 1   2   3   4   5   6   7 bad 
3. Reusing medication in the future is satisfying (for me) 1   2   3   4   5   6   7 dissatisfying (for me) 
4. Reusing medication in the future is worthless 1   2   3   4   5   6   7 worthwhile 
5. Most people whose opinions I value, would approve of my decision to reuse medication in the future strongly disagree 1   2   3   
4   5   6   7 strongly agree 
6. Most people who are important to me would want me to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 
strongly agree 
7. It would be expected of me to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
8. Most people who are important to me would think that ------------- reuse medication in the future  I should 1   2   3   4   5   6   7  
I should not 
9. I expect to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
10. I want to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
11. I intend to reuse medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
12. I am confident that I could reuse medication in the future if I wanted to strongly disagree 1   2   3   4   5   6   7 strongly agree 
13. For me to reuse medication in the future is possible 1   2   3   4   5   6   7 impossible 
14. I think for me to contribute toward reducing the harmful effects of medication on the environment is extremely bad 1   2   3   4   
5   6   7 extremely good 
15. I think for me to contribute toward reducing the NHS drug expenditure is extremely bad 1   2   3   4   5   6   7 extremely good 
16. I think for me to receive low quality medication is extremely bad 1   2   3   4   5   6   7 extremely good 
17. I think for me to receive unsafe medication is extremely bad 1   2   3   4   5   6   7 extremely good 
18. I think for me to receive incorrect medication is extremely bad 1   2   3   4   5   6   7 extremely good 
19. Reusing sealed, returned blister-pack medication will help me contribute toward reducing the harmful effects of medication on 
the environment definitely disagree -3   -2   -1   0   1   2   3 definitely agree 
20. Reusing sealed, returned blister-pack medication will help me contribute toward reducing NHS drug expenditure definitely 
disagree -3   -2   -1   0   1   2   3 definitely agree 
21.  Reusing sealed, returned blister-pack medication will result in me receiving low quality medication definitely disagree -3   -2     
-1   0   1   2   3 definitely agree 
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22. Reusing sealed, returned blister-pack medication will result in me receiving unsafe medication definitely disagree -3   -2   -1   0   
1   2   3 definitely agree 
23. Reusing sealed, returned blister-pack medication will result in me receiving incorrect medication definitely disagree -3   -2   -1   
0   1   2   3 definitely agree 
24. My doctor would believe that I should reuse sealed, returned blister-pack medication definitely disagree -3   -2   -1   0   1   2   3 
definitely agree 
25. My pharmacist would believe that I should reuse sealed, returned blister-pack medication definitely disagree  -3    -2   -1   0   1   
2   3 definitely agree 
26. My close friends would believe that I should reuse sealed, returned blister-pack medication definitely disagree  -3    -2   -1   0   
1   2   3 definitely agree 
27. My family would believe that I should reuse sealed, returned blister-pack medication definitely disagree  -3    -2   -1   0   1   2   
3 definitely agree 
28. Generally speaking, how much do you want to do what your doctor believes you should do? Not at all 1   2   3   4   5   6   7 very 
much 
29. Generally speaking, how much do you want to do what your pharmacist believes you should do? Not at all 1   2   3   4   5   6   7 
very much 
30. Generally speaking, how much do you want to do what close friends believe you should do? Not at all 1   2   3   4   5   6   7 very 
much 
31. Generally speaking, how much do you want to do what your family believes you should do? Not at all 1   2   3   4   5   6   7 very 
much 
32. I expect that any medication offered to me for reuse will be in the original, sealed, blister-packaging definitely no 1   2   3   4   5   
6   7 definitely yes 
33. I expect to see evidence that any medication offered to me for reuse would have been quality-checked definitely no 1   2   3   4   
5   6   7 definitely yes 
34. I expect to see evidence that any medication offered to me for reuse would have been safety-checked definitely no 1   2   3   4   
5   6   7 definitely yes 
35. I expect that any medication offered to me for reuse will have more than six months of shelf-life remaining definitely no 1   2   
3   4   5   6   7 definitely yes 
36. It would make it easier for me to reuse medication if I could see that it was in the original, sealed, blister-packaging strongly 
disagree -3   -2   -1   0   1   2   3 strongly agree 
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37. It would make it easier for me to reuse medication if I could see that it had been quality-checked strongly disagree -3   -2   -1   
0   1   2   3 strongly agree 
38. It would make it easier for me to reuse medication if I could see that it had been safety-checked strongly disagree -3   -2   -1   0   
1   2   3 strongly agree 
39. It would make it easier for me to reuse medication if I could see that it had more than six months of shelf-life remaining 
strongly disagree -3   -2   -1   0   1   2   3 strongly agree 
40. Are you currently taking medication for a long term condition? 
a) Yes 
b) No 
41. Choose one option that best describes your age range? 
a) 25 or under 
b) 26-40 
c) 41-55 
d) 56 or older 
e) I prefer not to say 
42. What is your gender? 
a) Male 
b) Female 
c) Other (please specify here) 
d) I prefer not to say 
43. What is your religion? 
a) No religion 







i) I prefer not to say 
44. Choose one option that best describes your ethnicity? 
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a) White (English / Welsh / Scottish / Northern Irish/British) 
b) White (Irish) 
c) White (Gypsy or Irish traveller) 
d) Any other White background, please describe below 
e) Mixed / Multiple ethnic groups (White and Black Caribbean) 
f) Mixed / Multiple ethnic groups (White and Black African) 
g) Mixed / Multiple ethnic groups (White and Asian) 
h) Any other Mixed / Multiple ethnic background, please describe here 
i) Asian / Asian British (Indian) 
j) Asian / Asian British (Pakistani) 
k) Asian / Asian British (Bangladeshi) 
l) Asian / Asian British (Chinese) 
m) Any other Asian background, please describe here 
n) Black / Black British (African) 
o) Black / Black British (Caribbean) 
p) Any other Black / African / Caribbean background, please describe below 
q) Arab 
r) Any other ethnic group, please describe here 
c) I prefer not to say 
45. Choose one option that best describes your highest level of educational achievement? 
a) University Higher Degree (e.g. MSc, PhD) 
b) First degree level qualification including foundation degrees, graduate membership of a 
c) professional Institute, PGCE 
d) Diploma in higher education 
e) Teaching qualification (excluding PGCE) 
f) Nursing or other medical qualification not yet mentioned 
g) A Level 
h) Welsh Baccalaureate 
i) International Baccalaureate 
j) AS Level 
k) Higher Grade/Advanced Higher (Scotland) 
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l) Certificate of sixth year studies 
m) GCSE/O Level 
n) CSE 
o) Standard/Ordinary (O) Grade / Lower (Scotland) 
p) Other school (including school leaving exam certificate or matriculation) 
q) I prefer not to say 
c) Other 





Appendix 13 Final version (v4) of Medicine Reuse Questionnaire (MRQ) which was disseminated nationwide to capture 
people’s beliefs and willingness to reuse medicine in the future. 
  
Data Protection 
Researchers from the University of Reading would like to ask your opinion about a potentially personal or sensitive topic. Please be 
assured that all the answers will be treated as confidential and will be used for market research purposes. All data will be processed in 
adherence to Market Research Society’s Code of Conduct and Data Protection Act 1998. All data collected in this survey will be held 
anonymously and securely. No personal identifying data is asked for or retained. Cookies and personal data stored by your web browser 
are not used in this survey. This study has received research ethics approval as per the University of Reading Research Ethics 
Committee procedures. 
Is this the right survey for you? 




Please help by providing some more information about you 
2. Which of the following (or another) long term health condition(s) do you have? 
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e) Chronic kidney disease   
f) Condition affecting the heart (coronary heart disease, atrial fibrillation, heart failure) 





l) Inflammatory bowel disease (Crohn's disease or ulcerative colitis) 
m) Others, please specify here 
 
3. Are you currently taking any type of medication for your long term condition(s)? 
a) Yes 
b) No, but I have done in the past 
c) No, and I have never taken any medication for my long term condition(s)  
4. Choose one option that best describes your age range? 
a) 18 or 19   
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b) 20-24   
c) 25-29 
d) 30-34 
e) 35-39   
f) 40-44 







n) 80 or over 
o) I prefer not to say  
5. What is your gender? 
a) Male 
b) Female 
c) Other (please specify here) 
d) I prefer not to say 
6. Choose one option that best describes your ethnicity? 
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a) White (English / Welsh / Scottish / Northern Irish/British) 
b) White (Irish) 
c) White (Gypsy or Irish traveller) 
d) Any other White background, please describe below 
e) Mixed / Multiple ethnic groups (White and Black Caribbean) 
f) Mixed / Multiple ethnic groups (White and Black African) 
g) Mixed / Multiple ethnic groups (White and Asian) 
h) Any other Mixed / Multiple ethnic background, please describe here 
i) Asian / Asian British (Indian) 
j) Asian / Asian British (Pakistani) 
k) Asian / Asian British (Bangladeshi) 
l) Asian / Asian British (Chinese) 
m) Any other Asian background, please describe here 
n) Black / Black British (African) 
o) Black / Black British (Caribbean) 
p) Any other Black / African / Caribbean background, please describe below 
q) Arab 
r) Any other ethnic group, please describe here 
s) I prefer not to say 
7. Choose one option that best describes your highest level of educational achievement? 
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a) University Higher Degree (e.g. MSc, PhD) 
b) First degree level qualification including foundation degrees, graduate membership of a 
c) professional Institute, PGCE 
d) Diploma in higher education 
e) Teaching qualification (excluding PGCE) 
f) Nursing or other medical qualification not yet mentioned 
g) A Level 
h) Welsh Baccalaureate 
i) International Baccalaureate 
j) AS Level 
k) Higher Grade/Advanced Higher (Scotland) 
l) Certificate of sixth year studies 
m) GCSE/O Level 
n) CSE 
o) Standard/Ordinary (O) Grade / Lower (Scotland) 
p) Other school (including school leaving exam certificate or matriculation) 
q) I prefer not to say 
r) Other 
8. In which region of the UK do you currently live? 
a) East of England   
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b) East Midlands 
c) London 
d) North East and Cumbria 
e) Northern Ireland 
f) North West 
g) Scotland 
h) South East 
i) South West 
j) Cymru Wales 
k) West Midlands 
l) Yorkshire and the Humber 
m) Other, please specify here 
 
Survey about reusing medication 
Welcome to a survey about reusing medication. The survey is completed anonymously. The survey can be saved part way through and 
takes 20 minutes to complete. The aim of this survey is to learn about your beliefs in relation to the concept of reusing medication. We 
want to know if you would personally consider reusing medication in the future. We define reusing medication as the idea that you 
would accept for your own personal use a prescription medication that has been previously given out to another patient but then 
returned to a pharmacy, where the pharmacist has verified that the medication: has been kept by the other patient for less than three 
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months, has more than 6 months of shelf-life remaining, has not been tampered with, has been kept under normal storage conditions, 
and has been kept in an original sealed blister pack (i.e. medication strip). When we refer to reusing medication, we are interested in 
prescribed medication that an individual/patient may use for a long term illness. The individual/patient would be well enough to make 
their own healthcare decisions. 
How to complete this survey? 
The survey focusses on concepts relating to reusing sealed, returned blister-pack medication. We would like to highlight that reusing 
medication is not currently permitted in the UK so this questionnaire is phrased in relation to the future only. In the main section below, 
we ask your opinion using rating scales; please select the button that best represents your opinion along each answer line provided. 
Please read each question carefully and answer all the questions to the best of your ability. There are no right or wrong responses; we 
are just interested in your personal point of view. If you are not currently taking prescribed medication for your long term condition, we 
are still interested in receiving your views. We simply ask that you answer the questions as though you were receiving prescribed 
medication for your long term condition. We will now proceed to the main survey section. 
2. Main section 
9. Complete the following sentence: Reusing medication in the future is Harmful 1   2   3   4   5   6   7 beneficial 
10. Complete the following sentence: Reusing medication in the future is good 1   2   3   4   5   6   7 bad 




12. Complete the following sentence: Reusing medication in the future is worthless 1   2   3   4   5   6   7 worthwhile 
13. How far do you agree with the following statement: Most people whose opinions I value, would approve if I decided to reuse 
medication in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
14. How far do you agree with the following statement: Most people who are important to me would want me to reuse medication 
in the future strongly disagree 1   2   3   4   5   6   7 strongly agree 
15. How far do you agree with the following statement: I would be expected by others to reuse medication in the future strongly 
disagree 1   2   3   4   5   6   7 strongly agree 
16. Complete the following sentence: Most people who are important to me would think that [..........] reuse medication in the future 
I should 1   2   3   4   5   6   7  I should not 
17. How far do you agree with the following statement: I expect to reuse medication in the future strongly disagree 1   2   3   4   5   
6   7 strongly agree 
18. How far do you agree with the following statement: I want to reuse medication in the future strongly disagree 1   2   3   4   5   6   
7 strongly agree 
19. How far do you agree with the following statement: I intend to reuse medication in the future strongly disagree 1   2   3   4   5   
6   7 strongly agree 
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20. How far do you agree with the following statement: I am confident that I could reuse medication in the future if I wanted to 
strongly disagree 1   2   3   4   5   6   7 strongly agree 
21. Complete the following sentence: For me it is [..........] to reuse medication in the future is possible 1   2   3   4   5   6   7 
impossible 
22. Complete the following sentence: I think for me to contribute toward reducing the harmful effects of medication on the 
environment is [..........] extremely bad 1   2   3   4   5   6   7 extremely good 
23. Complete the following sentence: I think for me to contribute toward reducing the amount of money spent by the NHS on 
medication is [..........] extremely bad 1   2   3   4   5   6   7 extremely good  
24. Complete the following sentence: I think for me to receive low quality medication is [..........] extremely bad 1   2   3   4   5   6   
7 extremely good 
25. Complete the following sentence: I think for me to receive unsafe medication is [..........] extremely bad 1   2   3   4   5   6   7 
extremely good 
26. Complete the following sentence: I think for me to receive incorrect medication is [..........] extremely bad 1   2   3   4   5   6   7 
extremely good 
27. How far do you agree with the following statement: Reusing sealed, returned blister-pack medication will help me contribute 
toward reducing the harmful effects of medication on the environment definitely disagree 1   2   3   4   5   6   7 definitely agree 
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28. How far do you agree with the following statement: Reusing sealed, returned blister-pack medication will help me contribute 
toward reducing the amount of money spent by the NHS on medication definitely disagree 1   2   3   4   5   6   7 definitely agree 
29.   Complete the following sentence: Reusing sealed, returned blister-pack medication is [..........] to result in me receiving low 
quality medication extremely unlikely 1   2   3   4   5   6   7 extremely likely 
30. Complete the following sentence: Reusing sealed, returned blister-pack medication is [..........] to result in me receiving unsafe 
medication extremely unlikely 1   2   3   4   5   6   7 extremely likely  
31. Complete the following sentence: Reusing sealed, returned blister-pack medication is [..........] to result in me receiving 
incorrect medication extremely unlikely 1   2   3   4   5   6   7 extremely likely  
32. How far do you agree with the following statement: My doctor would believe that I should reuse sealed, returned blister-pack 
medication definitely disagree 1   2   3   4   5   6   7  definitely agree 
33. How far do you agree with the following statement: My pharmacist would believe that I should reuse sealed, returned blister-
pack medication definitely disagree  1   2   3   4   5   6   7  definitely agree 
34. How far do you agree with the following statement: My close friends would believe that I should reuse sealed, returned blister-
pack medication definitely disagree  1   2   3   4   5   6   7  definitely agree 
35. How far do you agree with the following statement: My family would believe that I should reuse sealed, returned blister-pack 
medication definitely disagree  1   2   3   4   5   6   7 definitely agree 
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36. Answer the following question: Generally speaking, how much do you want to do what your doctor believes you should do? 
Not at all 1   2   3   4   5   6   7 very much 
37. Answer the following question: Generally speaking, how much do you want to do what your pharmacist believes you should 
do? Not at all 1   2   3   4   5   6   7 very much 
38. Answer the following question: Generally speaking, how much do you want to do what your close friends believes you should 
do? Not at all 1   2   3   4   5   6   7 very much 
39. Answer the following question: Generally speaking, how much do you want to do what your family believes you should do? 
Not at all 1   2   3   4   5   6   7 very much 
40. Do you agree with the following statement: I expect that any medication offered to me for reuse will be in the original, sealed, 
blister packaging definitely no 1   2   3   4   5   6   7 definitely yes 
41. Do you agree with the following statement: I expect to see evidence that any medication offered to me for reuse would have 
been quality-checked definitely no 1   2   3   4   5   6   7 definitely yes 
42. Do you agree with the following statement: I expect to see evidence that any medication offered to me for reuse would have 
been safety-checked definitely no 1   2   3   4   5   6   7 definitely yes 
43. Do you agree with the following statement: I expect that any medication offered to me for reuse will have more than six 
months of shelf-life remaining definitely no 1   2   3   4   5   6   7 definitely yes 
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44. How far do you agree with the following statement: It would make it easier for me to reuse medication if I could see that it was 
in the original, sealed, blister packaging strongly disagree -3   -2   -1   0   1   2   3 strongly agree 
45. How far do you agree with the following statement: It would make it easier for me to reuse medication if I could see that it had 
been quality-checked strongly disagree -3   -2   -1   0   1   2   3 strongly agree 
46. How far do you agree with the following statement: It would make it easier for me to reuse medication if I could see that it had 
been safety-checked strongly disagree -3   -2   -1   0   1   2   3 strongly agree 
47. How far do you agree with the following statement: It would make it easier for me to reuse medication if I could see that it had 
more than six months of shelf-life remaining strongly disagree -3   -2   -1   0   1   2   3 strongly agree 









Appendix 14 Correlation matrix between independent (predictor) variables  
 
Correlations 
 ID AD SND PBCD BBIN NBIN CBIN 
        
Pearson 
Correlation 
ID 1.000 .736 .804 .732 .541 .550 .192 
AD .736 1.000 .743 .637 .591 .497 .191 
SND .804 .743 1.000 .669 .525 .582 .135 
PBCD .732 .637 .669 1.000 .539 .468 .219 
BBIN .541 .591 .525 .539 1.000 .579 .271 
NBIN .550 .497 .582 .468 .579 1.000 .190 
CBIN .192 .191 .135 .219 .271 .190 1.000 
Sig. (1-tailed) ID . .000 .000 .000 .000 .000 .000 
AD .000 . .000 .000 .000 .000 .000 
SND .000 .000 . .000 .000 .000 .000 
PBCD .000 .000 .000 . .000 .000 .000 
BBIN .000 .000 .000 .000 . .000 .000 
NBIN .000 .000 .000 .000 .000 . .000 
CBIN .000 .000 .000 .000 .000 .000 . 
N ID 1003 1003 1003 1003 1003 1003 1003 
AD 1003 1003 1003 1003 1003 1003 1003 
SND 1003 1003 1003 1003 1003 1003 1003 
PBCD 1003 1003 1003 1003 1003 1003 1003 
BBIN 1003 1003 1003 1003 1003 1003 1003 
NBIN 1003 1003 1003 1003 1003 1003 1003 
CBIN 1003 1003 1003 1003 1003 1003 1003 
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Interval for B Correlations 
Collinearity 
Statistics 






order Partial Part Tolerance VIF 
1 (Constant) -.004 .124  -.034 .973 -.247 .239      
AD .201 .026 .206 7.775 .000 .150 .252 .736 .239 .126 .376 2.659 
SND .468 .031 .419 15.116 .000 .407 .528 .804 .432 .245 .342 2.921 
PBCD .312 .026 .283 12.092 .000 .262 .363 .732 .358 .196 .479 2.088 
BBIN .000 .001 .003 .137 .891 -.002 .002 .541 .004 .002 .510 1.960 
NBIN .003 .001 .066 3.040 .002 .001 .006 .550 .096 .049 .557 1.796 
CBIN .001 .001 .021 1.224 .221 -.001 .003 .192 .039 .020 .911 1.098 
a. Dependent Variable: ID 
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Appendix 16 Normal P-P plot of regression standardised residual, the points (line) 
lied in a reasonably straight diagonal line from bottom left to top right confirmed no 






Appendix 17 Scatter plot of the standardised residuals, roughly rectangular 
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Model R R Square 
Adjusted R 
Square 




1 .859a .738 .736 .923 1.951 
a. Predictors: (Constant), CBIN, SND, BBIN, NBIN, PBCD, AD 
b. Dependent Variable: ID 
 







Square F Sig. 
1 Regression 2387.287 6 397.881 467.488 .000b 
Residual 847.699 996 .851   
Total 3234.987 1002    
a. Dependent Variable: ID 





Appendix 19 Simple bivariate correlation between the direct and indirect measures of 
the same construct of TPB 
 
Correlations between direct measure of attitude (AD) and indirect measure of 
behavioural belief 
 AD BBIN 
AD Pearson Correlation 1 .591** 
Sig. (2-tailed)  .000 
N 1003 1003 
BBIN Pearson Correlation .591** 1 
Sig. (2-tailed) .000  
N 1003 1003 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
Correlations between direct measure of subjective norm (SND) and indirect measure 
of normative belief (NBIN) 
 SND NBIN 
SND Pearson Correlation 1 .582** 
Sig. (2-tailed)  .000 
N 1003 1003 
NBIN Pearson Correlation .582** 1 
Sig. (2-tailed) .000  
N 1003 1003 
**. Correlation is significant at the 0.01 level (2-tailed). 
  
Correlations between direct measure of PBCD and indirect measure of control belief 
(CBIN) 
 PBCD CBIN 
PBCD Pearson Correlation 1 .219** 
Sig. (2-tailed)  .000 
N 1003 1003 
CBIN Pearson Correlation .219** 1 
Sig. (2-tailed) .000  
N 1003 1003 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
  
